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ABSTRACT 
 
 It is generally agreed that many proteins are structurally dynamic; sampling many 
conformations while in solution and also adopting new conformations upon 
complexation with a ligand. Many of these flexible enzymes are of biological interest, 
and hindering their function via binding of competitive inhibitors would open up valuable 
therapeutic avenues. Unfortunately due to the conformation-dependent nature of ligand 
binding, the act of discovering a new small molecule that will bind these particular 
proteins is analogous to aiming at a moving target. The following work focuses on one 
particular enzyme, glutamate racemase. Glutamate racemase is an essential and non-
redundant enzyme in all species of bacteria, and inhibition of this enzyme results in cell 
wall degradation, followed by imminent cell death. Inhibitors of glutamate racemase 
could act as novel antibiotics against a target to which there are no current antibiotics, 
and thus no known resistance. My studies focus on three interdependent phenomenon 
related to enzymes: protein dynamics, ligand binding, and catalysis. Three main thrusts 
of my research lay at the intersection of these physical phenomenon. First and 
foremost, the Spies lab is interested in structure-based computer-aided drug discovery, 
and the discovery of glutamate racemase inhibitors is a project located at the 
intersection of ligand binding and catalysis, where small molecules inhibit the catalytic 
process. My second project builds on this by adding a deeper understanding of 
noncompetitive GR inhibitors and allostery in general. This entails exploring the 
relationship between protein dynamics and catalysis. Finally, my third project involves 
more fundamental biochemistry in that we closely examine facets of molecular 
recognition such as conformational changes induced by ligand binding, and the role of 
interstitial water. The results of the second two projects then feed back into our in silico 
methods in order to improve our capacity to predict small molecule binders of glutamate 
racemase. Much of the knowledge detailed here can be applied to similar proteins of 
alternate classes, thus improving structure-based computer-aided drug discovery 
against many flexible proteins.  
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GENERAL INTRODUCTION 
 
I. Enzyme Dynamics and Ligand Binding 
 
 Our capacity to determine high-resolution structures of biological 
macromolecules (protein, DNA, lipid membranes) has expanded rapidly with the 
advancement of techniques such as solid-state nuclear magnetic resonance 
(NMR), x-ray crystallography, neutron crystallography, and electron microscopy. 
Unfortunately, our ability to analyze the dynamics of these macromolecules is 
lagging. Early experiments confirmed that all proteins are undergoing a dynamic 
process referred to as "breathing". Exchange of deuterons with protons on the 
protein backbone, even within the most buried regions of the protein, provided 
evidence that conformational flexibility must allow temporary access of solvent to 
these residues1. Proteins in solution are all subject to these constant random 
thermal motions. Breathing motions are challenging to distinguish with current 
biophysical techniques, but proteins are also flexible on a larger scale. Individual 
residue side-chains and the carbon back-bone itself are subject to large motions, 
as evidenced by the techniques described above. These motions cannot be 
ignored in the functional processes of ligand binding and enzyme catalysis, and 
should thus be included in any quantitative structural modeling of proteins and 
ligands. 
 Two schools of thought have dominated current explanations of the role of 
conformational flexibility in ligand-binding. First is the idea of a conformational 
energy landscape, which is at equilibrium in the presence of constant external 
factors (binding partners, temperature, pH, etc.). This energy landscape is pre-
populated with protein conformations of varying energy, where low energy 
conformations are highly populated and high energy conformations are sparsely 
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populated. The introduction of a binding partner, such as a small molecule ligand, 
into the system, shifts this equilibrium by binding with preference to the most 
compatible protein conformation (aka. the protein conformation that results in the 
lowest energy complex)2. The alternate and popular school of thought, referred to 
as "induced-fit", dictates that a protein exists in solution at its most energetically 
favorable unliganded conformation, and the presence of a binding partner results 
in physical interactions, which lead to the subsequent induction of the protein 
conformation that produces the lowest energy complex3. The "correct" 
mechanism, or the possibility that both are equally important, is still hotly debated 
due to a lack of experimental evidence in ruling out one or the other.  
 Another important role of protein flexibility is that involved in allostery. 
Allostery is the phenomenon where a binding partner binds an enzyme at a site 
distinct from the active site (where chemistry occurs) and results in apparent 
changes (positive or negative) to either substrate binding or catalysis. Allostery 
was first well-defined during the investigation of oxygen-binding by hemoglobin in 
the 1960s by two groups: Monod, Wyman and Changeux2a (Institut Pasteur), and 
Koshland, Nemethy, and Filmer3 (Brookhaven National Laboratory). Despite 
being a phenomenon of great importance and constant scrutiny, the molecular 
mechanism of most allosteric interactions in enzymes is still not well understood 
at the atomistic level. In an attempt to mimic the abundance of natural allosteric 
regulators, drug therapies are increasingly exploiting allostery as an effective 
route for enzyme inhibition or activation. In order to discover and develop novel 
allosteric regulators, a greater understanding of the link between protein 
conformational dynamics and catalysis is required. The studies and results 
contained within this thesis contribute to the general knowledge regarding the 
trifecta of protein conformational dynamics, ligand binding, and catalysis, with a 
focused application toward computer-aided and structure-based drug discovery. 
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II. State of the Art in Accounting for Protein Flexibility/Solvation in 
Computer-Aided Drug Discovery 
 
 Virtual screening is becoming increasingly more popular in pharmaceutical 
settings for discovery of small-molecules against a particular protein target. The 
method is generally faster and substantially more cost-effective than traditional 
high-throughput screening campaigns. Additionally, one is not limited to the 
chemical entities contained within a particular physical library. With virtual 
screening, any compound which can be dreamt up can be modeled and included 
in the screening. The key modeling component of virtual screening is the docking 
of a small-molecule into a designated pocket on a protein receptor. The protein 
receptor structure must be known, either from high-resolution experimental data 
(often acquired via NMR or x-ray crystallography) or rigorous homology-modeling 
in the case of no experimental data. The pocket where ligand binding occurs 
must also be known, generally an easy decision in the case of competitive 
inhibitors (binding to the active site), but exponentially more difficult a designation 
in the case of novel allosteric regulators a process (aided by pocket analysis 
algorithms). Current molecular docking employs search algorithms, which vary 
from being of genetic, stochastic, or simulation-based, are in fact quite successful 
at generating a docked-pose that matches experimentally-derived structural 
data4. A study by Warren and coworkers showed that for 90% of the included 
systems, docking produced a result that matched the crystallographically-
determined pose within 2 Å4. 
 Typical docking algorithms allow for flexibility in the small-molecule around 
rotational bonds and within cyclic moieties. For a fragment library, where the 
average molecular weight is 150-280 Da, this means simulating flexibility for 10-
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20 heavy atoms on average. The incorporation of receptor flexibility into 
simulation, where a 30 kDa protein is approximately 4,000 atoms, would 
obviously and quickly become too computationally expensive to screen large 
compound libraries. To circumvent this limitation, some algorithms have been 
developed that allow flexibility just in residue side-chains within the binding 
pocket. While this is, in principle, an improvement, side-chain movements 
represent only a fraction of the conformational picture for the protein receptor. 
One particular study within this thesis shows that virtual screening can be made 
much more efficacious (as quantified by the "hit-rate", number of binding 
compounds per total compounds tested) if a particular conformation of the 
receptor is chosen, here the conformation corresponding to that theorized as the 
"transition-state" or reactive state conformation. 
 An alternative to docking to a single receptor is ensemble docking, where 
a small molecule is docked to multiple conformations of the protein receptor. 
These conformations can be generated from experimental data, eg. multiple co-
crystal structures, or they can be generated with molecular dynamics simulations. 
This leads us to a discussion of current molecular dynamics simulation 
techniques. Current techniques allow simulation of every atom within the target 
protein as well as explicit waters and salts. Thus, the same 30 kDa protein above 
would require ~24,000 atoms in its simulation with a 70x70x70 Å3 simulation cell. 
With current computational power, simulations of this protein could reach 
timescales in the 10s of nanoseconds within one week on 32 processors. 
Microsecond-length simulations are less common, but certainly plausible using 
super-computing and parallel-computing setups. Long simulations are hampered 
by the physical realism of physics-based force field. Common force fields can be 
categorized as being either knowledge- or physics-based, where knowledge-
based force fields are based on large datasets derived from multiple systems 
while physical-based force fields are based on a biophysically-determined set of 
"rules" for bond lengths, angles, strain, etc.  Either type of force field has 
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strengths and weaknesses and are often employed in a system-dependent, ad 
hoc manner. Over the course of long simulations, current force fields have a 
tendency to drift toward the allowance of unnatural phenomenon. These issues 
are currently being addressed by labs that specialize in force field generation. 
Regardless, nanosecond-length simulations do provide valuable information 
regarding the dynamic motions that are considerably larger and more complex 
than local thermal fluctuations. A unique adaptation of classical MD simulation, 
referred to as "steered" MD simulation, allows the user to manipulate the system 
in order to force a physical phenomenon. In one of the studies described here 
within, a force is applied to a bound substrate along a fixed vector, in order to 
simulate the unbinding in a matter of picoseconds, instead of waiting indefinitely 
for the substrate to become unbound in a classical MD simulation. This unbinding 
process generates unique protein conformations, which are relevant to the 
catalytic cycle of this particular enzyme. Not surprisingly, the marriage of various 
types of MD simulations and docking is proving to be extremely fruitful in the 
discovery and development of inhibitors for flexible proteins.  
 Lastly, and perhaps most importantly, is the need for computational 
predictions of accurate and precise binding energy between a theoretical ligand 
and its protein receptor. This is key to the ranking of docked poses in virtual 
screening, as well as the optimization of a lead compounds via analysis of 
subsequent derivative compounds. This area of computer-aided drug discovery 
is quite immature, compared to ligand placement and MD simulation. Current 
methods for free energy calculation range from the short and inexpensive (such 
as a docking program's scoring function4) to the long and expensive (such as 
simulation-based free-energy perturbation [FEP]5). The key to a successful free 
energy calculation in computer-aided drug discovery is the balance of 
computational expense (ie. time) and accuracy. The accuracy of a free energy 
calculation should, in principle, be dependent on the ability to appropriately 
account for every physical component of a protein-ligand interaction: protein 
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desolvation, ligand desolvation, van der Waals interactions, entropic restriction of 
the ligand, electrostatic interactions, dipole-dipole interactions, etc. The studies 
within this thesis will focus on three classes of free energy prediction: scoring 
functions (London dG6 and Autodock7), end-point free energy calculation (MM-
PBSA8 and its sister, MM-BEMSA9) and the Extended Linear Response (ELR10). 
Proper energy evaluations lead to proper comparisons of multiple ligands for a 
given receptor, and will form the foundation for expeditious and efficacious hit 
identification and lead optimization in a computer-aided drug discovery 
campaign.  
  
III. Glutamate Racemase, an untapped source for future antibiotics 
 
The peptidoglycan cell wall is an organic polymer specific to bacteria. 
Composed of crosslinked sugars and pentapeptides, the peptidoglycan layer 
forms a rigid mesh that protects bacterial cells from osmotic stress11. The 
inclusion of highly conserved D-amino acids into the pentapeptide portion of this 
mesh is believed to be a mechanism of preventing degradation by common 
proteases11. D-glutamate is a major constituent of the peptidoglycan cell wall11. 
Additionally, specific bacteria such as B. anthracis also require substantial 
amounts of D-glutamate for synthesis of the poly-γ-D-glutamic-acid (PDGA) 
capsule, a key component for virulence12. The bacterial enzyme, glutamate 
racemase (GR), is responsible for the reversible stereoinversion of L-glutamate 
to D-glutamate. Key to the selection of GR as the target of a drug discovery 
campaign is its necessity and non-redundancy in bacteria. Several knockout 
studies have shown that in the absence of GR, bacteria are D-glutamate-
auxotrophic13, confirming the singular method of D-glutamate acquisition as 
being through GR. Also important is that there is no human homologue of GR, 
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since there is no requirement for this particular D-amino acid in any processes 
endogenous to humans. Adding to its attractiveness as a drug target is the fact 
that GR plays a role in phase I of peptidoglycan biosynthesis, while all active 
drugs that also target the peptidoglycan cell wall act on enzymes categorized as 
being in phase III (extracellular)11. Where resistance may potentially arise (or 
already exists) in phase III due to exposure to existing drugs, there is less of a 
threat of resistance for a completely novel strategy. 
Glutamate racemase (GR) belongs to the cofactor-independent family of 
amino acid racemases. GR acts via a general acid/base mechanism utilizing two 
active site cysteine residues to abstract the Cα proton and donate a proton to the 
opposite face14. This chemistry is quite impressive considering the high pKa 
(~29)15 of the Cα proton of glutamate coupled with the lack of pyridoxal-5-
phosphate or metal cofactor. The active site is saturated with hydrogen-bond 
donating and accepting residues. An over-representation of threonine residues in 
the active site has led to some researchers to refer to it as a “threonine pocket”16. 
The catalytic cysteine residues are C74 and C185 (B. subtilis numbering). These 
residues were located by predictions based on homology models and confirmed 
by site-directed mutagenesis17. The reaction forms a planar anionic intermediate 
as a result of the initial cleavage of the α-carbon-hydrogen bond14. Kinetic 
isotope effect measurements show that cleavage and reformation of a carbon-
hydrogen bond on the opposite face occur in step-wise manner and are partially 
rate-determining steps18. Several conserved residues within the active site 
(Asp10, Asp36, Glu152, and His186) have been implicated as aiding in the 
reaction by stabilizing the anionic intermediate17b.  
The x-ray crystal structure has been determined for glutamate racemases 
isolated from a variety of bacterial species (see Chapter 4 for a complete list with 
references/PDB codes). The majority of the co-crystal structures show GR bound 
to glutamate, glutamate-analogs, or oxygen-rich salts. The protein possesses a 
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general α/β fold, which composes two domains that enclose a relatively small 
active site. NMR studies have shown that GR is a highly flexible enzyme capable 
of sampling many conformations19. It has been proposed that this flexibility allows 
substrate binding and product release from the buried active site.  Work within 
this thesis will show that GR can bind a wide variety of chemical moieties, 
another testament to its flexibility. Also, this thesis will explore whether such 
flexibility also plays a role in the immense catalytic power of GR (Chapter 5). 
It is also important to discuss the tertiary and quaternary structure of 
glutamate racemase, as well as conformational changes that accompany 
substrate binding. From here on, I will discuss details regarding the enzyme as 
they apply to RacE, the GR isozyme of Bacillus subtilis (the isozyme with which 
the majority of the following inhibitor studies were conducted). RacE of B. subtilis 
and RacE1/2 of B. anthracis have many structural similarities, and the active site 
is highly conserved over all studied species, thus inhibitors discovered against 
RacE can be assumed to be candidates for inhibition against the GR isozymes 
from B. anthracis, F. tularensis, and H. pylori as well. RacE is found at 
equilibrium in solution between a monomer and homodimer state20. The active 
site is located at the interface of two domains within each monomer, the amino-
terminal domain (domain A) and the carboxy-terminal domain (domain B). Amino 
acid residues from either domain are involved in the catalytic mechanism. Upon 
binding of substrate, a hinge movement occurs between domain A and domain B 
bringing active site residues closer together and forming the “closed” form of the 
enzyme20. This conformational change is required for catalysis. It is believed that 
since domain B is more involved in interactions between the two dimers and thus 
experiences more restricted mobility, domain A is more likely responsible for 
separation that forms the “open” form, allowing the product to leave and new 
substrate to bind19b.    
9 
 
The majority of the following studies focus on GR isozymes isolated from 
B. subtilis (non-pathogenic), H. pylori (pathogenic), F. tularensis (pathogenic), 
and B. anthracis (pathogenic). Unlike the vast majority of bacteria, B. anthracis 
possesses two genes that encode glutamate racemases: racE1 and racE2. 
Recent studies show that both proteins encoded by these genes (RacE1 and 
RacE2) are functional and share 67% amino acid sequence homology, although 
some structural and enzymatic differences exist between the two16. A RacE1 
knockout mutant and RacE2 knockout mutant show significant differences in 
phenotype13a. When RacE1 is knocked out, only a moderate decrease in growth 
with full recovery after addition of D-glutamate is observed. In contrast, when 
RacE2 is knocked out, bacterial growth decreases more significantly and addition 
of D-glutamate only achieves partial recovery13a. These studies show a disparity 
in the degree of necessity of each RacE isozyme. GR was also knocked out in 
Francisella tularensis and resulted in bacteria displaying complete auxotrophy for 
D-glutamate13b.  
Antibiotics against each of the highlighted pathogenic bacteria are in high 
demand. Bacillus anthracis is the causative agent of inhalational anthrax, and 
has been catergorized as a Class A bioterrorism agent by the US government21. 
Additionally, Francisella tularensis causes tularemia, an illness that causes 
widespread death in small mammals such as rodents, rabbits, and beavers; and 
also has the capacity to infect humans with flu-like symptoms, which are 
potentially lethal if left untreated. The US government has also added F. 
tularensis to the list of Class A bioterrorism agents21. Helicobacter pylori was 
proven to be linked to both ulceritis and gastic carcinoma in the 1990s22, thus 
potential antibiotics could serve as a novel anti-cancer therapeutic. Finally, 
Bacillus subtilis is a non-pathogenic soil microbe. The GR isozyme isolated from 
this bacteria has been well characterized functionally and structurally. It was the 
first liganded crystal structure, providing the first model for computation, and has 
thus served as a quality model system in many of the following studies.   
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Currents methods of treatment for B. anthracis infections include 
vaccination and heavy doses of oral antibiotics. Vaccination is only effective 
when given well in advance of exposure. Today, the two most commonly used 
antibiotics against anthrax are ciprofloxacin and doxycycline, which are two types 
of fluoroquinolones23. Ciprofloxacin acts by binding DNA gyrase and preventing 
the unwinding of chromosomal DNA, thus interfering with bacterial DNA 
replication. Doxycycline works by binding ribosomes and preventing the binding 
of amino-acyl tRNAs, thus inhibiting protein translation. In the case of tularemia, 
the current first-line treatment is a combination of streptomycin (an 
aminoglycoside) and tetracycline (a polyketide antibiotic)24. Both of these 
antbiotics work by inhibiting protein biosynthesis, and given in combination, are 
believed to reduce the occurrence of bacterial resistance. Similarly, H. pylori 
infections are currently treated with a combination of antibiotics (clarithromycin 
and amoxicillin) as well as a proton pump inhibitor to alter the stomach pH and 
reduce the favorability of growth conditions25. Clarithromycin is a macrolide that 
interferes with protein biosynthesis, while amoxicillin is a beta-lactam antibiotic 
that inhibits bacterial cell wall production at the cross-linking step (Phase III). 
None of the current first-line treatments for the mentioned bacterial species have 
mechanisms of action that target enzymes in Phase I of peptidoglycan 
biosynthesis, and only one treatment targets peptidoglycan at all. Thus, this 
combination of enzyme target and bacterial species is an unsaturated area of 
research, where any discoveries made herein would contribute greatly to the 
universal arsenal of antibacterial therapies. 
Studies have been conducted to investigate potential inhibitors of 
glutamate racemase in a variety of species. The first potent glutamate racemase 
inhibitors with strong antibacterial capacities were developed in 2002 by 
researchers at Eli Lilly and Co.26. These competitive inhibitors are highly-
substituted D-glutamate analogues that exhibit maximal inhibition concentrations 
(MICs) as low as 10 ng/mL26. Unfortunately, their activity is currently limited to 
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Streptococcus pneumoniae. In 2007, a group from AstraZeneca Global Structural 
Chemistry discovered a potent glutamate racemase inhibitor (Compound A) of 
Helicobacter pylori that acts through a novel uncompetitive mechanism19b. This 
particular compound takes advantage of the hinge-like conformational change 
that accompanies substrate binding. By binding to an allosteric site and 
displacing a key tryptophan residue, Compound A locks the enzyme in the 
“closed” conformation, thus preventing the release of substrate and lowering the 
Vmax considerably. In H. pylori, Compound A has an IC50 value of 1.4 μM and an 
MIC of 4 μg/mL19b. Substituent variation was used to produce a library of 
Compound A analogs, thus uncovering inhibitors with IC50 values as low as 16 
nM27. Unfortunately and somewhat unsurprising, this series of compounds 
suffered first from poor solubility and membrane permeability (unsuitable for oral 
administration), and then a lack of efficacy in the mouse model. 
The same group from AstraZeneca went on to discover 9-benzyl purine 
variants that inhibit glutamate racemase potently in Enterococcus faecium and 
Enterococcus faecalis28. Using high-throughput screening, the 9-benzyl purine 
scaffold was selected and again, substituent variation was used to improve 
potency. Inhibitors with IC50 values as low as 1.0 μM
28 were found. Using the 
same 9-benzyl purine scaffold, substructure searches within the AstraZeneca 
corporate collection were performed to “scaffold-hop” to an 8-benzyl pteridine 
structure which extended inhibitory specificity to include Staphylococcus aureus, 
as well as E. faecium and E. faecalis27. This series of inhibitors also suffers from 
poor physico-chemical properties, specifically solubility. The importance of 
discovering GR inhibitors with quality lipophilicity scores before optimization of 
binding potency is highlighted in Chapter 3. 
 This thesis contains studies that detail the discovery and characterization 
of 15 novel millimolar inhibitors and 12 novel micromolar inhibitors of glutamate 
racemase. Of the 27 new inhibitors, 9 were confirmed to inhibit via a competitive 
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mechanism and 1 was confirmed to inhibit via a noncompetitive mechanism. The 
potency of the remaining inhibitors was accomplished via determination of their 
IC50, which cannot distinguish between inhibitory mechanisms. The strongest 
inhibitor has an inhibition constant (Ki) of 2.5 micromolar and, unlike previous 
high-potency GR inhibitors, an impressive lipophilicity profile. Several of the most 
potent compounds were also assayed for antibacterial activity and demonstrated 
high micromolar inhibition of bacterial growth for Gram-positive species. Many of 
these inhibitors represent exciting new scaffolds for future development of 
antibacterial therapeutics. One particular series of inhibitors (Chapter 3) was 
composed entirely of novel chemical entities and prompted the successful 
application for a method patent covering their use in antibacterial formulations, as 
well as three composition of matter patents (US Provisional Application No. 
61/779,727).      
 
IV. Overlying Themes in the Following Thesis 
 
 The following five chapters of this thesis are verbatim replications of a 
publication reproduced with permission from the publishers. Each study herein is 
a combination of experimental and computational work with an overarching goal 
of improving our understanding of the biophysical workings that lay at the nexus 
of protein flexibility, ligand binding, and catalytic power. There are three themes 
that transcend the entirety of this thesis: (1) improved modeling of receptor 
flexibility in virtual screening (Chapter 1, Chapter 2) and lead optimization 
(Chapter 3); (2) inclusion of solvation (Chapter 2) and explicit water molecules 
(Chapter 4) in binding energy evaluations; (3) investigation into receptor flexibility 
as a determinant of catalytic rate via pKa perturbation (Chapter 5). The contents 
of this thesis form a comprehensive depiction of ligand binding and catalysis as 
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they apply to the antibacterial drug target, glutamate racemase. It is my hope that 
these case studies may add to the general knowledge of the physical 
phenomenon that drive protein-ligand complexation as well as the mechanism by 
which allosteric inhibitors negatively affect catalytic rates. The results of such 
studies are of paramount importance to computer-aided drug discovery. 
Improvement in the efficacy and timeliness of the hit identification and lead 
optimization stages of drug discovery will have positive downstream effects on 
the overall cost and time required for a drug to move from conception to 
regulatory approval.  
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CHAPTER 1: EXPLOITING ENZYME PLASTICITY AND REACTIVITY IN 
VIRTUAL SCREENING:  THE DISCOVERY OF GLUTAMATE RACEMASE 
INHIBITORS WITH HIGH LIGAND EFFICIENCY VALUES.  
ABSTRACT Glutamate racemase is an attractive anti-microbial drug target. 
Virtual screening using a transition-state conformation of the enzyme resulted in 
the discovery of several μM competitive inhibitors, dissimilar from current amino 
acid-like inhibitors, providing novel scaffolds for drug discovery. The most 
effective of these competitive inhibitors possesses a very high ligand efficiency 
value of -0.6 kcal/mol/heavy atom, and is effective against three distinct 
glutamate racemases representing two species of Bacillus. The benefits of 
employing the transition-state conformation of the receptor in virtual screening 
are discussed.   
 Glutamate racemase (GR) catalyzes stereoinversion at the Cα of 
glutamate1, and is a source of D-glutamate in bacteria. D-glutamate is an 
essential component of the peptidoglycan layer of bacterial cell walls, and is a 
target for antibacterial drug development2. GR possesses an exquisite substrate 
specificity, catalyzing stereoinversion of Cα via a 1,1 proton transfer, utilizing  a 
“two-base” mechanism consisting of two cysteine residues that flank the Cα3.  
GR-catalyzed racemization proceeds without the assistance of a cofactor, which 
has generated intense interest in its mechanism, as well as the related enzymes 
such as diaminopimelate (DAP) epimerase4. GR-ligand co-crystal structures do 
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not provide a reasonable explanation, a posteriori, for how the Cα proton is 
abstracted by the catalytic cysteine base, without invoking a reorganization of the 
active site5. However, recent MD-QM/MM studies on the B. subtilis GR have 
yielded a “reactive” conformation resulting from a repositioning of active site 
moieties such that the carbanionic transition state is saturated with hydrogen 
bond donors5b. 
  The plasticity of GR poses immense challenges for classic structure-based 
drug design6. The current study seeks to surmount these obstacles by employing 
a virtual screening regime, in which the receptor is the “reactive” form of B. 
subtilis GR, as described in Spies et al.5b. This methodology is summarized in the 
flowchart in Figure 1. The reactive conformation of glutamate racemase, 
characterized in Spies et al.5b, was employed in the present study as a receptor 
for virtual screening of a large lead-like library of compounds. This approach is 
appealing in the sense that the reactive form of the enzyme is characterized by a 
compressed active site that exhibits dramatically enhanced protein-ligand 
interaction energy5b. After virtual screening and scoring approximately one million 
compounds, the docked enzyme-ligand complexes that yielded the greatest 
computationally determined pKi values (where Ki is the dissociation constant) or 
the most negative interaction energies were slated for experimental investigation 
(Table 1). The various types of outcomes are also listed in Figure 1.  
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Figure 1. Flowchart for Inhibitor Discovery Using a 
Conformationally Active Form of Glutamate Racemase (GR). 
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Table 1. Highest-ranking Hits Emerging from Virtual Screening of 
a 
†
Lead-like Library of ~1 Million Compounds to the 
‡
Reactive (i.e. 
Transition State) Form of GR Versus the Outcome of Experimental 
GR Assays.
 
Compound 
Predicted 
Interaction Energy 
(kcal/mol) from 
docked poses 
§
Predicte
d pKi 
from 
docked 
poses 
*
Experimental 
Results 
 
1 
-21.996 10.1 
Colloidal 
Aggregate
ℓ
 
 
2 
-25.897 10.1 IC50= 3.0 mM 
 
3
£
 
-13.530 9.9 
Ki =42 ± 10 
μM 
 
4 
-20.511 9.5 
IC50= > 2.4 
mM
¥
 
 
5 
-12.156 9.1 
Ki =59 ± 13 
μM 
 
6
₩
 
-23.950 8.3 
Ki  = 
1.9 mM 
 
7
₩
 
-25.015 7.2 IC50= 3.5 mM 
 
8 
-14.367 6.6 IC50= 4.0 mM 
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Table 1 Footnote. †The Chemical Computing Group Conformational Database Version 
2007, where lead-likeness is based on Oprea’s parametersx7; see Computational 
Procedures in S.I. 
‡The reactive form of GR, as characterized by Spies et al.9 
§As determined by the London dG scoring function, implemented within the LigX utility of 
MOE (v2008.10) 8; values above pKi=9.0 were considered for experimental investigation. 
*All Ki or IC50 values determined by the circular dichroism assay described in SI, except 
for 1 and 4. 
ℓ1 appeared to display non-competitive inhibition with an apparent Ki = 90 ± 7 μM, but 
was found to inhibit GR through colloidal aggregation.  
¥Inhibition by 4 was measured using the coupled-enzyme assay and the actual IC50 is 
expected to be higher due to partial inhibition of the coupled-enzyme, L-GDH (see SI for 
details). 
£Synthesis and derivatization of 3 are described by Fatiadi and Bou et al.9 
₩6 and 7 were chosen for their high interaction energies, while 8 was a readily 
available fragment of 2, 4, 5, and 6. 
Two lead compounds were identified (where lead compound refers to a bona 
fide competitive inhibitor with μM-range Ki). Table 1 provides a full account of all 
of the tested compounds with the greatest predicted pKi values and their 
experimental Ki values. Compounds 1-5 have dG scores in the top 1% of the 
originally retained 500 compounds from the virtual screen. All of these 
compounds were found to be inhibitors (two in the μM range, and two in the mM 
range), while 1 was a colloidal aggregator (vide infra). Scoring with dG was 
notably superior to simply using ligand interaction energies, as performed in 
Spies et al.9 which generated only a few mM inhibitors. Furthermore, in the 
current study, interaction energies for the two best inhibitors, 3 and 5, were very 
low, underscoring the poor utility of this metric.       
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Figure 2 shows the initial rate kinetic data for GR-inhibition by 3 and 5 
(obtained by a circular dichroism assay5b, described in the Supporting 
Information section), which was globally fitted to a competitive inhibition model 
(fitted parameters located in Table 2), respectively.  To our knowledge these are 
the first μM competitive inhibitors for GR that are not amino acids. Importantly, 
the more effective of these, 3, also inhibits GR isozymes from B. anthracis with 
and without the so-called “valine bridge”, which has been shown to confer 
species specificity against the only other class of effective competitive inhibitors 
for GR2b, 10 (Figure A.2), suggesting that 3 may be developed as a broad anti-
microbial chemotherapeutic.  
Surprisingly, 1 was found to exhibit apparent non-competitive inhibition against 
GR (Figure 3A). Shoichet and coworkers have thoroughly documented the pitfalls 
of hits, from virtual (and high throughput) screening, that show apparent non-
competitive inhibition11. It is often the case that such inhibitors form colloidal 
aggregates, which lead to local protein denaturation of the target enzyme, and 
thus apparent non-competitive inhibition. Colloidal aggregators can easily be 
identified by performing inhibition assays in the presence of increasing 
concentrations of mild detergents12. This procedure was performed on 1, which 
B A 
KI = 59 ± 13 µMKI= 42 ± 10 µM
Figure 2. Experimental results for competitive inhibition of GR by compounds 3 (A) 
and 5 (B). Michaelis-Menten curves are globally fit to competitive inhibition models. 
See SI for experimental methods described in full.  
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showed almost total alleviation of inhibition in the presence of detergent, clearly 
identifying it as a colloidal aggregator, and thus a false positive lead (Figure 3B).  
 
            
  
It is instructive to examine the docked poses of 3 into GR using a more 
thorough approach than was used in the high throughput docking that was 
employed in the initial screen. Docking into both the reactive form of GR and the 
crystal structure (PDB 1ZUW) were performed to compare the benefit of 
employing the reactive form in the original virtual screening. In these additional 
docking studies 3 is 
minimized for each docked pose, followed by rescoring with the London dG 
scoring function (the computational details are described in the Supporting 
Information section). Two salient features emerge from this docking study: 1) the 
shape of the active site pocket for the reactive form of GR enforces a very tight 
distribution of possible complex structures with 3 (Figures 4A and C), while the 
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Figure 3. 1 yields apparent non-competitive inhibition using global kinetic analysis (A), but is 
shown to actually be a colloidal aggregator using the detergent assay of Shoichet and co-
workers
13
 (B); the presence of 0.01% Triton X-100 in the assay mixture almost fully alleviates 
the enzyme inhibition (see Supporting Information section for a full description of this 
method).   
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crystal structure (Figures 4B and D) has a wide range of distributions (the 
differential in tightness of placement is quantified below) 2) calculated binding 
affinities between 3 and the reactive form of GR are uniformly stronger than that 
of 3 and the crystal structure, (∆G = -13.0 ± 0.80 kcal/mol for the reactive 
complex versus -11.1 ± 0.80 kcal/mol for the crystal complex). Free energy 
values obtained from the dG scoring function are not meant to provide a rigorous 
estimate of the actual free energy of binding, but rather to provide a metric for 
ranking the affinity of a ligand for its receptor in an aqueous environment (see 
Supporting Information for a full discussion of the dG scoring function). The 
averaged calculated dG value for the transition state complex and the crystal 
structure complex with 3, together with the ligand maps in Figure 4A and C, 
indicate a more favorable binding to the transition state receptor. 
            
One may quantify the tightness in the distribution of the docked poses in the 
reactive complex with 3 versus the crystal structure by calculating the overlap in 
molecular volume between the docked poses, such that a high degree of overlap 
(i.e., a perfect overlap in which a compound is always docked to the exact 
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volume) has a value of 1, while no overlap at all between docked poses yields a 
value of 0. Calculation of the Tanimoto volume (Tvol), which is described in the 
Supporting Information section, has been shown to be a superior descriptor of 
similarity between docked complexes versus the more often used root mean 
square value13. Here we calculated a Tvol of 0.79 ± 0.03 for 3 docked into the 
reactive form of GR, versus a value of 0.64 ± 0.17 for 3 docked into the crystal 
structure. This disparity is graphically illustrated in the overlap of docked poses 
for both complexes in Figures 4C and D, respectively. 
The reactive form of GR tightly places docked poses of 3 into highly similar 
positions, as supported by the high Tvol value. However, the crystal structure 
receptor yields a wide range of positions for 3 with consistently lower calculated 
pKi values.  Taken together, these volume overlap and calculated binding studies 
establish that the selection of the reactive form of GR for virtual screening is an 
attractive alternative approach for finding high affinity lead compounds, as 
described in the current study.   
    Although 3 is not, a priori, a substrate analog, it is, in many ways, a 
conformational analog to the cyclic glutamate carbanion, the reactive 
intermediate described in Spies et al.5b, which is evidenced by calculating the Tvol 
of the glutamate carbanion vs. the docked poses of 3 (Tvol = 0.55), as illustrated 
in Figure A.3. However, as Figure A.3 indicates, the overlap between the cyclic 
glutamate carbanion and 3, while reasonable in terms of molecular volume, is not 
electrostatically optimal, due primarily to the region around the Cα and Cα 
positions of the glutamate carbanion. One may contrast the binding of 3 versus 
glutamine, a substrate analog, which has a Ki of 50 mM. It is interesting to note 
that glutamine lacks the ionic and hydrogen bonding complementarity for forming 
intramolecular cyclized species as observed with glutamate. It may be that GR’s 
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affinity for substrate and transition state is partially derived from these cyclized 
forms. 
The active site configuration of the complex between GR and 3 is structurally 
reminiscent of proline racemase (a structurally related family of cofactor 
independent-racemases) with the transition state analog pyrrole-2-carboxylic acid 
(PYC)14, which exhibits two binding states with Ki1 = 4.6 μM and K i2 = 30 μM. 
The crystal structure of proline racemase reveals that PYC is compressed 
between two Cys residues, and the carboxylate is receiving five hydrogen bonds 
from the active site residues. Transition to the active form of proline racemase 
involves a conformation change that accommodates the planarity of the proline 
ring carbanionic intermediate, which is highly analogous to the case of the cyclic 
glutamate carbanion described in Spies et al.9, as well as the nature of the lead 
compounds identified in the current study. In all of these systems, the plane of 
the ring is perpendicular to the axis connecting the two flanking Cys sulfur atoms. 
A superpose of reactive and crystal structure forms of the docked GR-complexes 
illustrates that this perpendicularity between the plane of the ring and the sulfur 
atoms is only present in the reactive form, while the docked crystal structure 
complex is tilted and possesses significant ring strain. A characteristic feature of 
all of the docked crystal structure complexes with 3 is ring strain, with O-C-C-O 
carbonyl-carbonyl dihedral angles of approximately ~25˚, versus ~5˚ for 
complexes with the reactive form as receptor. The differential hydrogen bonding 
pattern in the docked crystal structure complex, relative to the reactive 
conformation, is responsible for the sub-optimal ligation with 3. Additionally, there 
is a significant reduction in the volume of the active site pocket in the reactive 
form versus the crystal structure (from 188 Å3 in the crystal structure to 159 Å3 in 
the reactive form). 
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     The most significant property of 3 is its very large ligand efficiency (LE) value 
of -0.6 kcal/mol/heavy atom. LE values are of paramount  importance in 
fragment-based drug discovery (FBDD), which has been a highly successful and 
emerging approach for identifying promising drug candidates15, 16. The FBDD 
approach aims to grow small, weak-binding (yet possessing high LE value) 
inhibitors into nM inhibitors, which retain Lipinski-like rule-of-five compliance 
throughout the process. LE values of -0.3 kcal/mol/heavy atom or greater are 
considered to be good, since careful optimization from MW ~ 150 to > 400 should 
yield a compound in the ~ tens of nM range16. However, 3 possesses an LE 
value far surpassing that of a standard fragment, such that the addition of a 
modest four heavy atoms places it in the nM range. Thus, 3 is an excellent point 
from which to begin an optimization campaign, particularly in light of the fact that 
it is effective against three glutamate racemases, each unique in their oligomeric 
equilibrium as well as the presence or absence of the valine bridge (Val149 in 
RacE2; Figure A.2 in the Supporting Information section).       
C74 
C185 
Figure 5. Superpose of docked complex of GR with 3 from the 
reactive form (elemental color/ball and stick rendering) and GR with 
3 from the crystal structure (cobalt blue/stick rendering). Each 
complex is from the top scoring docked configuration (see 
Supporting Information for further details). Only the residues of the 
reactive form are shown for clarity. The Connolly (solvent-excluded) 
surface of the pocket of the reactive form of GR is rendered in 
colored mesh (purple is hydrogen bonding, green is hydrophobic and 
blue is polar). 
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Table 2. Optimized Parameters from Global Nonlinear 
Regression (Competitive Inhibition Model) 
 
Inhibitor 3 5 
KM (mM) 0.34 ± 0.08 0.30 ± 0.05 
Vmax (nmol/sec) 0.20 ± 0.01 0.19 ± 0.01 
KI (μM) 42 ± 10 59 ± 13 
R
2
  0.97 0.98 
 
There are two widely accepted models that account for protein flexibility in 
small molecule binding, which may be of use when considering the preferential 
docking of lead compounds into the reactive form of an enzyme versus the 
corresponding crystal structure. The Monod-Wyman-Changeux (MWC) model 
describes an unliganded form of the enzyme, which may be in equilibrium with 
numerous conformations17. The ligand may preferentially bind to one of these 
sampled receptor conformations. Alternatively, the Koshland-Nemethy-Filmer 
(KNF) model describes an “induced-fit” sequence, in which the ligand promotes a 
series of conformational changes in the receptor18. The virtual screening 
methodology presented in the current work is appropriate for systems that exhibit 
behavior similar to the MWC model, since receptor conformational sampling may 
be determined a priori (i.e. the reactive conformation is simply an additional, 
albeit rare, form that may be elucidated by any number of methods, such as 
those described in Spies et al.5b). However, systems exhibiting KNF behavior 
assume conformational states that may be unique for a particular protein-ligand 
complex, suggesting ambiguity in the receptor target. 
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detailed results, controls. This material is available free of charge via the Internet 
at http://pubs.acs.org. 
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CHAPTER 2: HYBRID STEERED MOLECULAR DYNAMICS-DOCKING: AN 
EFFICIENT SOLUTION TO THE PROBLEM OF RANKING INHIBITOR 
AFFINITIES AGAINST A FLEXIBLE DRUG TARGET. 
 
 
 
Abstract 
Existing techniques which attempt to predict the affinity of protein-ligand 
interactions have demonstrated a direct relationship between computational cost 
and prediction accuracy. We present here the first application of a hybrid 
ensemble docking and steered molecular dynamics scheme (with a minimized 
computational cost), which achieves a binding affinity rank-ordering of ligands 
with a Spearman correlation coefficient of 0.79 and an RMS error of 0.7 kcal/mol. 
The scheme, termed Flexible Enzyme Receptor Method by Steered Molecular 
Dynamics (FERM-SMD), is applied to an in-house collection of 17 validated 
ligands of glutamate racemase. The resulting improved accuracy in affinity 
prediction allows elucidation of the key structural components of a heretofore 
unreported glutamate racemase inhibitor (Ki = 9 μM), a promising new lead in the 
development of antibacterial therapeutics. 
 
Introduction  
 The grand challenge of computer-aided drug discovery and design is the 
ability to rank-order the binding affinity of known ligands/inhibitors at a 
reasonable level of both accuracy and precision. This allows one to predict 
potential chemical modifications of an inhibitory scaffold class with high 
confidence, which offers a potentially transformative tool for medicinal chemists. 
However, current methods have not displayed substantial progress.  
 Docking and scoring methods used on single crystal structures (or 
accurate homology models) have been shown to perform well at both ligand 
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placement and distinguishing binders from non-binders (i.e., enrichment studies). 
Furthermore, docking and scoring has worked well in the realm of virtual 
screening (VS), where the goal is to enrich test sets with novel binding scaffolds 
with approximately micromolar equilibrium dissociation constants[1]. However, 
problems persist here as well, as recently reviewed by Martha Head[1]. 
Nevertheless, all current docking and scoring schemes completely lack the ability 
to rank-order drug leads at the level of resolution necessary for efficient drug 
optimization. There are a plethora of docking packages and approaches that 
account for receptor flexibility[2-7], by employing various versions of ensemble 
docking, and show improvements in ligand placement versus single crystal 
structure cross-docking. However, it should be emphasized that none of these 
approaches has demonstrated any improvements in rank-ordering relative ligand 
binding affinities. The current consensus is that affinity rank-ordering is beyond 
the means of any simple scoring function, even when flexibility is taken into 
account[1, 8-10]. 
Late-phase drug discovery depends critically on the ability to predict how 
affinity to a 3D pharmacophore changes with the structure of the lead compound. 
The particular role that relative free energy calculations play in the drug lead 
optimization process has been recently reviewed[9, 11]. More sophisticated 
treatments to directly calculate the free energy of binding of a ligand to a target 
have made noteworthy progress in the last decade, and have recently been 
reviewed by Shirts et al. [9] On the other hand, direct free energy calculation 
methods based on molecular dynamics (MD) simulations such as thermodynamic 
integration (TI)[12] and weighted histogram analysis method (WHAM)[13, 14] are 
both technically challenging to implement and usually very computationally 
expensive. Furthermore, there is not yet a wide consensus that such methods 
meaningfully improve rank-ordering, relative to well designed endpoint methods 
that utilize implicit solvation models (MD/MM/PBSA/GBSA)[9, 15]. Additionally, 
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even the most inexpensive TI and WHAM-based calculations of binding free 
energies are certainly not applicable to large numbers of compounds.  
 Hybrid MD/Docking studies have recently shown progress at improving 
affinity rank-ordering relative to docking against a single crystal structure[16], but 
rely on multiple docking simulations for every ligand tested.  Here we present a 
novel hybrid method for accurate and precise affinity rank-ordering of ligands 
against a challenging enzyme drug target, which employs a combination of 
steered molecular dynamics (SMD) simulations, ensemble docking and solvation 
free energy calculations of the enzyme. The method has been termed Flexible 
Enzyme Receptor Method by Steered Molecular Dynamics (FERM-SMD), and 
gives outstanding correlations with experimental values at a fraction of the 
simulation costs of methods that rely on extensive MD-based sampling (vide 
infra). SMD yields information beyond the normal MD timescale (10s to 100s of 
ns) by applying a harmonic force potential along a defined path. Although the 
magnitude of the forces and timescales employed may not be compared to the 
experimental (i.e., in vitro) studies, it has been shown that SMD simulations have 
accurately predicted macromolecular behavior, often with short simulation times. 
SMD simulations have been used to determine a variety of macromolecular 
phenomena, including binding/unbinding of small molecule-protein complexes, 
protein-protein adhesion and stretching of muscle proteins[17-20]. 
The receptor employed to test this hybrid SMD/Docking approach to ligand 
affinity rank ordering is the enzyme glutamate racemase (GR), which catalyzes 
the reversible isomerization of L- to D-glutamate[21], a key step in synthesis of the 
peptidoglycan cell wall of Gram-positive and -negative bacteria[22], and is 
accordingly a recognized drug target for development of antibiotics. GR is a 
member of the pyridoxal phosphate-independent family of racemases and 
epimerases, which have been the subject of recent mechanistic and structural 
advances[23-30]. Knockout studies have shown that the absence of an active form 
of GR is lethal for the target cells[31]. Despite attempts from several academic and 
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pharmaceutical labs, progress in lead discovery and therapeutic development 
based on GR inhibition has been limited. Successful leads (IC50’s in the low μM- 
and high nM-range) are limited to a competitive class of 4-substituted glutamate 
analogs[32], an uncompetitive class of pyrazolopyrimidinediones[33], and two 
competitive inhibitors located via virtual screening against GR transition state 
structures[29]. GR is a challenging system to study in silico due to its inherent 
flexibility. This is not an uncommon problem with enzyme targets, and 
undermines the core assumption of the majority of tools used in CADD (i.e., drug 
design targeting a unique receptor structure). The ligand set employed here, a 
total of 17 compounds, is composed entirely of validated, competitive GR 
inhibitors (with the exception of D-glutamate, the native substrate) discovered in-
house from previous virtual screening campaigns against GR as described by 
Spies and coworkers[26].  
Contrary to the technique successfully employed by Spies and coworkers[26] 
as well as Whalen and coworkers[29], which focuses on targeting an enzyme 
conformation related to the chemical step of the catalytic cycle (i.e., the catalytic 
transition state), this study attempts to represent receptor flexibility with 
conformations sampled in the process of substrate unbinding. In this study, we 
present the utilization of FERM-SMD in the elucidation of the structure-affinity 
relationship of a novel competitive GR inhibitor (heretofore unreported), which 
displays a Ki of 9 μM (the lowest Ki yet reported for a GR inhibitor). Importantly, 
the rank-ordering results presented here meet or exceed a number of critical 
accuracy and precision thresholds often cited as performance standards in 
CADD.  
 
Results 
Discovery of Glutamate Racemase Inhibitors of Varying Scaffolds and 
Potencies.  
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All ligands referred to in this study fall into two categories based on their 
method of selection for use: 1) those identified from a previous in silico screening 
study and 2) glutamate analogs (See SI Data for a full account of the source of 
active compounds). The group of ligands identified from virtual screening can be 
further categorized into: 1) hits originally ranked in the virtual screening study and 
2) hits derived from ranked compounds but not present in the original library of 
compounds. Co-crystal structures exist only for compounds 4 (D-glutamate, PDB 
1ZUW), 16 (citrate, PDB 2JFV), and 17 (tartrate, PDB 2JFW). Despite being co-
crystallized with GR previously, inhibition by compounds 16 and 17 had not been 
characterized until now. All compounds derived from virtual screening underwent 
full structural characterization as well as controls for non-specific inhibition, which 
can be found in the Supplemental Information (Fig. B.6 and B.7).  
 All compounds were assayed for inhibition against glutamate racemase 
from Bacillus subtilis (RacE, abbreviated in this study as GR) in-house. 
Compounds 2, 3, and 9 were presented previously as being competitive 
inhibitors of BsGR by our group[26, 29].  Compounds 1, 5-8, and 10-17 are 
presented here for the first time as being inhibitors of GR. Compound 4 is the D- 
enantiomer of the native substrate, glutamate. Inhibitors discovered here range in 
potency from low-µM (Ki = 9 µM) to high-mM (IC50 = 50+ mM), a range of 5 log-
units (Fig. B.4). Additionally, this set of 17 ligands is unique in its wide diversity of 
structures (see Table B.1 for all structures), a testament to the flexibility of GR in 
that the active site can accommodate inhibitors with solvent accessible volumes 
ranging from 307 Å3 to 482 Å3. Worth highlighting is a promising new class of GR 
inhibitors represented by 1 and 6. Compound 1 is particularly impressive in that it 
possesses a ligand efficiency of 0.53 kcal/mol/heavy atom and is a verified 
competitive inhibitor (Fig. B.4, as verified by global fitting to varying inhibition 
models). This high ligand efficiency may facilitate the development of a nM 
inhibitor that maintains a low molecular weight[34].  The scaffolds of these 
sulfonate-containing aromatic compounds offer an assortment of possible 
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modifications that have the potential of increasing the potency into the nM-range.   
Additionally, this scaffold lies in a similar chemical space as known therapeutics 
(particularly, the recently reviewed class of sulfa drugs[35]), indicating an 
increased likelihood of bioactivity[36-40]. 
1
Ki = 9 M
6
IC50 = 600 M
 
Docking to the GR Crystal Structure Gives Little-to-No Information About 
Rank Order of the Ligand Set.  
Docking of inhibitors to a single crystal structure of glutamate racemase 
from B. subtilis (PDB 1ZUW) results in a poor Spearman correlation coefficient 
(denoted, R) between predicted and actual binding energy (Fig. 6, R = 0.53). 
Specifically, this method of docking and scoring more often errs on the side of 
overestimating the potency of inhibitors (Table B.1 for affinity predictions). A 
handful of inhibitors displayed inhibition in the low mM range (IC50 = 1-10 mM) 
but were predicted by docking to possess binding constants in the hundreds and 
in some cases even tens of µM. This trend of overestimation of affinity would 
indicate that an unfavorable component of complex formation is not being 
accounted for in this method. An important corollary of the above is that the RMS 
error (1.2 kcal/mol) from the linear regression is beyond the limit for what is 
considered “practical accuracy” (1 kcal/mol)[9, 41], which reduces the usefulness of 
this correlation in structure-based drug design.  
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Figure 6. Correlation of binding energy for 17 inhibitor-GR complexes as 
predicted by docking to the crystal structure and experimental-derived binding 
affinities (as Ki or IC50 values), many of which are presented here for the first 
time. Experimental results were determined using circular dichroism or a pre-
established colorimetric coupled-enzyme assay, depending on the optical activity 
of inhibitor compounds. Docking studies were conducted using a single monomer 
of GR from the previously solved co-crystallization of GR from B. subtilis, RacE, 
with D-glutamate (1ZUW). Ligands were allowed to explore space limited to the 
GR active site. Only the predicted binding energy of the top-ranked binding pose 
for each inhibitor is represented on the graph. Data is fit to a semi-log regression 
and the Spearman correlation coefficient, R, is noted. The ± 1 kcal/mol threshold 
is marked (dotted lines). 
 
Classical MD Simulations of GR-Ligand Complexes Show Receptor 
Heterogeneity at the Equilibrated Active Site.  
Half-nanosecond MD simulations were conducted on the top-docked 
poses of all GR-inhibitor complexes, following simulated annealing energy 
minimization, in an attempt to better represent the true complex and improve 
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binding energy predictions. Time series data for all of the MD trajectories of GR-
inhibitor complexes are located in Figure B.5 of the SI. We observed that the final 
equilibrated complexes varied widely in their degree of opening at the active site 
(i.e., the area of the active site entrance). The area is defined by the γ-carbons of 
four proline residues that form a plane at the mouth of the active site (residues 
41, 44, 146 and 150). The spectrum of areas induced by the presence of inhibitor 
ranged from 47.4 Å2 (for 1) to 63.6 Å2 (for 7).This metric for opening is also used 
in the SMD studies (vide infra). Figure 7 illustrates the opening metric.  
 
 
 
 
Figure 7. Image of GR (white surface area) with 3 (stick, blue/red/green) bound in 
active site. The γ-carbon atom of four proline residues (red; Pro41, Pro44, 
Pro146, Pro150) designate the perimeter of the active site entrance. Five 
distances (yellow) composing two irregular triangles are calculated to 
approximate the area of the active site entrance of varying inhibitor-GR 
complexes after energy minimization and 500 psec of molecular dynamics 
simulation. 
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 It is reasonable that large changes in the degree of opening of the active 
site, and generally large changes in the structure of GR (which seem to be 
captured or represented in the distribution of equilibrated GR-ligand complexes) 
will alter physical parameters that determine the ligand affinity. For instance, one 
would expect large changes in the protein solvation energy of a very open GR 
complex versus a closed complex, due to its very polar and H-bond donating 
interior. This question is best addressed by the use of steered MD simulations 
(vide infra), since high energy transitions on the ligand binding trajectory can be 
obtained without prohibitively long simulation time.   
 
Steered MD Unbinding Simulation of the Native Substrate (Glutamate) 
Shows a Correlated Pattern between Protein Solvation Energy and Area of 
Active Site Opening.  
In order to investigate if there is a relationship between the degree of 
opening and the protein solvation energy we employ SMD to capture a 
reasonable ensemble for the entire unbinding process for the substrate, D-glu. 
By plotting the area of the active site entrance and the protein solvation energy 
as a function of the distance between glutamate and GR (obtained from our SMD 
simulations), a pattern between protein conformation and solvation (Fig. 8) 
becomes apparent. The active site entrance area opens incrementally as 
glutamate is being pulled out of the active site, suggesting that the active site is 
closed tightly in the Michaelis-Menten complex and conformational changes must 
occur to accommodate the passage of glutamate back through the entrance 
during product release. The entrance area reaches a maximum when the 
glutamate center of mass is 46.7 Å from the center of mass of GR and this 
maximum is immediately followed by a decrease in entrance area indicating the 
relaxation of GR upon complete substrate release into bulk solvent. This SMD 
simulation agrees with the previous notion that GR undergoes conformational 
changes during its catalytic cycle, and now shows that these conformational 
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changes correspond to significant changes in the protein solvation energy, which 
will directly affect complex affinity (i.e., more negative protein solvation energies 
will contribute to weaker ligand binding; vide infra).  
 
 
 
Figure 8. a) Area of active site entrance and corresponding protein solvation 
energy at varying time points along the trajectory of a Steered Molecular 
Dynamics simulation. The x-axis corresponds to the distance between the center 
of the mass of D-glutamate and the center of mass of GR as D-glutamate is 
being pulled out of the active site. The area of the active site was calculated as 
explained above. Protein solvation energy was calculated for each time-point 
using the Poisson-Boltzmann method with an internal dielectric of 25, a solvent 
dielectric of 78, and a salt concentration of 0.1 M. The region shaded in yellow 
represents entrance areas observed for inhibitor-GR complexes after standard 
MD simulation. Twelve structures were selected arbitrarily for analysis. Arrows 
indicate structures selected for use in ensemble docking. b) The user-defined exit 
vector for D-glutamate (shown in stick rendering) from the active site of B. subtilis 
GR employed for SMD unbinding simulations is shown as a red arrow leaving the 
active site entrance. The external force was applied only along the pulling vector. 
The glutamate was not constrained in the plane orthogonal to the pulling vector 
(see Computational Methods section for a detailed description of the SMD 
unbinding).  
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The data from the SMD simulation in Figure 8 covers a relatively large 
range of openings, relative to the areas of opening seen in equilibrated GR-
ligand complexes obtained from classical MD simulations (Fig. B.5). The range of 
openings seen in GR-ligand complexes from classical MD is depicted by the 
yellow shaded area in Figure 8 (i.e., opened GR structures captured by ligands 
may be a subset of structures in the SMD D-glu-unbinding trajectory). If the 
distribution of conformations of GR is relatively independent of the nature of any 
particular active site ligand, then a single SMD unbinding simulation with the 
natural substrate (which is also the ligand in the original co-crystal structure) 
would be a sufficient approximation of the liganded ensemble of GR, and obviate 
the need for unbinding simulations for any particular ligand of interest. In other 
words, this simple, single SMD with D-glu is used to construct a new target, in 
lieu of the crystal structure. It is important to stress that the SMD simulation is 
only ever performed one time (i.e., on the native substrate), which is used to 
prepare the new target ensemble, which will be docked against the library of 
ligands used in this study.  
 
The Flexible Enzyme Receptor Method for Steered-MD Docking (FERM-
SMD).  
The following docking and scoring method incorporates the structural data 
obtained from the SMD procedure described above for the binding trajectory of 
the native substrate with GR in order to improve ligand rank ordering relative to 
classical docking (where only a single structure is used as a receptor).  The 
dominant trend in the erroneous rank-ordering of classical docking with GR is 
both the assignment of high affinities to weak inhibitors and the large scatter in 
the correlation between predicted and experimental binding energies. The 
incorporation of an ensemble of structures taken from the GR-substrate 
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unbinding trajectory allows one to largely correct for these problems with 
classical docking, as described below.  
 Figure 8 clearly shows the trend in solvation energy of GR with opening. 
When calculating ligand binding free energy values with endpoint methods 
(reviewed recently[42]), ΔGbind is composed of constituent parts of a 
thermodynamic box that involves solvation of the individual components. The 
binding energy expression is: 
 
 
 
Equation 1 shows that the more negative the value of ΔGbind,solv then the more 
positive will be the overall ΔGsolv,receptor for a given ligand, assuming all other 
parameters are constant. Thus, structural changes in the receptor that lead to 
more favorable solvation energies will result in more unfavorable (i.e., weaker) 
binding of a given ligand, assuming that the solvation energy of the GR-ligand 
complex is relatively unchanged. 
Our hypothesis is that this is the major feature that is causing over 
estimation of ligand affinity for GR using classical docking. For the case of GR, 
this means that the larger openings of GR-ligand complexes and their more 
favorable solvation energies of their corresponding protein component would 
lower binding affinities of ligands that populate those states (assuming that the 
GR-ligand complex solvation energy is not greatly different than the fully closed 
state). This concept is illustrated in Figure 9, which depicts a central manifold that 
represents the native substrate (dark grey structure) unbinding trajectory, which 
has been elucidated with SMD (Fig. 8a). A substrate analog (black structure, 
upper manifold of Fig. 9) has a high affinity for the closed state (which closely 
matches the crystal structure), and little affinity for more opened states; this 
represents a situation where binding affinity would be well predicted using 
classical docking methods, and approximates a true positive. On the other hand, 
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some compounds (light grey structure, lower manifold of Fig. 9) will have an 
affinity for multiple structures along the ligand unbinding trajectory. To the extent 
that open forms are highly complementary to a given ligand, the classical docking 
assumptions fail, for numerous reasons, as outlined above. Therefore, 
compounds that "capture" or form complexes with more open GR structures 
should be identified and have a weighted docking score that accurately reflects 
the reduced affinity. A weighting scheme based on a statistical 
thermodynamically-determined ensemble from SMD is one approach to construct 
a corrected binding energy calculation. However, energies obtained via SMD are 
notoriously not reflective of experimental conditions[18,19]. In the FERM-SMD 
scheme presented below, the inhibitor-enzyme distribution is determined by a 
weighting factor based on the relative binding affinity of a given ligand within the 
SMD ensemble, while the ΔΔGprotein,solv (i.e., the change that occurs in the open 
state relative to the closed state) is used to correct the predicted binding affinity 
of each inhibitor-enzyme complex, as described below. 
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Figure 9. Scheme for Hybrid Steered Molecular Dynamics-Docking and how it 
might elucidate rank-order decoys (RODs) amongst a set containing true 
positives. In the boxed region is a simplified representation of steered molecular 
dynamics (SMD) including the removal of substrate (yellow) along the indicated 
vector (arrow), and resulting in the subsequent opening of GR. Structure 
ascertained from SMD are then used as receptors in docking of inhibitor 1 (blue) 
and inhibitor 2 (red).  A true positive (as is the case for inhibitor 1) will result in 
high affinity binding to the closed for (Kd = X) and low affinity binding to the open 
form (Kd > X). A rank-order decoy (as is the case for inhibitor 2) will result in high 
affinity binding to the closed form (Kd = Y) but also high affinity binding to the 
open form due its ability to also bind an alternate binding mode only present in 
the open form (Kd < Y). 
 
 
The FERM-SMD/Docking weighting and correction method is summarized as 
follows:  
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     Eq. 2 
                Eq. 3 
      Eq. 4 
 
where,           is the predicted binding metric (more negative value 
corresponds to tighter binding);    is the correction factor for docking to the n
th 
structure of an ensemble of target structures obtained by steered MD unbinding 
of the natural substrate (i.e., a single SMD simulation used for all docking 
studies);         is the predicted change in free energy for binding of a given 
ligand to the nth structure of an ensemble of target structures obtained from SMD, 
as described above;         is the change in solvation energy of the n
th structure 
of the SMD ensemble, going from a low dielectric constant to that of aqueous 
solvent, by numerically solving the Poisson-Boltzmann (PB) equation;         is 
the change in solvation energy of a reference structure of the SMD ensemble 
(here the most closed or starting structure), going from a low dielectric constant 
to that of aqueous solvent, using PB approaches (as above);    is the weighting 
factor for docking a given compound to the nth structure of the SMD ensemble; 
    is the equilibrium dissociation constant obtained for docking a given ligand to 
the nth structure of the SMD ensemble using AutoDock.      
      
       represents a 
summation of all of the calculated equilibrium constants determined via docking 
to the SMD ensemble for ligand  .  
 The FERM-SMD/Docking approach is to simply dock any given ligand to 
representative structures from a single SMD simulation from Figure 8 
(performed on D-glu), which are indicated by the black arrows (in Fig. 8A), and 
span the range from essentially fully closed to the most open (for overlay of 
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structures, see Fig. B.1). When applied to the 17-ligand set of GR, the correlation 
between predicted and experimental binding energies increases to R = 0.79 with 
an RMS error of 0.70 kcal/mol. This is a significant improvement relative to 
orthodox docking, in both of the critical areas of R value and the RMS error (i.e., 
scatter). Importantly, these large improvements were obtained with little 
additional simulation time (vide infra). This is a noteworthy improvement in the 
field of predicting ligand affinities and performs well against both expensive free 
energy approaches (TI and WHAM[13, 43, 44]) and significantly surpasses most end 
point methods (MD/MM/PBSA/GBSA type[15, 43, 45, 46]) as well as other ensemble 
MD/Docking methods[16]; when one considers the improvement in rank-ordering 
(relative to standard docking) of a set of ligands per simulation time, relative to 
more expensive techniques, the FERM-SMD/Docking approach is exceedingly 
attractive. This will be fully discussed below.  
  
 
Figure 10. Correlation of binding free energies as predicted by FERM-
SMD/Docking and experimental binding affinities from various inhibitor-GR 
complexes. FERMScore values are predicted using the FERM-SMD/Docking 
scheme described above. Experimental binding constants are approximates 
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based on experimentally-derived KM, Ki and IC50 values. Data is fit to a semi-log 
regression and the Spearman correlation coefficient is noted. The ± 1 kcal/mol 
threshold is marked (dotted lines). 
 
In order to explore whether significant improvement in the correlation 
could be attributed simply to ensemble docking regardless of where receptor 
structures were acquired, the FERM-SMD/docking method was performed where 
SMD-derived structures were replaced with three structures acquired from a 16-
nanosecond classical MD simulation of an apo-RacE monomer. QR analysis was 
conducted on snapshots from the classical MD simulation to provide the three 
most structurally-distinct snapshots and best represent the sampled structural 
space. QR analysis has been shown previously to successfully distill MD results 
structurally without losing representation energetically[47,48]. With all other aspects 
of the scheme remaining the same, this modified method did not improve upon 
the correlation achieved by orthodox docking (Fig. B.3). This finding reaffirms the 
ability of SMD to sample a greater structural space and this supports the idea 
that relatively large global fluctuations are a key parameter in correcting rank 
ordering with a flexible target. Also worth noting, individual docking to any one of 
the three structures acquired from SMD does not result in an improvement in the 
correlation over orthodox docking to the crystal structure (Fig. B.2), pointing to 
the importance of ensemble docking and ruling out the possibility of FERM-
SMD’s success being simply the result of a single structure providing a more 
optimal receptor.   
A particularly difficult challenge for any computational method is to rank 
order congeneric sets. All of the compounds in our 17 ligand set have a low 
molecular weight (124-260) and negative charges, consisting of carboxylates 
and/or sulfonates (except 2, which has an oxyanion), with some variation in the 
number of rotatable bonds. If one examines, for instance the subset of 
compounds that have single sulfates, and compares the rank-order performance 
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of orthodox docking versus FERM-SMD/Docking (Table 3, see Table B.1 for a 
complete table of predicted and experimental affinities), it is apparent that the 
former results in a narrowing and incorrect ordering, while the latter results in a 
spreading out of the affinities that mirrors the experimental trend. It is instructive 
to examine how the SMD ensemble is used to dock and score compounds into a 
more realistic rank-ordering. Figure 11 compares the "well-behaved" 1 which 
possesses a relatively enhanced binding affinity for the closed form of GR (Fig. 
11a and 11b) to 10, which tends to partition into more open forms of GR, relative 
to 1. This differential partitioning would pose serious problems for accurate rank-
ordering using classical docking, but is corrected using FERM-SMD scoring.  
 
Table 3. Predicted and experimental binding constants of select sulfonate-
containing ligands to exemplify the superior rank-ordering of the FERM-SMD 
method. 
Compound Predicted Binding Constant (mM) Actual Binding Constant (mM) 
 Crystal Only FERM-SMD  
1 0.29 
 
0.002 0.009 
6 0.76 0.44 0.6 
10 0.23 0.91 1.9 
15 62.0 8.9 63 
    
*Relative binding constants are predicted by docking to the crystal structure 
(“Crystal Only”) or by docking to the SMD-derived ensemble (“FERM-SMD”) and 
calculated using the logarithmic regression shown in the correlations in Figure 6 
(y= -0.334ln(x)+5.883 ) or Figure 10 (y= -0.163ln(x)+1.194), respectively. 
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Figure 11. Example of partitioning of false positive (rank-order) decoys into open 
forms of GR from the SMD ensemble used in the FERM-SMD/Docking 
procedure. Panels a and b illustrate the case of a "well behaved" ligand, in that it 
does not partition into opened structures; Panel a is the ligand map for the top 
docked pose of 1 to the closed form, which is strongly favored in this case; panel 
b is the top docked conformation into an opened structure from the GR SMD 
ensemble, which has a strongly diminished affinity for the target, showing a 
change in the hydrogen bond donors to sulfate and more solvent exposure of the 
ligand relative to the closed complex. Panel c and d summarize the binding 
pattern of the rank-order decoy, 10, which partitions into the more opened forms 
of GR (relative to compound 1); the FERM-SMD/Docking approach identifies and 
corrects the scores of these rank-order decoys, as described in the text.  
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Discussion  
Presented here for the first time is a set of bona fide inhibitors of 
glutamate racemase (13 of the 17 ligands analyzed by FERM-SMD/Docking) 
spanning a large range of potencies and scaffolds. Especially interesting is the 
discovery of a unique family of sulfonate-containing aromatic compounds 
characterized best by 1, which has the lowest Ki (9 µM) of any GR inhibitor yet 
characterized. It is noteworthy that several studies have identified antibacterial 
and antifungal activity as well as the low toxicity of 1 (and derivatives thereof)[38, 
39], however the target and nature of the bioactivity were not determined. 
Compound 1 is one of our most promising leads for optimization, and thus it is 
essential that the structural moieties responsible for its relatively high affinity and 
ligand efficiency be clarified. Not surprisingly, Figure 11 indicates that rank-
ordering, and thus logical structure based design is problematic without 
increased accuracy and precision in the prediction of binding free energies. 
Surmounting this barrier will facilitate the development of sorely-needed 
antibacterial therapeutics. 
It has become clear that the main failure of docking for a flexible target, 
such as GR, is the gross assumption of a single representative structure for the 
receptor. Previous studies have reported the successful implementation of 
ensemble docking in virtual screening as a means of addressing receptor 
flexibility and improving enrichment and the accuracy of ligand placement[2, 7, 49]. 
This study aims at extending the reach of classical docking into the realm of 
affinity rank-ordering by enhancing target information (i.e., steered ensemble 
docking). The wide variety of programs and approaches for representing local 
receptor flexibility by using thermal sampling techniques mixed with classical 
scoring functions are not appropriate for solving the affinity rank-order problem. 
The authors are not aware of any published study in which such approaches are 
tested for the ability to rank-order validated sets of inhibitors.  
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The FERM-SMD/Docking approach represents receptor flexibility in an 
inexpensive manner by utilizing ensemble docking of SMD-derived structures, 
which when combined with solvation free energy calculations, corrects for 
previously inaccurate rank-ordering of ligands. This relatively inexpensive SMD 
simulation provides a much improved target (ensemble) than the single crystal 
structure used in orthodox docking and virtual screening. The improvement in 
Spearman correlation coefficient (R = 0.79) and precision (RMSE = 0.7 kcal/mol) 
due to the FERM-SMD/Docking, places this approach amongst the highest 
accuracy (as measured by rank-order correlation) methods that have been 
published. The best methods for achieving high accuracy and precision are 
mostly alchemical approaches (e.g., TI)[9, 11, 44, 50, 51], reaching R values in the 
range of 0.72 to 0.85 and RMSE values in the range of 0.4 kcal/mol to 0.7 
kcal/mol. However, several studies achieved high accuracy (R > 0.7) using 
endpoint approaches (e.g., MM/GBSA[15]), but these often had much lower 
precision than alchemical methods[9, 15, 43, 45, 46]. Several authors have cited a 1 
kcal/mol threshold value as having real benefits in the workflow of lead 
optimization[9, 41]. However, the benefits of precise prediction of relative ligand 
affinities extend beyond simple synthetic convenience. This is especially true in 
the rapidly changing landscape of natural products synthesis, as recently 
reviewed by Li and Vederas[52]. Currently, the intersection of drug discovery and 
natural products is characterized by great compound diversity and even greater 
synthetic expense, thus the importance of accurate rank-ordering goes beyond 
improvement of workflow and will most likely mean the difference between 
pursuit and abandonment of a candidate compound. Consequently, accuracy 
and precision is best achieved with either alchemical approaches or an efficient 
ensemble docking and scoring method, such as FERM-SMD or the 
Docking/MD/LIE of Stjernschantz and Oostenbrink (2010)[16].   
One recent and noteworthy study by Stjernschantz and Oostenbrink 
outlined the successful implementation of a hybrid docking and MD scheme that 
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employs end-point Linear Interaction Energy (LIE) calculations for cytochrome 
P450 2C9[16]. Under the assumption that a multitude of binding poses not only 
exist but each contribute to the overall binding affinity of a ligand to P450 C29, 
classical docking to a crystal structure was carried out and 4 pre-determined 
poses (of varying ligand orientation within the active site) were selected from the 
docking results. These select four complexes were then subjected to 2 nsec of 
MD simulation and binding energy calculations via LIE. The correlation of 
predicted and experimental binding energies of a set of 12 ligands was improved 
significantly (R=0.83, RMSE=0.7 kcal/mol) over ChemScore alone (R=0.55; the 
scoring function utilized by GOLD)[16]. This method is comparable in accuracy 
and precision to the scheme presented here but differs greatly in its 
computational requirement. Contrary to the FERM-SMD method, the method 
discussed above requires four individual MD simulations for each ligand. The 
FERM-SMD method uses approximately 50 psec production simulation time for 
the actual SMD, while alchemical methods often employ about 20 nsec per 
ligand, depending on the number of λ values used per transformation, often 
resulting in hundreds of nsec per entire ligand set[42].  
Another study, by Colizzi et al.[53], recognizes that orthodox docking fails to 
represent the true binding energy of a congeneric set of β-hydroxyacyl-ACP 
dehydratase inhibitors. By exploiting the power of SMD to capture conformational 
states that are otherwise not sampled by classical MD, the method developed in 
this study correctly partitions inhibitors into “active” (IC50 values in the low μM-
range) and “inactive” compounds by comparing the force profiles produced from 
individual inhibitor-unbinding SMD simulations. Like the study conducted by 
Stjernschantz and Oostenbrink, this method requires individual MD simulations 
for each inhibitor, a more costly undertaking than the single SMD simulation 
required by FERM-SMD. Additionally, the method developed by Colizzi et al. has 
not yet demonstrated whether the generated force profiles have the resolution to 
allow for accurate rank-ordering of a set of ligands, only general partitioning of 
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inhibitors that vary in potency by a factor of at least two orders of magnitude (ie. 
an enrichment study). 
Currently, the FERM-SMD method is not without limitations. Primarily, the 
applicability of the method is limited by the ability to correctly represent unbinding 
in a steered molecular dynamics simulation. Specifically, correct sampling is 
essential to the accuracy of the subsequent docking and scoring. For this 
system, the pulling vector used in SMD was easily estimated (as should also be 
the case for other enzymes with buried active sites and a single substrate 
entrance/exit). However, in the case of enzymes with large, poorly-defined active 
sites, determining the correct pulling vector for an unbinding SMD is far less 
trivial. If the unbinding (or binding) trajectory is non-obvious, elucidation may be 
achieved by multiple exit vector SMD simulations, which may significantly reduce 
the efficiency of the improvement in accuracy. However, even this may be 
preferable to performing alchemical calculations on a large set of ligands. 
Additionally, at this time, FERM-SMD is not an accurate means of calculating 
absolute binding free energies. It should be noted that a variety of MD sampling 
approaches have been used to determine precise absolute free energies of 
binding for one or a few compounds[50, 54, 55], with errors of only 1 or 2 kcal/mol, 
but here we only consider comparisons of methods for accurate and precise 
determination of relative binding free energy from validated sets of inhibitors.   
 Mobley et al. suggested that it may be necessary to account for not only 
protein conformational changes alone, but also to determine the free energy 
differences associated with the conformational transitions in the receptor, in order 
to achieve free energy calculations with high accuracy[50]. Indeed, FERM-
SMD/Docking takes into account a correction based on estimated changes in the 
ΔGSolv,Receptor between different structures of the ensemble, which are used to 
correct the docking score, where it is assumed that ΔGSolv,Receptor is the dominant 
factor in free energy changes between structures in the ensemble. Thus, this 
parallels the predictions made by Mobley et al. that not only would one have to 
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account for structural changes that occur in the target, but also to consider 
energetic changes that occur between such structures. However, it is surprising 
that a correction simply based on endpoint ΔGSolv,Receptor using PB approaches 
would be sufficient to achieve the large enhancement seen in this study. This 
may be due to the accuracy of the AutoDock scoring function to predict ligand 
affinities (for binding to a single receptor structure, i.e., with no receptor 
flexibility), which includes empirically parameterized terms for ligand desolvation 
and entropy. Furthermore, the version of AutoDock used in this study (a module 
of the YASARA Structure package, YASARA Biosciences[56]) employs a more 
sophisticated charge acquisition scheme than standard AutoDock packages, 
based on a semi-empirical quantum chemical RESP-like autoSMILES method[57, 
58].  
In the future, it would be desirable to apply this method to other flexible 
enzyme targets in order to test the applicability of FERM-SMD/Docking across a 
range of enzyme classes as well as reveal any additional inadequacies or biases 
inherent to the system. As pointed out by Shirts et al., obtaining high-accuracy 
ligand binding data has been surprisingly problematic[9]. However, the recently 
NIH-funded initiative, Community Structure-Activity Resource (CSAR)[59], has 
begun to address this problem by curating high quality binding and structural 
data from previously proprietary pharmaceutical databases.  
A hybrid Steered-MD-Docking procedure has been described, which 
corrects the rank ordering of a set of 17 inhibitors of the highly flexible, 
antimicrobial drug target, glutamate racemase. The current study employs this 
technique in the elucidation of binding determinants for a new class of sulfonate 
GR-inhibitors, best exemplified by 1, which was shown in this study to be a 
competitive inhibitor with a Ki of 9 µM. This hybrid SMD-Docking approach is 
shown to have high accuracy, precision and efficiency (i.e., improvement in R 
value per total simulation time), when compared to the many other methods that 
attempt to predict binding affinities for protein-ligand complexation.  
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Materials and Methods 
Materials. Inhibitor compounds were acquired from a variety of 
vendors. Chemical or common names are listed and catalog numbers as well as 
numeration utilized in the current study is noted in parenthesis. Croconic acid (2, 
LT00453399) was purchased from Labotest (Bremen, Germany).  4-Hydroxy-1,3-
benzenedisulfonic acid (3, BAS 00124393) was purchased from Asinex 
(Moscow, Russia). From Sigma Aldrich (St. Louis, MO) we obtained the 
following: α-ketoglutarate (5, K1875), tartrate (16, 228729), D-glutamate (4, 
G1001), D-glucuronic acid (8, G5269), citrate (17, C8532), 4-pyridazine 
carboxylic acid (12, 297763), (R)-(+)-2-pyrrolidone-5-carboxylic acid (13, 
422614), 2-hydroxy-5-nitrobenzenesulfonic acid (11, S364169), chloroaniline-4-
sulfonic acid (6, S438774), and benzimidazole-2-sulfonic acid (1, 530646).  Both 
dipicolinic acid (9, 02321) and L-pyroglutamic acid (14, 83160) were supplied by 
Fluka, while formylbenzenesulfonic acid (10, S0122) and methyl-propene-
sulfonic acid (15, M1408) were purchased from TCI America (Portland, 
OR). Compound 13a (7) was generously provided by Igor Komarov (Kyiv Taras 
Shevchenko University, Kyiv, Ukraine)[60]. The %-purity and method of purity 
analysis for each active compound is listed in Table B.1. Concerning the 
coupled-enzyme assay, all reagents were purchased from Sigma Aldrich: 
iodonitrotetrazolium (I8377), diaphorase (D5540), ATP (A7699), NAD+ (N7004), 
and L-glutamate dehydrogenase (G2501). All reagents related to buffer 
preparation for protein purification and circular dichroism were purchased from 
Sigma-Aldrich. Amicon centrifugal filtration devices were purchased from 
Millipore (Billerica, MA). Finally, HIS-Select Cobalt Affinity Gel (H8162) was 
purchased from Sigma-Aldrich. 
Protein Expression and Purification. A 10 mL starter culture of LB medium with 
100 μg/mL ampicillin was prepared from the stock E. coli BL21 (DE3) cells 
containing pET-15b plasmid (cells and plasmid acquired from Novagen/EMD 
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Biosciences [San Diego, CA]) with the gene encoding RacE from B. subtilis and 
grown overnight at 37 °C with rotation. The 10 mL starter culture was back-
diluted into 1 L fresh LB medium with 100 μg/mL ampicillin. Cells were grown at 
37 °C with shaking until the optical density at 600 nm reached 0.5-0.8. Protein 
expression was induced upon addition of a final concentration of 0.1 mM IPTG. 
Following induction, cells were grown for an additional 16-20 h at 37 °C with 
shaking (16 °C for mutant proteins). Cells were harvested by centrifugation at 
5,000 x g for 15 min.  Cell lysis was achieved through sonication (3x 20 sec 
cycles, 23 kHz and 20 W), using a 100 Sonic Dimembrator (Fisher Scientific). 
Insoluble materials were pelleted by centrifugation at 30,000 x g for 30 min and 
clarified lysate was applied to batch-style affinity chromatography using His-
Select Cobalt Affinity Gel. Concentrated eluant was incubated at 37 °C for 15 min 
with 1 mM ATP and 1 mM MgCl2 to remove high molecular weight contaminants 
suspected to be chaperones. Eluant was then diluted 10-fold with H2O and 
submitted to ion exchange chromatography using a BioRad Uno Q1 column on a 
BioRad BioLogic DuoFlow HPLC. Pooled fractions were then exchanged into 
protein storage buffer (50 mM Tris, 100 mM NaCl, 0.2 mM DTT, pH 8.0) and 
concentrated utilizing a 10,000 MWCO Amicon centrifugal filter device.  Finally, 
protein stocks were stored at a final concentration of 7-10 mg/mL with 20% 
glycerol at -20 °C. 
Enzyme Kinetics via Circular Dichroism. Racemization of D-glutamate to L-
glutamate by glutamate racemase (GR) was assayed by measuring molar 
ellipticity at 225nm continuously for 15 min using a JASCO J-720 
spectropolarimeter (JASCO Inc., Easton, MD). IC50 curves were acquired in the 
presence of 0.5 μM GR and 1 mM D-glutamate with varying concentrations of the 
inhibitor compound. Data was analyzed using the accompanying software, 
JASCO Spectra Manager v1.54A.  Ki values were acquired through global fitting 
of three Michaelis-Menten curves conducted in the presence of three distinct 
concentrations of inhibitor and 0.5 μM GR. Global fitting to varying inhibition 
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models was completed using GraphPad Prism v5. All assays were performed at 
25 °C. 
Enzyme Kinetics via the Coupled-Enzyme Assay. For compounds whose 
contribution to the spectropolarimeter noise was too great to acquire accurate 
kinetic curves (i.e., compounds required in excess or compounds with substantial 
optical activity), the previously established coupled-enzyme assay for 
measurement of D-glutamate to L-glutamate racemization was utilized[61]. IC50 
curves and Ki values were acquired in the same manner in the presence of 0.38 
μM GR. Absorbance at 500 nm (production of reduced INT) was measured using 
a Varian Cary-300 UV-VIS spectrometer (Agilent Technologies). Data was 
acquired using the accompanying Cary Kinetics software. All assays were 
performed at 25 °C. 
Classical MD Simulations. The molecular dynamics simulations were performed 
with the YASARA Structure package version 9.11.9 (YASARA Biosciences)[56]. A 
periodic simulation cell with dimensions of 54.99 Å, 64.39 Å, and 57.77 Å was 
employed with explicit solvent , using the monomer (C chain) of PDB 1ZUW (B. 
subtilis RacE GR with ligand D-glu). The AMBER03 force field was used with 
long-range electrostatic potentials calculated with the Particle Mesh Ewald (PME) 
method, with a cutoff of 7.864 Å[62-64]. The substrate force field parameters were 
generated with the AutoSMILES utility[57], which employs semi-empirical 
AM1geometry optimization and assignment of charges, followed by assignment 
of AM1BCC atom and bond types with refinement using RESP charges, and 
finally the assignments of general AMBER force field atom types. The hydrogen 
bond network of GR is optimized using the method of Hooft and coworkers[65], in 
order to address ambiguities from multiple side chain conformations and 
protonation states that are not resolved by the electron density. YASARA’s pKa 
utility was used to assign pKa values at pH 7.0
[66]. The box was filled with water, 
with a maximum sum of all bumps per water of 1.0 Å, and a density of 0.997 
g/ml.  The simulation cell was neutralized with NaCl (0.9% final concentration; % 
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by mass). Waters were deleted to readjust the solvent density to 0.997 g/ml.  A 
short MD was run on the solvent only. The entire system was then energy 
minimized using first a steepest descent minimization to remove conformational 
stress, followed by a simulated annealing minimization until convergence (<0.05 
kJ/mol/200 steps). The MD simulation was then initiated, using the NVT 
ensemble at 298 K, and integration time steps for intramolecular and 
intermolecular forces every 1.25 fs and 2.5 fs, respectively.  
Steered Molecular Dynamics Simulation. The singular steered MD simulation 
was carried out using the YASARA Structure package v9.11.9. Before applying 
the steering potentials in the production phase, the classical MD procedure, 
described above, was executed. The production phase consisted of external 
steering forces applied to the center of mass of the GR enzyme and the 
glutamate ligand. A vector leading out of the constricted entrance to the active 
site of GR was selected (Shown in Fig. 8B, depicted as a red arrow) for constant 
velocity pulling of the glutamate ligand into bulk solvent. The velocity of the ligand 
in the pulling vector was set in a window of 0.2 to 0.5 Å/ps using a scaled pulling 
force of 5000 pN. The large magnitude of the applied steering force constant 
allows one to make a stiff spring approximation, which has been shown to 
significantly minimize fluctuations of the pulling coordinate[67] from one trajectory 
to another. The external force was applied only along the pulling vector. The 
glutamate ligand was not constrained in the plane orthogonal to the pulling 
vector. The forces and the velocity in the pulling direction were calculated at 
every time step. The entire production simulation consisted of ~ 50 ps, which 
resulted in a translocation of the glutamate ligand a distance of ~ 30 Å from the 
active site of GR. 
Preparation of Docking Receptors. Twelve structures were selected from the 
SMD simulation at regular time intervals and active site entrance area was 
approximated by calculating the area of a plane defined by four points (the ɣ-
carbons of Pro41, Pro44, Pro146, and Pro150). Three structures were selected 
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from that subset to reflect three points, approximately equidistant, along the 
continuum of active site entrance areas. The structures correspond to the 
following distances between the centers of mass of the glutamate molecule and 
GR: 28.8, 43.7, and 46.7 Å, respectively. Structures were prepared for virtual 
docking by first deleting all water molecules, salt ions and the substrate, D-
glutamate. A simulation cell was centered on the catalytic cysteine residues, 
Cys74 and Cys185, and dimensions of the cell were adjusted for individual 
structures to encompass the entirety of the active site. The same preparation 
was used for docking to the crystal structure of RacE from B. subtilis (1ZUW, 
chain C). 
Virtual Docking of Known GR Ligands. Ligands were constructed and minimized 
in MOE v2009.10[68] and imported into YASARA for virtual docking. YASARA 
v9.11.9[56] employs AutoDock 4[58] in its docking functionality. AutoDock uses a 
Lamarckian genetic algorithm to sample ligand conformations and binding 
modes. The following general docking parameters were used: 25 independent 
docking runs, each with a total of 2.5 x 106 energy evaluations, a torsional 
degrees of freedom value of 8, grid point spacing was left at the default of 0.375 
Å, and the force field selected was AMBER03. Specific to the genetic algorithm, 
the following parameters were used: a population size of 150, 2.7 x 104 
generations, an elitism value of 1, a mutation rate of 0.02, and a crossover rate of 
0.8. Final poses were considered distinct if they varied by > 5 Å RMSD. 
AutoDock uses a semi-empirical free energy force field to predict free energies of 
binding which accounts for intermolecular and intramolecular energies, as well as 
charge-based desolvation. Calculated binding energies and corresponding 
binding constants, acquired from the docking output file, were applied to the 
FERM-SMD correction equation (see Results). All correlation datasets are fit to a 
semi-log equation and indicated R values represent the Spearman’s coefficient of 
rank correlation as calculated by GraphPad Prism v5.0. 
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Protein Solvation Energy Calculations. The protein solvation energy was 
calculated for each structure attained from the SMD simulation using the 
Poisson-Boltzmann method. In the Poisson-Boltzmann method, the calculated 
solvation energy is based on numerical solution of the differential Poisson 
equation (also called the finite difference method) and the solvent is represented 
as a continuum having a relatively high dielectric constant, while the protein and 
ligand may be viewed as point charges projected onto a grid in a low dielectric 
continuum. Structures were prepared by deleting all water molecules, salt ions 
and substrates. The internal dielectric was set to 25, which resulted in more 
consistent energy predictions between structures and was thus determined to be 
most representative for the highly-hydrophilic glutamate racemase active site. 
The overall trend in solvation energies over the span of the SMD was the same 
with an internal dielectric of 2 (Fig. B.8). The external dielectric was set to 78 and 
the salt concentration was set to 0.1 M. Solvation energies were reported in 
kcal/mol. 
 
Acknowledgements 
This work was supported by NIH AI076830 (M. A. S.). Special thanks to Dr. Keith 
Westcott for his contribution to the Keith R. Westcott Graduate Student Education Fund 
(K. L. W.). 
 
References  
[1] M. S. Head in Drug Design: Structure- and Ligand-based Approaches, Vol. 
(Eds.: K. M. Merz, Jr., D. Ringe and C. H. Reynolds), New York, NY, Cambridge 
University Press, 2010, pp. 98-119. 
[2] G. Bottegoni, I. Kufareva, M. Totrov and R. Abagyan, J. Med. Chem. 2009, 
52, 397-406. 
[3] H. Claussen, C. Buning, M. Rarey and T. Lengauer, J. Mol. Bio. 2001, 308, 
377-395. 
62 
[4] C. R. Corbeil, P. Englebienne and N. Moitessier, J. Chem. Inf. Model. 2007, 
47, 435-449. 
[5] I. W. Davis, K. Raha, M. S. Head and D. Baker, Protein Sci. 2009, 18, 1998-
2002. 
[6] R. M. Knegtel, I. D. Kuntz and C. M. Oshiro, J. Mol. Bio. 1997, 266, 424-440. 
[7] M. Mori, F. Manetti and M. Botta, J. Chem. Inf. Model. 2010, Articles ASAP,  
[8] G. L. Warren, C. W. Andrews, A. M. Capelli, B. Clarke, J. LaLonde, M. H. 
Lambert, M. Lindvall, N. Nevins, S. F. Semus, S. Senger, G. Tedesco, I. D. Wall, 
J. M. Woolven, C. E. Peishoff and M. S. Head, J. Med. Chem. 2006, 49, 5912-31. 
[9] M. R. Shirts, D. L. Mobley and S. P. Brown in Drug design : structure- and 
ligand-based approaches, Vol. 1 (Eds.: K. M. Merz, D. Ringe and C. H. 
Reynolds), Cambridge [U.K.] ; New York, Cambridge University Press, 2010, pp. 
61. 
[10] G. L. Warren, C. E. Peishoff and M. S. Head in Computational and structural 
approaches to drug discovery : ligand-protein interactions, Vol. 1 (Eds: R. Stroud 
and J. Finer-Moore), Cambridge, RSC Publishing, 2008, pp. 137-153. 
[11] W. L. Jorgensen, Acc. Chem. Res. 2009, 42, 724-733. 
[12] M. Clark, F. Guarnieri, I. Shkurko and J. Wiseman, J. Chem. Inf. Model. 
2006, 46, 231-242. 
[13] B. Roux, Comput. Phys. Commun. 1995, 91, 275-282. 
[14] S. Kumar, J. M. Rosenberg, D. Bouzida, R. H. Swendswn and P. A. Kollman, 
J. Comp. Chem. 1992, 13, 1011-1021. 
[15] C. R. W. Guimaraes and A. M. Mathiowetz, J. Chem. Inf. Model. 2010, 50, 
547-559. 
[16] E. Stjernschantz and C. Oostenbrink, Biophys. J. 2010, 98, 2682-2691. 
[17] B. Isralewitz, M. Gao and K. Schulten, Curr. Opin. Struct. Bio. 2001, 11, 224-
230. 
[18] H. Lu, B. Isralewitz, A. Krammar, V. Vogel and K. Schulten, Biophys. J. 
1998, 75, 662-671. 
63 
[19] P. E. Marszalek, H. Lu, H. Li, M. Carrion-Vazquez, A. F. Oberhauser, K. 
Schulten and J. M. Fernandez, Nature 1999, 402, 100-103. 
[20] E. Evans and K. Ritchie, Biophys. J. 1997, 72, 1541-1555. 
[21] M. E. Tanner, K. A. Gallo and J. R. Knowles, Biochemistry 1993, 32, 3998-
4006. 
[22] C. T. Walsh, J. Biol. Chem. 1989, 264, 2393-2396. 
[23] S. N. Ruzheinikov, M. A. Taal, S. E. Sedelnikova, P. J. Baker and D. W. 
Rice, Structure 2005, 13, 1707-13. 
[24] C. W. Koo and J. S. Blanchard, Biochemistry 1999, 38, 4416-22. 
[25] B. Pillai, M. M. Cherney, C. M. Diaper, A. Sutherland, J. S. Blanchard, J. C. 
Vederas and M. N. James, Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 8668-73. 
[26] M. A. Spies, J. G. Reese, D. Dodd, K. L. Pankow, S. R. Blanke and J. 
Baudry, J. Am. Chem. Soc. 2009, 131, 5274-5284. 
[27] A. Buschiazzo, M. Goytia, F. Schaeffer, W. Degrave, W. Shepard, C. 
Gregoire, N. Chamond, A. Cosson, A. Berneman, N. Coatnoan, P. M. Alzari and 
P. Minoprio, Proc. Natl. Acad. Sci. U. S. A. 2005, 103, 1705-1710. 
[28] T. Lundqvist, S. L. Fisher, G. Kern, R. H. Folmer, Y. Xue, D. T. Newton, T. A. 
Keating, R. A. Alm and B. L. de Jonge, Nature 2007, 447, 817-22. 
[29] K. L. Whalen, K. L. Pankow, S. R. Blanke and M. A. Spies, Med. Chem. Lett. 
2010, 8, 9-13. 
[30] B. Pillai, M. Cherney, C. M. Diaper, A. Sutherland, J. S. Blanchard, J. C. 
Vederas and M. N. G. James, Biochem. Biophys. Res. Commun. 2007, 363, 547-
553. 
[31] K. Y. Shatalin and A. A. Neyfakh, FEMS Microbiol. Lett. 2005, 245, 315-319. 
[32] A. de Dios, L. Prieto, J. A. Martin, A. Rubio, J. Ezquerra, M. Tebbe, B. Lopez 
de Uralde, J. Martin, A. Sanchez, D. L. LeTourneau, J. E. McGee, C. Boylan, T. 
R. Parr, Jr. and M. C. Smith, J. Med. Chem. 2002, 45, 4559-70. 
[33] G. S. Basarab, P. J. Hill, A. Rastagar and P. J. H. Webborn, Bioorg. 
Medicinal Chem. Lett. 2008, 18, 4716-4722. 
64 
[34] A. L. Hopkins, C. R. Groom and A. Alex, Drug Discovery Today 2004, 9, 
430-431. 
[35] R. O'Shea and H. E. Moser, J. Med. Chem. 2008, 51, 2891-2878. 
[36] G. Dannhardt and B. K. Kohl, Arch. Pharm. Pharm. Med. Chem. 2000, 333, 
123-129. 
[37] M. Mor, F. Bordi, C. Silva, S. Rivara, V. Zuliani, F. Vacondio, M. Rivara, E. 
Barocelli, S. Bertoni, V. Ballabeni, F. Magnanini, M. Impicciatore and P. V. Plazzi, 
Bioorg. Medicinal Chem. Lett. 2004, 12, 663-674. 
[38] M. Willson, J. J. Perie, F. Malecaze, F. Opperdoes and M. Callens, Eur. J. 
Med. Chem. 1992, 27, 799-808. 
[39] Z. Parashchin, Russ. J. Org. Chem. 1998, 34, 253. 
[40] P. Krogsgaard-Larsen, E. Falch, A. Schousboe, D. R. Curtis and D. Lodge, 
J. Neurochem. 1980, 34, 756-759. 
[41] A. R. Leach, B. K. Shoichet and C. E. Peishoff, J. Med. Chem. 2006, 49, 
5851-5855. 
[42] T. Steinbrecher and A. Labahn, Curr. Med. Chem. 2010, 17, 767-785. 
[43] D. A. Pearlman, J. Med. Chem. 2005, 48, 7796-7807. 
[44] H. Fujitani, Y. Tanida, M. Ito, M. R. Shirts, G. Jayachandran, C. D. Snow, E. 
J. Sorin and V. S. Pande, J. Chem. Phys. 2005, 123, 84-108. 
[45] C. F. Wong and J. A. McCammon, J. Am. Chem. Soc. 1986, 108, 3830-
3832. 
[46] B. Kuhn, P. Gerber, T. Schulz-Gasch and M. Stahl, J. Med. Chem. 2005, 48, 
4040-4048. 
[47] R. E. Amaro, R. Baron and J. A. McCammon, J. Comput. Aided Mol. Des. 
2008, 22, 693-705. 
[48] P. O'Donoghue and Z. Luthey-Schulten, J. Mol. Biol. 2005, 346, 875-894. 
[49] M. Totrov and R. Abagyan, Curr. Opin. Struct. Biol. 2008, 18, 178-184. 
[50] D. L. Mobley, A. P. Graves, J. D. Chodera, A. C. McReynolds, B. K. Shoichet 
and K. A. Dill, 2007, 371, 1118-1134. 
65 
[51] D. A. Pearlman in Free Energy Calculations in Rational Drug Design, Vol. 
(Eds.: M. Rami Reddy and M. D. Erion), New York, NY, Eds. Academic/Plenum, 
2001, pp. 9-33. 
[52] J. W.-H. Li and J. C. Vederas, Science 2009, 325, 161-165. 
[53] F. Colizzi, R. Perozzo, L. Scapozza, M. Recanatini and A. Cavalli, J. Am. 
Chem. Soc. 2010, 132, 7361-7371. 
[54] Y. Deng and B. Roux, J. Phys. Chem. B 2008, 113, 2234-2246. 
[55] J. Wang, Y. Deng and B. Roux, Biophys. J. 2006, 91, 2798-2814. 
[56] (2010). YASARA (9.11.9 9.11.9). Vienna, Austria, YASARA Biosciences 
GmbH. 
[57] A. Jakalian, D. B. Jack and C. I. Bayly, J. Comp. Chem. 2002, 23, 1623-
1641. 
[58] G. M. Morris, R. Huey, W. Lindstrom, M. F. Sanner, R. K. Belew, D. S. 
Goodsell and A. J. Olson, J. Comp. Chem. 2009, 30, 2785-2791. 
[59] CSAR: Community Structure-Activity Resource (2010), 
http://www.csardock.org/. 
[60] D. S. Radchenko, O. O. Grygorenko and I. V. Komarov, Tetrahedron: 
Asymmetry 2008, 19, 2924-2930. 
[61] R. Rej, Anal. Biochem. 1982, 119, 205-210. 
[62] W. D. Cornell, P. Cieplak, C. I. Bayly, I. R. Gould, K. M. Merz, Jr., D. M. 
Ferguson, D. C. Spellmeyer, T. Fox, J. Caldwell and P. A. Kollman, J. Am. 
Chem. Soc. 1995, 117, 5179-5197. 
[63] Y. Duan, C. Wu, S. Chowdhury, M. C. Lee, G. Xiong, W. Zhang, R. Yang, P. 
Cieplak, R. Luo, T. Lee, J. Caldwell, J. Wang and P. Kollman, J. Comput. Chem. 
2003, 24, 1999-2012. 
[64] U. Essmann, L. Perera, M. L. Berkowitz, T. Darden, H. Lee and L. G. 
Pedersen, J. Chem. Phys. 1995, 103, 8577-8593. 
[65] R. W. W. Hooft, G. Vriend, C. Sander and E. E. Abola, 1996, 381, 272. 
66 
[66] E. Krieger, J. E. Nielsen, C. A. E. M. Spronk and G. Vriend, J. Mol. Graph. 
Model. 2006, 25, 481-486. 
[67] S. Park and K. Schulten, J. Chem. Phys. 2004, 120, 5946-5961. 
[68] Molecular Operating Environment (2008.10 2008.10). Montreal, Quebec, 
Canada, Chemical Computing Group. 
 
 
 
 
 
 
 
 
 
 
 
Reprinted (adapted) with permission from Whalen, K. L.; Chau, A. C.; Spies, M. A. 
ChemMedChem, published online August 8th, 2013; DOI: 10.1002/cmdc.201300271. 
Copyright 2013 John Wiley and Sons.  A. C. Chau contributed in silico docking. M. A. Spies 
contributed intellectual direction. 
67 
 
CHAPTER 3: IN SILICO OPTIMIZATION OF A FRAGMENT-BASED HIT 
YIELDS BIOLOGICALLY ACTIVE, HIGH EFFICIENCY INHIBITORS FOR 
GLUTAMATE RACEMASE. 
 
Abstract 
  A novel lead compound for inhibition of the antibacterial drug target, 
glutamate racemase, is optimized for both ligand efficiency and lipophilic 
efficiency. A previously developed hybrid MD-docking and scoring scheme, 
FERM-SMD, is utilized to predict relative potencies of potential derivatives 
prior to chemical synthesis. This scheme was successful in distinguishing 
between high and low affinity binders with minimal experimental structural 
information, saving time and resources in the process.  In vitro potency is 
increased approximately 4-fold against glutamate racemase from the model 
organism, B. subtilis. Lead derivatives show 2- to 4-fold increased 
antimicrobial potency over the parent scaffold. In addition, specificity toward B. 
subtilis, over E. coli and S. aureus, show dependency on the chemical 
substituent added to the parent scaffold. Finally, insight is gained into the 
capacity for these compounds to reach the target enzyme in vivo using a 
bacterial cell wall lysis assay. The result of this study is a novel small 
molecule inhibitor of GR with the following characteristics: Ki = 2.5 μM, LE = 
0.45 kcal/mol/atom, LiPE = 6.0, MIC50 = 260 μg/mL against B. subtilis, 
EC50,lysis = 520 μg/mL against B. subtilis
Introduction 
In an era of increasingly prolific multi- and total-drug resistant species of 
bacteria such as E. coli, M. tuberculosis and S. aureus, the need for rapid 
discovery of novel antibiotic classes is greater than any previous time in 
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history. Compounding this problem is the pronounced dearth of both 
antimicrobial lead compounds as well as FDA-approved drugs emerging from 
the drug discovery enterprise, including both academia and industry[1]. An 
illuminating review by O'Shea and coworkers[2] reveals that no novel class of 
antibacterials was developed and approved between 1960 and 2001 despite 
exhaustive efforts and the parallel development of key techniques. Since the 
introduction of streptogramins and quinolones in the early 1960s, the growing 
need for antimicrobials has outpaced the rate of approval of novel drugs. 
Passage down the pipeline of drug discovery is complicated by the 
requirement that any antimicrobial target must be essential within a class of 
bacteria as well as non-essential or absent in humans; or possess significant 
structural distinction from any human homologues. Additionally, inhibitors 
must satisfy stringent physico-chemical requirements that ensure 
bioavailability, minimal toxicity, and efficacy. Recent reviews of the current 
state of affairs in drug discovery have revealed that lack of chemical diversity 
in HTS- and genomics-based drug discovery campaigns has been a 
significant culprit in the failure to obtain novel antimicrobial lead compounds[1, 
3].  
Bacteria require a number of D-amino acids for the biosynthesis of the 
peptidoglycan cell wall. It has been well established that improper 
peptidoglycan cross-linking is the basis for a number of known antimicrobial 
drugs, including the β-lactam class and vancomycins, which act to promote 
osmotic lysis[4].  In addition to preventing cross-linking itself, inhibiting 
enzymes that catalyze the formation of D-amino acids also leads to lysis due 
to high internal osmotic pressure. The two ubiquitous D-amino acids in 
bacterial cell walls are D-alanine and D-glutamate, which are biosynthesized 
by alanine and glutamate racemases, respectively. The natural product D-
cycloserine is a mechanism based inhibitor of alanine racemase, a PLP- 
containing enzyme, and has been shown to kill bacteria by making them 
osmotically sensitive[5]. Similar studies have also been carried out on 
glutamate racemase (abbrev. GR; EC 5.1.1.3) inhibitors, establishing a mode 
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of action involving damage to the maturation of the peptidoglycan cell wall[6]. 
Unlike AR, GR is a cofactor-independent racemase, which catalyzes a step-
wise proton abstraction/donation via two cysteines acting in a general 
acid/base mechanism[7]. The general α/β-fold forms two domains, which 
enclose a relatively small buried active site that is saturated with polar 
residues. Not surprisingly, GR knockout studies on several pathogenic 
organisms resulted in D-glutamate auxotrophs[8].  Thus, the strategy of 
attenuating the pool of D-amino acids is an attractive option for the 
development of novel antimicrobial agents. However, the only compound in 
this class that is approved for clinical use is the natural product D-cycloserine, 
and only in combination with other antibiotics, due to its undesirable side 
effects. 
 To date, only a handful of potent inhibitors have been discovered for 
bacterial glutamate racemases. A SAR approach produced a 4S-substituted 
D-glutamate analog, which had low-micromolar potency against glutamate 
racemase from S. pneumoniae, but suffered from species specificity due to 
steric clashing with a species-variable valine bridge to a hydrophobic pocket 
proximal to the binding cleft[9]. Later, a high-throughput screening campaign of 
nearly 400,000 compounds resulted in the serendipitous discovery of an 
uncompetitive inhibitor, which binds to a species-specific allosteric site[6]. 
More recently, a virtual screening campaign targeting a transition-state-like 
model of the target enzyme produced several low-micromolar, competitive 
inhibitors[10]. A trend in the molecular makeup of these inhibitors was clear: 
aromatic or cyclic compounds containing sulfonic acid moieties. This isn't 
surprising considering previous work that supports the presence of a cyclic 
carbanion/aci-dienolate transition in the glutamate racemase reaction, which 
places significant negative charge density in the back of the active site[11]. The 
superiority of these sulfonic acids over carboxylates (such as that in the 
natural substrate) could be due to the more dispersed partial negative charge 
in the sulfonate, compared to the SP2 hybridization of a carboxylate. Most 
recently, a unique ensemble docking scheme was applied to GR from B. 
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subtilis to successfully rank several sulfonate-containing aromatic compounds 
with potencies ranging from low micromolar to high millimolar[12]. The best of 
these compounds, 1H-benzimidazole-2-sulfonic acid (Ki = 9 μM) is the subject 
of this study. 
 We present here a fragment-based approach to optimization of the 
previously mentioned lead compound using entirely in silico methods for 
derivative ranking prior to synthesis and experimental testing. Fragment-
based methods offer a number of distinct advantages in drug discovery, 
particularly the optimization of ligand efficiency (LE) and lipophilic efficiency 
(LiPE) while maintaining potency[13]. Placement and subsequent scoring of 
potential derivative compounds was achieved via ensemble docking with a 
unique scoring scheme described in Whalen and coworkers.[12] In the current 
study, thirty-three derivatives of the lead compound were docked to an 
ensemble of conformations generated using steered molecular dynamics and 
ranked using a modified binding energy score. Six derivatives were 
synthesized and assayed experimentally, resulting in the discovery of two 
competitive inhibitors with increased inhibitory potency, as well as excellent 
ligand and lipophilic efficiencies. Additionally, compounds were assayed for 
bacterial growth inhibition as well as induction of cell wall lysis, ultimately 
establishing that this class of GR inhibitors targets bacterial cell wall synthesis 
in vivo. 
Results and Discussion 
BISA, a Scaffold for Optimization 
 Compound 1 (Figure 15, 4-hydroxy-1,3-benzenedisulfonic acid) was 
discovered in a virtual screening campaign against GR using the Chemical 
Computing Group Lead-like library (~1 million compounds)[10]. The inhibitory 
constant against GR from B. subtilis was 58 ± 13 µM. Scaffold hopping to 
compound 2 (Figure 15, 1H-benzimidazole-2-sulfonic acid) increases affinity 
against this target to 9 ± 2 µM. Compound 2 also shows equal potency 
against two isozymes of GR from B. anthracis (RacE1 and RacE2) as well as 
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GR from F. tularensis (MurI), two bacterial species currently considered as 
Tier 1 Biological Select Agents by the US government (Figure 12). The high 
ligand efficiency of this fragment, coupled with its cross-species activity made 
compound 2 an ideal candidate for optimization. 
 In order to generate a basis for rational lead optimization, a basic 
understanding of the physicochemical components of binding between ligand 
and receptor is required. As an alternative to x-ray crystallography or NMR, 
virtual docking was used to generate structural information regarding the 
interaction of GR and compound 2. Compound 2 was docked in silico to GR 
using a previously solved crystal structure (PDB: 1ZUW) as the receptor. The 
result of docking shows compound 2 with its sulfonic acid situated in the most 
buried region of the active site, between the catalytic cysteines (Figure 13). 
The sulfonate moiety is seen participating in several hydrogen bonding 
interactions with Asn75, Thr186, and Cys185. Additionally, the benzene 
moiety is interacting with Ser11 via an O-H--pi interaction. These moieties 
both appear to contribute to recognition of compound 2, and thus the 
optimization strategy focused on the addition of substituents that would 
produce additional interactions while preserving the original contacts. As seen 
by their solvent exposure and protein proximity (symbolized with light blue 
shading or a grey dotted line, respectively, in Figure 13), carbons 4, 5, and 6 
within the benzene ring could serve as starting points to build on additional 
chemical groups without encountering steric clash from active site residues. 
Depending on their size, substituents added at these positions have the 
capacity to reach additional binding pockets proximal to the main substrate 
binding cleft. 
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Figure 12. IC50 curves for the parent compound 2 against a range of GR 
isozymes isolated from the indicated bacterial species. Indicated IC50 values 
(in micromolar) acquired via fitting to a dose-response curve. 
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Figure 13. Top-ranked binding pose for compound 2 bound to GR from B. 
subtilis, as predicted by docking (a). Also, binging pose for compound 2 after 
4 nsec of MD simulation with explicit water (b). 
 
Derivative Selection and Synthesis 
An in silico library containing compounds 3 through 35 (Figure 15) was 
developed based on a previously established two-step synthetic process 
(Scheme 1) and the commercially-available 1,2-phenylenediamine derivatives. 
This synthetic scheme was chosen for its relative ease, while additional 
chemistry may be attempted in the future to further grow fragments out of the 
substrate-binding cleft. Before any compound was synthesized, the library 
was subjected to a hybrid ensemble docking scheme, referred to as the 
a)
b)
4
5
6
4
5
6
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Flexible Enzyme Receptor Method by Steered Molecular Dynamics (aka. 
FERM-SMD), previously described by Whalen and coworkers[12]. Figure 14 
details how unique conformations of the protein target were generated using 
steered molecular dynamics simulations to emulate the substrate unbinding 
trajectory. Starting with a crystal structure of D-glutamate bound to glutamate 
racemase, D-glutamate is pulled from the active site over the course of the 
simulation. In the process, the enzyme alters its structural conformation to 
allow substrate passage from the buried binding cleft. Three snapshots were 
chosen to represent three distinct structural states, distinguished by the 
entrance to the binding cleft: closed, partially open, and fully open (Figure 14). 
Compounds are docked to all three structures and their predicted binding 
affinities are adjusted according to the respective protein solvation energy 
(these varied greatly, and affected the accuracy of the binding affinity 
calculation) and weighted to indicate relative binding specificity to one of the 
three receptors. Previous studies have shown that the final score produced by 
FERM-SMD, deemed FERMscore, shares a high correlation with 
experimental binding affinities, particularly for congeneric ligands of GR. On a 
set of 17 ligands, FERM-SMD has a predictive accuracy of ± 1 kcal/mol[12]. 
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Figure 14. A steered molecular dynamics simulation was conducted on the 
glutamate-bound crystal structure of glutamate racemase from B. subtilis. A 
force was applied on the bound substrate along the vector indicated in the top 
picture (red arrow). Structures were obtained along the unbinding trajectory 
that correspond approximately to the following states: closed, partially open, 
and fully open. With substrate removed, these structures then provide the 
receptors for ensemble docking of the derivative library. Previous results 
indicate that the highest-affinity inhibitors will bind preferably to the closed 
conformation, over the partially and fully open conformations. 
FERMscores for the library of interest, spanning from 0.4 to 13.7, are 
indicated in Table 4. The parent compound, 2, scored the third highest 
FERMscore. The two compounds giving higher calculated FERMscores 
(compounds 18, and 29) in addition to a third compound, 4, that possessed a 
FERMscore in the top 15% of all derivatives were synthesized under contract 
by Enamine Ltd. (see Materials and Methods) and all compounds were 
heretofore synthetically novel. In addition to the compounds predicted to have 
improved binding affinity, three immediately available compounds (15, 24, and 
26) were acquired to test the predictive capacity of the employed scoring 
method. Compound 7 had an intermediate FERMscore, but distinct 
chemotype, which had not been heretofore tested on any GR and was thusly 
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chosen for testing. Unfortunately, several attempts to synthesize compound 7 
were unsuccessful, and it was eventually abandoned. The experimental 
results are detailed below. 
 
Scheme 1. Scheme for synthesis of 1H-benzimidazole-2-sulfonic acid 
derivatives using differing phenylenediamine starting points. 
 
In vitro Testing of Derivatives  
 Inhibition constants (Ki) were acquired for all derivatives against purified 
GR from B. subtilis (Figure 16, Table 5). Compounds 15, 24 and 26, all 
possessing predicted FERMscores lower than the parent compound, gave Ki 
values greater than or within error of that of the parent compound. Compound 
24 suffered from a nearly 100-fold loss in binding affinity, which was well 
predicted by FERM-SMD, as it possessed the lowest FERMscore of the 
compounds tested. Of the compounds predicted to be higher affinity binders 
by FERMscore, compound 18 and 29 have Ki values within error of the parent 
compound, although the Ki of 29 is improved, 6.4 μM versus 9 μM. This result 
was not surprising considering the FERMscores only vary by 5.4 units 
between the parent scaffold and the highest scoring derivative. Compound 4 
is also predicted to be high affinity, and shows 4-fold improved affinity over 
the parent compound, with a Ki of 2.5 μM. This is the most potent non-
glutamate-based, competitive inhibitor of glutamate racemase to date. Overall, 
FERM-SMD was successful in distinguishing between tight binding derivatives 
(Ki between 2.5 to 12 μM) and weaker binding derivatives (Ki between 13 and 
830 μM). 
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Figure 15. Parent scaffolds and lead derivatives considered in this study. 
Compounds of interest are highlighted accordingly: lavender = original virtual 
screening hit; cyan = parent scaffold; green = compounds tested with high 
predicted affinity; red = compounds tested with low predicted affinity; yellow = 
compound synthesis attempted, yet unsuccessful.
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Table 4. FERMscore assignments as predicted by FERM-SMD, ranked from highest to lowest 
score, corresponding to highest to lowest predicted binding affinity. 
Compound
 [a]
 FERMscore Compound FERMscore 
29 13.7 26 1.20 
18 9.25 7 1.15 
2 8.28 6 1.10 
5 4.92 23 1.03 
4 4.45 15 0.969 
34 3.75 20 0.902 
14 3.23 33 0.792 
13 2.99 16 0.781 
12 2.98 32 0.756 
9 2.97 28 0.756 
8 2.33 35 0.751 
22 1.76 25 0.750 
17 1.64 3 0.732 
21 1.44 10 0.723 
11 1.31 24 0.643 
19 1.29 31 0.534 
30 1.28 27 0.406 
[a] Compounds of interest are highlighted accordingly: green = compounds tested with high 
predicted affinity; cyan = parent scaffold; red = compounds tested with low predicted affinity; 
yellow = compound synthesis attempted, yet unsuccessful.  
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Figure 16. In vitro inhibition data used to acquire Ki values for each derivative. 
 
Ligand efficiency and lipophilic efficiency were calculated for each 
derivative (Table 5). Ligand efficiency is a method of normalizing binding 
affinities for compounds of differing molecular weights[14]. Additionally, several 
studies have shown that fragment-based drug discovery is more successful if 
high ligand-efficiency is maintained through lead optimization[14]. This practice 
lowers the occurrence of so-called "molecular obesity" as compounds are 
modified to achieve higher potency and favorable 
pharmacokinetic/pharmacodynamic profiles[14b]. With the exception of 
compound 15, each assayed derivative maintained high ligand efficiency ( > 
0.3 kcal/mol/atom). Of the compounds predicted to be high affinity by the 
FERM-SMD method, compound 4 and 29 exhibited higher efficiency than 
compound 18 (0.45, 0.34 and 0.30, respectively). Lipophilic efficiency is 
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another measure that is indicative of successful passage down the drug 
development pipeline, where affinity values are normalized for the partition 
coefficient (logP) of the inhibitor[15]. Compound 4 and 29 benefit from an 
improved lipophilic efficiency (6.0 and 6.6, respectively) over the parent 
scaffold (5.3). Ligand efficiency and lipophilicity efficiency values equal to or 
greater than 0.3 kcal/mol/atom and 6.0, respectively, are in the desirable 
range for further study and optimization[14a, 15].  
Additionally, novel compounds were tested for formation of colloidal 
aggregates, a common cause of false positive results. Previous studies have 
revealed that glutamate racemase is susceptible to inhibition by colloidal 
aggregates in a non-drug-like fashion. In order to distinguish between 
inhibition via colloidal aggregation and true binding, enzyme activity is 
measured in the presence of the inhibitor in question, as well as a sub-
micellular concentration of detergent, 0.01% Triton X-100. In the case that a 
compound is inhibiting an enzyme via a colloidal aggregation, the apparent 
inhibition will be completely relieved in the presence of detergent. Colloidal 
aggregates must be abandoned due to their non-drug-like mechanism. All 
novel compounds tested in this study proved not to operate via the colloidal 
aggregate mechanism (Figure C.10). 
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In vivo Testing of Biological Activity 
In order to assess the capacity of these compounds to reach the enzyme 
target in vivo, inhibition of bacterial growth as well as capacity to induce cell 
lysis was assayed with several species of bacteria. B. subtilis was 
investigated, as the isozyme of GR from this species was the model for all in 
silico predictions. Additionally, E. coli and S. aureus were investigated as 
each provides a unique challenge for inhibitor compounds: an additional 
physical barrier to entry in the case of Gram-negative E. coli and an 
abundance of efflux pumps in the case of S. aureus[16]. All tested derivatives 
of compound 2 show increased potency with regards to growth inhibition for B. 
subtilis (Figure 17). MIC50 values are increased 2- to 3-fold over the parent 
scaffold (Table 6). Surprisingly, the least potent compound in vitro, 24, shows 
the greatest potency in vivo. This result suggests that factors other than 
Table 5.  In vitro results for derivatives of the parent scaffold, 2. 
Compound Ki (uM) LE[a] LiPE[b] 
2 9.0 ± 2.0 0.53 5.3 
4 2.5 ± 0.4 0.45 6.0 
15 21 ± 5.0 0.46 4.4 
18 12 ± 3.6 0.30 5.0 
24 830 ± 75 0.20 1.9 
26 13 ± 2.4 0.48 4.5 
29 6.4 ± 3.5 0.34 6.6 
[a]  Ligand efficiencies (LE) determined by converting Ki values to binding 
energies and dividing by the number of non-hydrogen atoms. Units = 
kcal/mol/atom. [b]  Lipophilic efficiences (LiPE) determined by subtracting 
logP values from the log(Ki) for each compound. 
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enzyme binding affinity may complicate the overall efficacy of this chemotype 
of antimicrobial compounds.  
Compounds 4, 18, and 29 were also tested against E. coli and S. aureus 
(Figure 18). Compounds 18 and 29 were both highly specific for B. subtilis, 
showing no significant growth inhibition at concentrations below 3 mg/mL for 
E. coli and S. aureus (Table 6). On the contrary, compound 4 shows growth 
inhibition of both E. coli and S. aureus at concentrations approximately 2-fold 
higher than the MIC50 against B. subtilis (Table 6). Examination of their 
respective chemical structures yields one possible rationale for this distinction 
(see Figure 15 for structures). Compound 4 possesses a more compact 
chemical shape, most likely making contacts specific to the most buried, and 
most highly conserved, region of the GR active site. Whereas compounds 18 
and 29 contain larger chemical additions to the benzene ring, which may 
clash with the outer region of the GR active site, which is more structurally 
diverse region. These in vitro (and in silico) results support the fragment-
based strategy of growing the scaffold out of the highly buried active site 
without sacrificing the original contacts. 
In order to hone in on the mechanism of action for the derivatives assayed in 
this study, a commercially-available cytotoxicity assay, CytoTox-GloTM 
(Promega), marketed for use with mammalian cells, was adapted for use with 
the examined bacterial species. The relationship between cytotoxicity, 
specifically cell lysis, and the readout (luminescence) is outlined in Figure 19. 
If the compounds here reach the glutamate racemase target and inhibit the 
production of D-glutamate, the lack of this key component will result in an 
overall break-down in peptidoglycan synthesis, and subsequent cell lysis 
caused by osmotic stress. Lysed cells will leak intracellular proteases into the 
surrounding media. The CytoTox-GloTM reagent is composed of a pro-luciferin 
substrate, that once cleaved by proteases, can be acted upon by a supplied 
luciferase to produce the luminescent readout. Controls using FDA-approved 
antibiotics with known mechanisms of action were conducted to optimize the 
provided reagents (Figure 20a). S. aureus was exposed to varying 
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concentrations of ampicillin (a transpeptidase inhibitor) or tetracycline (a 
microbial ribosome inhibitor) for 24 hours, and then incubated with the 
CytoTox-GloTM reagent. As expected, ampicillin yields a dose-dependent 
increase in luminescence , while tetracycline elicits no increase in 
luminescence at concentrations up to 100-times the published MIC50 (Figure 
20a). This optimized assay was then applied to cells treated with our inhibitor 
derivatives. 
 
Figure 17. MIC50 curves for the parent scaffold and the two most potent 
derivatives against Bacillus subtilis. 
Table 6.   MIC50
[a] values for tested derivatives. 
Compound B. subtilis E. coli S. aureus 
2 0.72 ± 0.06 - - 
4 0.26 ± 0.11 1.6 ± 0.20  1.0 ± 0.25 
15 > 3 - - 
18 0.36 ± 0.02 > 3 > 3 
24 0.14 ± 0.02 - - 
26 > 3 - - 
29 0.32 ± 0.01 > 3 > 3 
[a]  in mg/mL 
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Figure 18. MIC50 curves for highest-ranked derivatives, by FERMscore, 
comparing species specificity between E. coli, B. subtilis, and S. aureus. 
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 The modified CytoTox-GloTM assay confirmed 4 as acting via an 
inhibitory mechanism that effects the peptidoglycan with both S. aureus and B. 
subtilis (Figure 20b). Luminescence increases concurrently with increased 
dosing of compound 4 for S. aureus. While the assayed concentrations do not 
span the entire MIC50, due to solubility limitations, an approximately 40% 
increase in luminescence was observed in the millimolar range of inhibitor. 
For B. subtilis, the species for which compound 4 elicits greater growth 
inhibition, we observe a dose-dependent increase of 400% in luminescence in 
the low-millimolar range. The observed EC50 for lysis occurs at 520 μg/mL, a  
concentration only slightly above that of the MIC50 for growth inhibition (260 
μg/mL). The proximity of these two values is supportive of cell lysis as being 
the main cause of cell death. Considering the many barriers an antibacterial 
compound must overcome, both physical (peptidoglycan and efflux) and 
chemical (metabolism), in order to reach the desired target protein, the ability 
of compound 4 to cause cell lysis is excellent support for its further 
development as an antibacterial therapeutic. 
 
Figure 19. Schematic of treatment of bacterial cells with CytoTox-GloTM assay. 
The CytoTox-GloTM reagent contains both the protease substrate, AAF-
luciferin, as well as luciferase. Bacterial cells contain intracellular enzymes 
capable of cleaving AAF-luciferin, releasing luciferin, the substrate of 
luciferase. 
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Figure 20. Controls for a commercially-available cytotoxicity assay that 
monitors cell wall lysis with a luminescent readout (a). Bacteria treated with 
two antibiotics, only one utilizing a mechanism of action that interferes with 
peptidoglycan synthesis, shows distinct luminescent dose responses. Cell 
lysis data for S aureus and B. subtilis cultures treated for 24 hours with 
compound 4 (b). Luminescence is measured in arbitrary units, corrected for 
the cell density of the sample (variable depending on growth inhibition), and 
presented as a percentage of untreated cell luminescence. 
Conclusion 
This study summarizes the successful utilization of a novel in silico docking 
and scoring scheme for selection of derivatives of a lead scaffold via rank-
ordering of binding affinity. The model system used here employs the 
antibacterial target, glutamate racemase, and a low-micromolar competitive 
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inhibitor, 1H-benzimidazole-2-sulfonic acid (compound 2), as the lead 
compound. This platform can potentially be used for optimization of lead 
compounds for other flexible drug targets. In current lead optimization 
campaigns, the rate-limiting step is often acquisition of high-resolution 
structural data, particularly for flexible enzymes, on the enzyme-drug complex. 
Binding pose predictions made by docking software have been largely 
validated as correct in many cases via comparison with experimental data, 
specifically several programs place ligands within 2 Å RMSD of the 
crystallographically determined pose for over 90% of the assessed ligands[17]. 
The perennial problem lies in the ability of the scoring functions to accurately 
rank-order docked ligands across a variety of targets[17]. By developing an in 
silico method of derivative ranking based on the docked complex of the parent 
scaffold with a predictive error of only  ± 1 kcal/mol for binding energy, we can 
remove the need for time- and resource-consuming NMR or x-ray 
crystallography experiments. Additionally, the ability to predict the binding 
potency of potential derivatives, renders the chemical synthesis of weak 
binders unnecessary. Here we show that the described scheme guides 
optimization of a lead compound, with a minimized resource and time 
investment.  
The goal of this exercise was to modify the existing chemical scaffold in 
order to increase binding affinity to the target enzyme, while also maintaining 
favorable physicochemical properties (here, ligand efficiency and lipophilic 
efficiency) and biological activity. A docked complex of compound 2 and 
glutamate racemase was used to assess the most optimal locations for 
substituent addition. Based on that analysis, a library of 33 derivatives of 
compound 2 were subjected to a hybrid ensemble docking scheme, FERM-
SMD, in order to rank their potential binding potencies. Of the 33 derivatives, 
6 compounds were tested experimentally producing the final selection of 
compound 4. Compound 4 has increased binding affinity for the purified 
enzyme: 2.5 μM versus 9 μM, high ligand efficiency:  0.45 kcal/mol/atom, high 
lipohilic efficiency: 6.0, increased growth inhibition of B. subtilis:  MIC50 = 260 
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μg/mL versus 720 μg/mL, and finally, effective bacterial cell lysis: EC50,lysis = 
520 μg/mL. The FERM-SMD methodology has afforded a facile optimization 
from a high-LE hit with relatively low synthetic cost by precisely identify 
binding rank-ordering. Future studies will focus these techniques on 
increasingly more complex derivative libraries, in order to achieve even 
greater in vitro and biological activity. 
Experimental Section 
Docking and FERM-SMD: Virtual Screening 
 
 The original FERM-SMD method is described in great detail by Whalen 
and coworkers[12]  BISA derivatives were prepared in silico using MOE 
v2011.10[18] (Chemical Computing Group). An ensemble of GR structures was 
generated using steered molecular dynamics simulation. Three structures 
were chosen at approximately the most closed (corresponding to 0 ps of 
simulation time), partially open (13.9 ps, simulation time), and fully open (20 
ps, simulation time). Docking to the ensemble of GR structures was achieved 
using YASARA v9.11.9[19], which utilizes an optimized version of AutoDock 
4[20]. Simulation cells were centered around the active site and expanded to 
include the residues surrounding the cleft entrance. Simulations cells had the 
following dimensions (in Å): "0 ps" receptor = 18.75 x 20.19 x 19.29; "13.9 ps" 
receptor = 19.08 x 21.56 x 18.07; and "20 ps" receptor = 18.94 x 21.31 x 
18.93. Receptor-ligand docking combinations that resulted in more than one 
high-ranking pose were visually assessed by the author, and the pose that 
placed the core scaffold in a position most similar to the parent scaffold 
position was chosen as the "true" pose. Resulting binding energies and 
affinities for docking to all three receptors were then imported into Excel 
(Microsoft Office) and adjusted for receptor-protein solvation, producing a final 
FERMscore[12]. 
 
Compound Synthesis and Acquisition 
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 Compound 1 (catalog #BAS 00124393, >98% purity) was acquired from 
Asinex, Ltd. (Moscow, Russia). Compounds 2 (catalog # 530646, 98% purity) 
was acquired from Sigma-Aldrich (St. Louis, MO, USA). Compound 15 
(catalog # 5648649, 100% purity) was acquired from ChemBridge Corp. (San 
Diego, CA, USA). Compound 24 (catalog # STK695918, 98% purity) was 
acquired from Vitas-M Laboratories, Ltd. (Moscow, Russia). Compound 26 
(catalog # Z57080960, 95% purity) was acquired from Enamine Ltd. (Kiev, 
Ukraine). Compounds 4, 18, and 29 were synthesized for the first time in 
published literature by collaborators at Enamine Ltd. (Kiev, Ukraine) following 
the synthetic process outlined in Scheme 1. 1H NMR spectra for each 
synthesized compound is provided in the Supplemental Information (Figures 
C.3-C.5). HPLC data showing purity analysis is available in the Supplemental 
Information for each newly synthesized compound (Figures C.6-C.8) 
 
  
Protein Expression and Purification 
  
 Genes of glutamate racemase were isolated from B. subtilis, B. 
anthracis (two isozymes), and F. tularensis, and expressed in E. coli and 
purified using a protocol previously described by Whalen and coworkers[12] 
Briefly, hexa-histidine-tagged recombinant proteins were purified via a two-
step process composed of cobalt-affinity (His-Select Affinity Resin, Sigma-
Aldrich) and anion exchange (UNO Q Continuous Bed column, BioRad). 
Proteins were stored in buffer containing 100 mM NaCl, 50 mM Tris, 0.2 mM 
DTT, pH 8.0 at a concentration of 7-10 mg/mL. Molecular weight was 
confirmed via SDS-PAGE analysis (Figure C.1), and protein foldedness was 
assessed using circular dichroism (Figure C.2). 
  
In Vitro Inhibition of Enzyme Activity 
 
 Steady-state kinetics for D to L racemization was measured using circular 
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dicroism on a JASCO J-715 Spectropolarimeter. All compound stocks were 
made up in 50 mM potassium borate buffer pH 8.0, at concentrations varying 
from 25-100 mM, depending on compound solubility. Reactions were carried 
out at 25°C in 50 mM potassium borate buffer pH 8.0 with 1 μM purified 
enzyme. CD signal (mdeg) was measured continuously at 220nm for 10 min. 
Plots of CD versus time were fit linearly to obtain initial velocity. Substrate was 
varied from 0.25 to 5 mM. For Ki determination, three Michaelis-Menten 
curves were obtained for each inhibitor: one in the presence of no inhibitor, 
and two in varying concentrations of the inhibitor. A single data set, composed 
of three curves, was fit to a competitive inhibition model using GraphPad 
Prizm v.5.0[21], and the Ki is obtained as a best-fit value. For IC50 
determination, reactions are supplemented with varying concentrations of the 
inhibitor, and the observed V0 in nmol/sec is normalized to a %-activity value 
based on an uninhibited reation. %-Activity values are plot versus the log of 
the inhibitor concentration. The data set is then fit to a log[inhibitor] versus 
response model (with variable slope) to calculate the IC50, using GraphPad 
Prizm v.5.0[21]. For LiPE calculations, compound logP values for the ionic 
species were calculated using MarvinSketch (ChemAxon). 
 
In Vivo Inhibition of Bacterial Growth 
 
 A 5 mL culture of bacteria (B. subtilis DB104, E. coli Acella, or S. aureus 
ATCC 12600) was incubated overnight at 37 ºC in Tryptic Soy Broth one day 
prior to the assay. 96-well plates were prepared with 2X media, phosphate-
buffered saline, the compound of interest and a 20 uL inoculum of bacteria, 
totally 200 uL per well. Compound stocks were prepared in phosphate-
buffered saline at a concentration of 10, 12.5 or 25 mM, depending on 
compound solubility. A serial dilution ranging from 0.1 to 3000 micromolar for 
the compound of interest was assayed. The overnight culture, at an optical 
density of approximately 2.0, was diluted 20-fold in water prior to inoculation, 
such that initial optical densities were approximately 0.01. A table of reagent 
volumes and diagram of plate layout can be found in Figure C.9 of the 
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Supplemental Information. Plates were mixed and incubated at 37 ºC for 24 hr. 
Absorbance at 600 nm was measured on a GloMax-Mutli Detection System. 
MIC50 values were determined by fitting data to a log[inhibitor] versus 
response model using GraphPad Prism v.5.0[21]. The bottom and top values 
are constrained to 20% and 100%, respectively. 
 
Cell Wall Lysis Assay 
 
 Bacterial cell wall lysis was assayed using a modification of the CytoTox-
Glo assay[22] (Promega Corp.). 100 µL of the contents of a 96-well plate 
treated as described above were moved to a white, round-bottom, 96-well 
plate. 25  µL of the CytoTox-Glo reagent buffer was added to each well, mixed 
and incubated at room temperature in the dark for 15 min. Luminescence was 
measured on a GloMax-Multi Detection System. Luminescent values were 
normalized based on the absorbance value at 600 nm for each respective well. 
Data was then fit to a log[agonist] versus response model, with no upper or 
lower constraints, using GraphPad Prism v5.0[21]. 
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CHAPTER 4: FLOODING ENZYMES: QUANTIFYING THE CONTRIBUTIONS 
OF INTERSTITIAL WATER AND CAVITY SHAPE TO LIGAND BINDING 
USING EXTENDED LINEAR RESPONSE FREE ENERGY CALCULATIONS* 
 
 
ABSTRACT: Glutamate racemase (GR) is a cofactor independent amino acid 
racemase that has recently garnered increasing attention as an antimicrobial 
drug target. There are numerous high resolution crystal structures of GR, yet 
these are invariably bound to either D-glutamate or very weakly bound oxygen-
based salts. Recent in silico screens have identified a number of new competitive 
inhibitor scaffolds, which are not based on D-Glu, but exploit many of the same 
hydrogen bond donor positions. In silico studies on 1-H-benzimidazole-2-sulfonic 
acid (BISA) show that the sulfonic acid points to the back of the GR active site, in 
the most buried region, analogous to the C2-carboxylate binding position in the 
GR-D-glutamate complex. Furthermore, BISA has been shown to be the 
strongest non-amino acid competitive inhibitor. Previously published 
computational studies have suggested that a portion of this binding strength 
derives from complexation with a more closed active site, relative to weaker 
ligands, and in which the internal water network is more isolated from bulk 
solvent. In order to validate key contacts between the buried sulfonate moiety of 
BISA and moieties in back of the enzyme active site, as well as to probe the 
energetic importance of the potentially large number of interstitial waters 
contacted by the BISA scaffold, we have designed several mutants of Asn75. 
GR-N75A removes a key hydrogen bond donor to the sulfonate of BISA, but also 
serves to introduce an additional interstitial water, due to the newly created 
space of the mutation. GR- N75L should also show the loss of a hydrogen bond 
donor to the sulfonate of BISA, but does not (a priori) seem to permit an 
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additional interstitial water contact.  In order to investigate the dynamics, 
structure and energies of this water-mediated complexation, we have employed 
the Extended Linear Response (ELR) approach for the calculation of binding free 
energies to GR, using the YASARA2 knowledge based force field on a set of ten 
GR complexes, and yielding an R-squared value of 0.85 and a RMSE of 2.0 
kJ/mol. Surprisingly, the inhibitor set produces a uniformly large interstitial water 
contribution to the electrostatic interaction energy (     ), ranging from 30 to > 
50%, except for the natural substrate (D-glutamate), which has only a 7% 
contribution of       from water. The broader implications for predicting and 
exploiting significant interstitial water contacts in ligand-enzyme complexation are 
discussed. 
1. INTRODUCTION 
  Numerous studies have established the bacterial cell wall and the 
enzymes responsible for its construction as valid targets for broad-spectrum 
antibiotics.1, 2 An essential enzyme in this class, which has not been targeted by 
antibiotics, is glutamate racemase (GR), which produces D-glutamate, an 
essential molecule for a number of pathogenic bacterial species. GR is a 
member of a family of co-factor-independent racemases and epimerases, which 
employs 1:1-proton transfer using juxtaposed thiol/thiolate general acid-bases 
and hydrogen-bonding to the Cα-carboxylate. Previously, GR knockouts have 
resulted in D-glutamate auxotrophs, validating the essentiality of GR.3, 4 
Structure-based,5 HTS,6 and QSAR7 approaches to obtaining active site 
competitive inhibitors have been problematic for disparate reasons, including 
flexibility of the enzyme and the inconsistent presence of a hydrophobic pocket 
proximal to the active site from species to species. Thus, it is highly desirable to 
obtain effective inhibitory scaffolds against GR, which have favorable drug-like 
physico-chemical properties. A greater understanding of the physical 
determinants of molecular recognition is the key to directing future efforts.   
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 The essential and conserved active site residues of GR-ligand recognition 
have been well established, especially for D-glutamate, by a number of methods, 
including: sequence conservation,8 mutagenesis studies,8-10 co-crystal 
structures,5, 6, 11-16 and computational studies.9, 17 These residues include (using 
B. subtilis numbering): Asp10, Ser11, Cys74, Asn75, Thr76, Cys185, His187 and 
Thr186; where Cys74 and Cys185 act as the general acid/base for racemization. 
Asn75 is in a unique position, forming the back “wall” of the active site directly 
between the catalytic cysteines - a central location for forming strong hydrogen 
bonds with the Cα-carboxylate of D-glutamate, as well as contributing to active 
site volume. Previous computational studies have indicated that its amide 
functional group is a major source of electrostatic interaction energy with the 
glutamate carbanionic transition state.9 MD simulations in the current study also 
implicate the amide functional group of Asn75 as being a hydrogen bond donor 
to the Cα-carboxylate of D-glutamate. However, computational studies with a 
number of other active site ligands indicate that Asn75 is part of a network of 
interstitial waters, which are associated with charged and polar inhibitors in the 
active site of GR. This network also involves the conserved residues Thr76 and 
Thr118. Thus, based on its total sequence conservation, and its role in ligand 
recognition, Asn75 is the most important residue of GR that has, heretofore, not 
been subjected to a mutagenesis investigation. In the current study we create the 
N75A and N75L mutants, both in vitro and in silico, in order to understand the 
importance of the amide functional group in both recognizing the native 
substrate, as well as several of the most efficient competitive inhibitors.   
 In addition to the Asn75, another major contributor to ligand-binding 
energy in GR is interstitial water, which was also identified as a major source of 
transition state stabilization.9 It is not surprising that the water-mediated contacts 
in GR are highly ligand dependent. A number of recent studies in other enzymes 
have indicated that water networks and interstitial water structure greatly depend 
on the particular nature of the enzyme-ligand contacts.18-21 
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 An examination of GR crystal structures deposited in the RCSB Protein 
Data Bank reveals a heterogeneity in the location and number of the crystal-
water oxygen atoms, which, in part, correlates to the type of ligand in the 
complex (Table 7). The scope of crystallographic data for GR-ligand complexes 
is limited to essentially D-Glu (and D-Glu analogs) and negatively charged 
oxygen-based buffers (acetate, citrate, phosphate, succinate, sulfate, and 
tartrate). A histogram comparing the numbers of interstitial waters between the 
former and the latter is illustrated in Figure 21. It is clear from the juxtaposition of 
these histograms that a variety of water-mediated GR-ligand contacts are 
possible. Unfortunately, although a number of recent competitive inhibitors for 
GR have been discovered, there remains a dearth of structural data, especially 
regarding tight binding complexes in the buried active site.  
 Previously, two attractive micromolar competitive inhibitors of GR from B. 
subtilis were identified. These compounds are1H-benzimidazole-2-sulfonic acid 
(1, Ki = 9 μM)
22 and croconic acid (2, Ki = 42 μM).
23 Both compounds possess 
high ligand-efficiency, making them potentially attractive scaffolds for lead 
optimization. However, the source of the strength of their binding energy (as well 
as the lack of binding energy in many other negatively charged competitive 
inhibitors) remains elusive. The current work integrates experimental studies on 
wild-type GR and the Asn75 mutants with computational studies, in order to 
parse the contributions to binding free energies for a number of different classes 
of competitive GR inhibitors, using the Extended Linear Response (ELR) method. 
The findings from these studies point to a stark difference in the use of water-
mediated ligand contacts between the natural substrate (D-Glu) and the set of 
non-congeneric inhibitors. The extent of these differences and the implications 
for future drug design against GR are discussed below.  
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Table 7. Analysis of all deposited GR co-crystal structures from the RCSB PDB. Number 
of interstitial waters indicated per monomer for each structure. 
PDB Species Ligand 
Monomer 
A 
Monomer 
B 
Monomer 
C 
Monomer 
D 
1B74 A. pyrophilus D-glutamine 1 - - - 
1ZUW B. subtilis D-glutamate 1 1 1 - 
2DWU B. anthracis 1 D-glutamate 1 2 2 - 
2GZM B. anthracis 2 D-glutamate 0 1 0 1 
2JFN E. coli D-glutamate 1 - - - 
2JFO E. faecalis D-glutamate 0 1 - - 
2JFP E. faecalis D-glutamate 1 1 - - 
2JFQ S. aureus D-glutamate 1 2 - - 
2JFU E. faecium phosphate ions 2 - - - 
2JFV E. faecium citrate 2 - - - 
2JFW E. faecium tartaric acid 4 - - - 
2JFX H. pylori D-glutamate 1 1 - - 
2JFY H. pylori D-glutamate 1 2 - - 
2JFZ H. pylori D-glutamate 2 1 - - 
2OHO S. pyogenes sulfate ion 0 3 - - 
2OHV S. pyogenes 
naphthylmethyl-
D-glu 
1 - - - 
2VVT E. faecalis D-glutamate 1 1 - - 
2W4I H. pylori D-glutamate 2 1 2 1 
3IST L. monocyto. succinic acid 2 2 - - 
3ISV L. monocyto. acetate ion 0 - - - 
3OUT F. tularensis D-glutamate 2 2 2 - 
3UHF C. jejuni D-glutamate 1 1 - - 
3UHO C. jejuni D-glutamate 1 1 - - 
4B1F H. pylori D-glutamate 2 2 - - 
*Structures were downloaded directly from the RCSB PDB and hydrogen atoms 
were added using the "Clean All" function of YASARA v9.11.9. All non-hydrogen 
atoms were fixed, and an energy minimization was performed to relax hydrogen 
atoms. Interstitial waters are defined as a single water molecule forming at least 
two hydrogen bonds: one with the bound ligand and one with the enzyme. 
Monomer labeling is arbitrary and does not correspond to PDB labeling. 
δSeveral deposited structures are unliganded and have been excluded from this 
analysis. Their PDB ID numbers correspond to 1B73, 3HFR, and 3UHP. 
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Figure 21. Frequency of interstitial waters in GR co-crystal structures. Results 
are separated by the indicated nature of the bound ligand. Each monomer in a 
particular crystal structure (where some contain dimers or trimers) is considered 
a single datum.  
 
  
2. MATERIALS AND METHODS 
2.1. Materials  
 Croconic acid  (LT00453399) was purchased from Labotest (Bremen, 
Germany).  From Sigma Aldrich (St. Louis, MO) we obtained the following: 1H-
benzimidazole-2-sulfonic acid (530646), D-glutamate (G1001), 
iodonitrotetrazolium (I8377), diaphorase (D5540), ATP (A7699), NAD+ (N7004), 
and L-glutamate dehydrogenase (G2501). All reagents related to buffer 
preparation for protein purification and circular dichroism were purchased from 
Sigma-Aldrich. Amicon centrifugal filtration devices were purchased from 
Millipore (Billerica, MA). Finally, HIS-Select Cobalt Affinity Gel (H8162) was 
0 1 2 3 4
0
20
40
60
80
Dglu-ligands
non-Dglu-ligands*
*non-Dglu-ligands include:
acetate, citrate, phosphate,
succinate, sulfate, and
tartrate.
# of interstitial waters
%
 o
f 
a
ll
 c
ry
s
ta
l 
s
tr
u
c
tu
re
m
o
n
o
m
e
rs
100 
 
purchased from Sigma-Aldrich. 
 
2.2. Experimental Methods 
2.2.1. Protein Expression and Purification 
 Recombinant protein was expressed in E. coli BL21 (DE3) cells containing 
a pET-15b plasmid with the N-terminal 6X-His-tagged gene of choice. Protein 
purification was achieved via cobalt-affinity chromatography followed by anion 
exchange chromatography. Details of both the expression and purification 
scheme were previously described by Whalen et al.24  
 
2.2.2. Mutant Construction 
 Mutant racE_N75A and racE_N75L were prepared using a QuickChange 
II XL Site-Directed Mutagenesis Kit (Stratagene, Santa Clara, CA) and primers 
obtained from Eurofins MWG Operon (Huntsville, AL). See Supplementary 
Information Table D.1 for primer sequences. Previously prepared and recently 
isolated pET15b containing the gene of interest was used as the template DNA. 
A BioRad MJ Mini Personal Thermal Cycler (BioRad, Hercules, CA) was used for 
all PCR reactions. Mutagenesis was confirmed via in-house DNA sequencing 
using an ABI 3730XL capillary sequencer. 
 
2.2.3. Protein Secondary Structure Determination 
 Circular dichroism was employed in structure determination. A 10 μM 
solution of the enzyme of interest in an optically clear borate buffer (50 mM boric 
acid, 100 mM KCl, 0.7 mM DTT; pH 8.0) was measured from 190-260 nm, with 5 
replicates. The averaged spectra was deconvoluted into respective secondary 
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structure motifs (α-helix, β-sheet, and disordered) using the DichroWeb online 
server. The CDSSTR method was utilized with database 4 as a reference.  
2.2.4. Enzyme Kinetics 
 Stereoisomerization of D-glutamate by glutamate racemase was assayed 
using a J-720 CD spectropolarimeter from JASCO (Easton, MD). A jacketed 
cylindrical cuvette with a volume of 750 μL and a path length of 10 mm was used 
for each assay. Readings were measured at 220nm continuously. All 
measurements were conducted at 25 ˚C. Concentrations of D-glutamate were 
varied from 0.25–5 mM in an optically clear borate buffer (50 mM boric acid, 100 
mM KCl, 0.7 mM DTT; pH 8.0). Reactions were initiated upon addition of enzyme 
(approx. 0.5 μM). Data acquisition was performed using  JASCO Spectra 
Manager v1.54A software, and fitting was performed using GraphPad Prism v5.0 
from GraphPad Software (San Diego, CA). Inhibitor IC50 curves were obtained 
using a coupled-enzyme assay25 with iodonitrotetrazolium absorbance at 500 nm 
as the readout, as both inhibitors studied were optically active at 220nm. Assays 
were again conducted at 25 ˚C in the presence of 3-6 μM GR. For comparison 
with calculated binding energy values, experimental IC50 values were converted 
to Ki values via the Cheng-Prussoff equation, and then binding free energies via 
the standard Gibbs free energy relation. 
 
2.3. Computational Methods 
2.3.1. Virtual Docking 
 The co-crystal structure of GR from B. subtilis bound to D-glutamate 
(1ZUW, chain C) was prepared for virtual docking by first deleting all water 
molecules, salt ions, peptide chains A and B, and the substrate, D-glutamate. A 
simulation cell was centered on the catalytic cysteine residues, Cys74 and 
Cys185, and dimensions of the cell were adjusted to encompass the entirety of 
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the active site resulting in the following cell dimensions (x-y-z): 19.9-15.2-17.2 Å. 
Residue 75 was left unaltered in the case of docking to the wild-type model, but 
for docking to the N75A and N75L models, Asn75 was replaced with an alanine 
or leucine residue in silico, respectively. All ligands, including D-glutamate, were 
constructed and minimized in MOE v2011.10 (Chemical Computing Group)26 and 
imported into YASARA for virtual docking. YASARA v12.4.127 employs AutoDock 
428 in its docking functionality. Specific details regarding pose generation and 
scoring can be found in Whalen et al.24 The top-ranking complexes were then 
used as starting structures for molecular dynamics simulations. 
2.3.2. Molecular Dynamics Simulation 
 The molecular dynamics simulations of the docked complexes (based on 
the PDB 1ZUW, as described above) were performed with the YASARA 
Structure package version 12.4.1 (YASARA Biosciences).27, 29, 30 A periodic 
simulation cell with boundaries extending 10 Å from the surface of the complex 
was employed with explicit solvent, and the cell was neutralized with NaCl (0.9% 
by mass). The YASARA2 force field was used with long-range electrostatic 
potentials calculated with the Particle Mesh Ewald (PME) method, with a cutoff of 
7.86 Å.31-33 The ligand force field parameters were generated with the 
AutoSMILES utility, which employs semi-empirical AM1 geometry optimization 
and assignment of charges, followed by assignment of AM1BCC atom and bond 
types with refinement using the RESP charges, and finally the assignments of 
general AMBER force field atom types. Optimization of the hydrogen bond 
network of the various GR-ligand complexes was obtained using the method 
established by Hooft et al., in order to address ambiguities arising from multiple 
side chain conformations and protonation states that are not well resolved in the 
electron density.34 Following neutralization, a final density of 0.997 g/mL was 
employed. A previously described simulation annealing protocol22 was followed 
before initiation of simulations using the NVT ensemble at 298 K, and integration 
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time steps of 1.25 and 2.5 fsec for intra- and intermolecular forces, respectively. 
MD simulations of individual ligand in solvent and salt were performed as above, 
within a simulation cell having x-y-z dimensions of approximately 70-70-70 Å, 
and a total volume of ~340,000 Å3. Snapshots were saved for all cases at 
intervals of 25 psec, and the electrostatic interaction energy (     ) and the van 
der Waals interaction energy (      ) were calculated at each of the time points, 
and averaged to yield the values in Table 11. Solvent accessible surface areas 
were constructed with a solvent probe radius of 1.4 Å and the following radii for 
the solute elements: polar hydrogens 0.32 Å, other hydrogens 1.0717 Å, carbon 
1.8 Å, oxygen 1.344 Å, nitrogen 1.14 Å, sulfur 2.0 Å. All surface area calculations 
were performed with the YASARA Structure package. 
2.3.3. Ligand Interaction Maps and Reports 
 Ligand interaction maps were generated from the final snapshots of the 4-
ns MD simulation using MOE v2011.10 (Chemical Computing Group).35 Pocket 
analysis was conducted on the same structures using the Site Finder utility of 
MOE, using the default alpha sphere radius.  
2.3.4. Multiple Regression Analysis Applied to Linear Response  
 Multiple regression analysis using the R statistical package, version 
2.13.1,36 was used to optimize the α, β, γ, and δ coefficients in Eq. 5. A linear 
model equating experimental binding free energies, listed in Table 11 and the 
computationally-derived values from Table 11 (i.e.       ,        , and      ) 
was employed to obtain optimized values for α-γ, and no restraints were used in 
the parameter optimization.  
 
3. RESULTS AND DISCUSSION 
3.1. Steady-state kinetics shows racemization activity in mutants, with mild 
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KM alterations. 
 As discussed above, we predict Asn75 to be key to pocket volume and 
polarity, and thus, water accommodation. Two variations of Asn75 mutants were 
constructed, where asparagine was swapped for alanine or leucine. Wildtype and 
mutant variants of GR from B. subtilis were purified recombinantly from E. coli 
(see Figure D.2 for SDS-PAGE). Circular dichroism shows that neither mutation 
causes significant changes to the secondary structure of GR (Figure 22, Table 
8). Mutant and wild-type enzymes were assayed to determine steady-state 
kinetic constants, KM and kcat, in the D- to L- direction of racemization (Table 9). 
The apparent KM values increased by a factor of 2-fold and 6-fold relative to wild-
type for GR-N75L and GR-N75A, respectively. It is difficult to explain what 
causes the variation in Michaelis constants between GR variants from these 
studies due to the complicated nature of this constant, which includes 
association, dissociation, and catalytic steps. More striking is the 28-fold increase 
in kcat caused by the N75A mutation. This phenomenon is currently the subject of 
a separate study. 
 
 
Figure 22. Comparison of the secondary structure of wild-type and mutant GRs 
confirms no unfolding or dramatic structural alteration induced by mutation to 
residue 75. Circular dichroism measurements made in triplicate using a Jasco J-
715 spectropolarimeter.  
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Table 8. Deconvolution of circular dichroism spectra into respective secondary 
structural motifs.  
 
*Deconvolution performed using the online server, DichroWeb. NRMSD given is 
for the comparison of experimental and calculated spectral data.  
 
 
 
Table 9. Steady-state kinetic parameters (D- to L- racemization) of wild-type and 
mutant GR. 
Protein KM (mM) kcat (s
-1) kcat/KM (s
-1 mM-1) 
GR-WT 0.13 ± 0.01 1.64 ± 0.03 12.6 ± 0.08 
GR-N75A 0.73 ± 0.09 45.6 ± 1.9 62.5 ± 0.13 
GR-N75L 0.49 ± 0.10 0.15 ± 0.01 0.31 ± 0.10 
*Steady-state kinetics measured by monitoring ellipticity at 220nm over time 
using a Jasco J-715 spectropolarimeter. D-glutamate concentrations varied from 
0.25-5.0mM, and data fit to the Michaelis-Menten equation (with errors from 
nonlinear regression fitting).  
 
 
Protein %-α-helix %-β-sheet %-disordered NRMSD 
GR-WT 60 14 24 0.001 
GR-N75L 65 12 22 0.003 
GR-N75A 59 16 25 0.001 
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3.2. Active Site Mutation Causes Ligand-Dependent and Residue-
Dependent Binding Effects 
 1H-benzimidazole-2-sulfonic acid (1) and croconic acid (2) are both 
competitive inhibitors with low-micromolar inhibitory constants that were 
previously discovered in virtual screening studies.22, 23 These compounds vary 
substantially in electrostatics and shape. The potency of each inhibitor was 
determined experimentally against either GR mutant. Compound 1 showed a 
50% increase in IC50 for the N75L mutation, and a striking 600% increase in IC50 
for the N75A mutation, compared to the IC50 for wildtype GR (Table 10). As 
suspected, the leucine and alanine substitutions cause binding energy changes 
of unequal magnitude, but surprisingly 1 suffers a greater binding energy loss in 
GR-N75A where we hypothesized additional water would be introduced to the 
active site. When comparing free energy binding values calculated from these 
IC50 values, the same trend holds true. In the case of compound 2, only modest 
IC50 decreases of 20% and 40% were observed for the N75L and N75A 
mutations, respectively, relative to the wildtype IC50 value (Table 10). Although 
there is a statistically significant decrease in the value of the IC50 for GR-N75A-2 
compared to WT, the significance of this change does not hold with respect to 
their Ki values. Nevertheless, complexation of both of these compounds, to both 
wildtype and mutant GR, were subjected to more in-depth structural and 
computational analyses. 
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Table 10. GR inhibitors and substrate examined in this study. 
# Ligand Name Ligand Structure IC50 Curve 
1 
1H-benzimidazole-
2-sulfonic acid 
(BISA) 
 
0 1 2 3 4
0
25
50
75
100 GR-WT
GR-N75A
IC50 = 128  40 M
IC50 = 890  140 M
GR-N75L
IC50 = 198  36 M
log [inhibitor] (M)
A
c
ti
vi
ty
 (
%
)
 
Ki (WT) = 9 ± 2 μM
22 
 
2 croconate 
 
0 1 2 3 4
0
25
50
75
100
IC50 = 94  15 M
GR-WT
GR-N75A
IC50 = 58  4 M
GR-N75L
IC50 = 74  12 M
log [inhibitor] (M)
A
c
ti
vi
ty
 (
%
)
 
Ki (WT) = 42 ± 10 μM
23 
 
3 D-glutamate 
 
KM (WT) = 130 ± 10 μM 
Kd = 110 ± 14 μM (Fig. S5) 
4 α-ketoglutarate 
 
IC50 (WT) = 430 μM
22 
5 
chloroaniline 
sulfonic acid 
 
IC50 (WT) = 720 μM
22 
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6 dipicolinic acid 
 
Ki (WT) = 2000 μM
9 
*Ligand structures shown with molecular surface (van der Waals) rendering. 
Hydrophobic regions are colored green, mildly polar regions are colored blue, 
and hydrogen bonding regions are colored purple. IC50 curves were 
experimentally acquired via methods described in the Materials and Methods 
section.    
 
3.3. Molecular Dynamics Simulations Indicate Morphological and Ligand-
binding Changes Resulting from N75A and N75L Mutations 
 In order to elucidate the nature and strength of the GR-ligand binding 
energies for a range of competitive inhibitors, we used a combination of docking, 
classical MD simulations and extended linear response (ELR) free energy 
calculations. Firstly, we describe the morphological characteristics of the GR-
ligand complexes, followed by an analysis of the sources of binding free energy, 
including the role of interstitial water.  
  
3.3.1. Placement of Ligands in GR Active Sites.  
 A docking protocol, based on AutoDock 4.2, was used to place all of the 
ligands employed in the MD simulations (see Computational Methods section). 
Subsequently, these complexes were all subjected to the same protocols for 
simulated annealing energy minimization, followed by 4 ns of classical MD 
simulations, using the YASARA2 knowledge-based force field, using an explicit 
solvent model and periodic boundaries (see Computational Methods for details). 
These MD simulations were later used in ELR free energy calculations as 
described below. This type of hierarchical approach has proven successful in 
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numerous LIE/ELR studies.37-39  
 
3.3.2. Molecular Dynamics Simulations of GR-Ligand Complexes. 
 MD simulations were  employed to obtain structural information for each 
inhibitor-GR complex. All ten complexes achieved RMSD equilibrium between 1 
and 1.5 ns (Figure D.1). Structures from the end of a 4 ns simulation were used 
to parse the GR-ligand interactions. GR-1 and -2 complexes were of particular 
interest, due to reasons outlined above.  A distinct characteristic of the GR-
N75A-1 complex is that the ligand is less solvent exposed (than the GR-WT- and 
GR-N75L-1 complexes). The morphological characteristics of these various GR-
ligand complexes may be described in a number of ways. A ligand pocket 
analysis of the three 1-bound complexes shows that the volume of the active site 
is markedly reduced for the GR-N75A-1 (Table D.2), relative to GR-N75L- and 
GR-WT-1 complexes. Furthermore, in addition to the reduction in the size of the 
active site of GR-N75A, the openness of its cleft is significantly reduced, relative 
to wild-type and GR-N75L complexes, as described in Figure 23 and Figure D.3. 
A cross-section of the three complexes of GR-1 from equilibrated MD snapshots 
at 4 ns are compared in Figure D.4. The wild-type complex contains a water 
channel that leads out of the back of the active site (away from the entrance), 
while the GR-N75A and GR-N75L active sites are not contiguous with this water 
channel (Figure D.4). The presence of this connected water channel in the wild-
type GR (and its absence in the mutants) is a stable characteristic seen 
throughout the MD simulations. Additionally, while there are only two, or one, 
interstitial waters present in the wild-type and GR-N75A complexes, respectively, 
there are four interstitial waters in the GR-N75L complex (Figure 23). Lastly, the 
key hydrogen-bond contacts between 1 and GR are more optimal in the wild-type 
complex than in either Asn75 mutant, and this will be fully discussed below.  
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 Given the gross morphological differences between the three GR species, 
it naturally follows that inhibitor 1 should be less solvent exposed in the N75A 
mutant, which is borne out in the ligand-interaction maps shown in Figure 23. 
Both the benzyl ring and sulfonate oxygens are somewhat less solvent exposed 
in GR-N75A, than in wild-type and GR-N75L complexes. 
 Although these MD simulations do provide some insight into the nature of 
GR-1 complexation, and more particularly the role of a key residue, Asn75, what 
is desired is a quantitative description of the free energy contributions of the GR 
pharmacophore. It is apparent from the relatively large plasticity exhibited by GR, 
from the MD analysis above, that diverse ligands may yield quite different GR-
liganded complexes, particularly with regard to active site volume and interstitial 
water. In fact, a number of recent reports have also highlighted the idiosyncratic 
nature of interstitial water structure in enzyme active sites, where the presence of 
interstitial water can act as a favorable21, 40 or unfavorable component of the total 
binding energy.18-20 In one particular study, Barandun and coworkers observed 
striking differences in binding energies between tRNA-guanine transglycosylase 
and  sets of lin-benzoquanine and lin-benzohypoxanthine inhibitors.20 Barandun 
et al. used X-ray crystallography to expose ligand-dependent conformational 
changes in key active site residues, which results in the import of interstitial 
water.20 Without high-resolution structural information such as that obtained by 
Barandun and coworkers, enzyme-plasticity and numerous water-mediated 
contacts make the determination of meaningful enzyme-ligand binding energies a 
non-trivial task. It would be extraordinarily useful to be able to predict the gross 
morphological changes as well as the specific active site alterations due to 
complexation with particular GR inhibitors, and more importantly their binding 
free energies. To that end we applied the Extended Linear Response (ELR) 
method for calculating binding free energies, to a set of 10 different GR-ligand 
complexes (vide infra). 
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Figure 23. Ligand interaction maps for the inhibitors, 1 (top) and 2 (bottom), 
bound to wild-type (A and D) GR-N75L (B and E), and GR-N75A (C and F) 
active sites support the energetic evaluations conducted via ELR. Maps 
generated from structures from the final snapshot of a 4-nsec MD simulation. 
Residues are indicated with labeled circles. Direct hydrogen bonding interactions 
are indicated with blue (backbone) or green (side-chain) dashed lines. Interstitial 
water-hydrogen bonding interactions are indicated with gold dashed lines. 
Solvent exposure is indicated with light blue shading and the active site surface 
proximal to the ligand is indicated with a grey line. 
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3.4. Binding Energy Calculations Using ELR 
 A permutation of the ELR methodology first described by Jorgensen has 
been applied to 10 different GR-ligand complexes.41 A number of ELR 
approaches41-44 have been described, and are based on the Linear Interaction 
Energy (LIE) method, first described by Aqvist et al.45 The seminal studies for 
utilizing the linear response approximation employ expressions for the hydration 
energy of ions, and it can be shown that the electrostatic portion of this free 
energy (     
  ) is defined by Equation 1.46, 47 This expression was then 
extrapolated by Aqvist and co-workers to the problem of considering ligand-
protein binding, where they showed that the electrostatic contribution to the 
binding free energy was expressed by Equation 2, where the    term now refers 
to the difference between protein and water systems.45 
     
    
 
 
            
                                                Eq. 1 
 
      
    
 
 
                     Eq. 2 
 
In the LIE approach, one obtains interaction energy components from molecular 
dynamics or Monte Carlo simulations, then parses the binding energy 
contributions into an electrostatic component (based on linear response) and a 
van der Waals component based on an empirically scalable parameter: 
        
 
 
                                              Eq. 3 
 
       indicates differences in the average electrostatic interaction energies 
between the two states (i.e. solvated and enzyme-bound systems). Statistical 
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analysis of multiple systems by Aqvist and coworkers lead to an optimal set α 
value of 0.161.45 Later studies employed a coefficient, called β, that is variable 
and ligand-dependent (ranging from 0.33 to 0.5) in place of the fixed        
coefficient of 0.5, thus deviating from linear response.48 These α and β parameter 
optimizations worked well for a number of systems,45, 48 but in the case of a 
thrombin target, it was necessary to add an additional offset term, γ, in order to 
reproduce the experimental binding free energies (Eq. 4).49 In this case the γ 
term was a relatively large offset at -2.9 kcal/mol. These, and other studies, led 
Aqvist and coworkers to speculate that this constant offset value was highly 
dependent on the type of receptor site.50 
             
                       Eq. 4 
 
An augmented approach to the above model (Eq. 5), in which changes in ligand 
solvent accessible surface area (∆SASA) are also empirically scaled was applied 
by Jorgensen and coworkers, using the OPLS force field, and investigating the 
binding of a set of sulfonamide inhibitors to human thrombin, arrived at solutions 
with significantly lower β values than the linear response approximation.42 Later 
studies, with various force fields, also found solutions with β values significantly 
different from linear response approximation.44, 51 
            
                                   Eq. 5 
 
 While the meaning of the β parameter is based on the linear response 
approximation, which derives from the potential of mean force from changing 
electric fields in polar solvents, the physical meaning of the α value is much more 
ambiguous. The α term has been empirically derived, and lacks any clear a priori 
physical meaning. Kollman and coworkers determined that the α value is highly 
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correlated to a weighted change in nonpolar SAS upon ligand binding,52 which 
they show to be dependent on the nature of the protein binding site (the more 
nonpolar the buried moiety, the more positive the weighting). Furthermore, 
optimization of the α parameter is expected to also implicitly include terms such 
as desolvation and entropy loss. Orthodox linear response-based methods are, 
however, not expected to explicitly account for long-range solvent-solute 
interactions, although more accurate methods for capturing such effects have 
been developed.53  It is not surprising then that significant variation in the values 
of α and β (as well as γ and δ) exist across systems and methodological 
approaches.  
 In the current study, we are applying the above ELR approach, using 
∆SASA and a constant offset value (δ) in order to reproduce the absolute binding 
free energies for the given set of ligands to GR. Furthermore, we are using the 
YASARA2 knowledge-based force field (KBFF) in 4 ns simulations for each GR-
ligand complex (see Computational Methods for details). Ten different GR 
complexes, employing compounds indicated in Table 10 were used in ELR 
calculations; Table 11 lists the average       and        interaction energies for 
both solvated and enzyme-bound systems. In all cases, these highly polar 
ligands had negative values for       in both the enzyme-bound form and the 
solvated system. However, all of the ligands had more negative       values in 
the solvated system than in the enzyme-bound form, leading to all positive values 
for       . As expected, the converse of this was true for the        , having all 
negative values. The change in solvent accessible surface area, as well as the 
experimentally-determined binding values are indicated in Table 11. 
 The adjustable parameters were then optimized using multiple regression 
analysis, and the results of this are indicated in Table 12. The residual standard 
error yielded a value of 2.0 kJ/mol, with an R value of 0.92. It is remarkable that 
the β value here (0.07 ± 0.01) is within error of the lowest RMS model of studies 
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on sulfonamide inhibitors of thrombin (β = 0.071 ± 0.0242), as well as a composite 
of ELR performed on 3 different protein kinases (β = 0.084854); and laying in 
between β values determined for CYP1A2 (= 0.014 to 0.03451)  and HIV-1 
reverse transcriptase (0.14443). Taken together these ELR studies using three 
different force fields and six different enzymes converge on solutions of β values 
that are definitively lower than the original linear approximation, but in toto are 
relatively precise. 
 The optimized α value in the current study is 0.04 ± 0.05. Previous LIE and 
ELR studies have shown that the α value has been arguably the most difficult 
parameter to estimate. Aqvist and coworkers obtained an optimized α value of 
0.18 on a system composed of four different targets,55 while other studies found 
diverse optimized values that ranged from being within error of zero43 to being 
quite large (> 0.5).51 A relatively large standard regression error on the α value 
was obtained for three different protein kinases by Tominaga and Jorgensen (α = 
0.077154). The optimized γ value in this study indicates that larger buried solvent 
accessible surface area correlates with more unfavorable binding energy, which 
means that there is something other than simple cavitation being reported. One 
possibility is the ejection of stabilized, interstitial waters in the apo-GR structure. 
Ejection of such waters has been estimated to be ~1.8 kcal/mol/water.56 Previous 
steered MD studies on GR indicated that severe alterations in the global shape of 
the enzyme occur in a ligand-dependent manner.22 GR structures that exhibited 
greater degrees of active site cavity opening (induced by steered MD removal of 
ligands) also exhibited significantly greater free energies of protein solvation, 
suggesting that the ligand-induced changes in complex structure may have a 
number of non-obvious energetic implications. 
 
 
116 
 
 
Table 11. Data used in the Extended Linear Response calculations.* 
Complex 
      
(kJ/mol) 
       
(kJ/mol) 
       
(kJ/mol) 
        
(kJ/mol) 
∆Gbind 
Experiment 
(kJ/mol) 
Calculated 
      
(Å2) 
1-WT -617 -199 +9 -137 -28.8 277 
1-N75A -581 -224 +45 -162 -19.5 307 
1-N75L -590 -220 +36 -158 -23.9 294 
1-wb -626 -62 - - - - 
2-WT -1643 -134 +60 -119 -25.0 232 
2-N75A -1671 -141 +32 -126 -26.4 231 
2-N75L -1684 -119 +19 -104 -26.4 230 
2-wb -1703 -15 - - - - 
3-WT -1071 -150 +53 -149 -22.2 270 
3-wb -1124 -1.4 - - - - 
4-WT -1717 -160 +167 -159 -19.4 247 
4-wb -1884 +0.6 - - - - 
5-WT -532 -166  +73 -125 -18.4 311 
5-wb -605 -41 - - - - 
6-WT -1753 -172  +140 -147 -15.4 274 
6-wb -1893 -25 - - - - 
*Carrots (   ) indicate the average of an ensemble, where the ensemble of 
structures is obtained from molecular dynamics simulations. Abbreviations: el, 
electrostatic; vdw, van der Waals; SASA, solvent accessible surface area; wb, 
water box.  
 
Table 12. Multiple regression coefficients from fitting to the Extended Linear 
Response model.* 
 Multiple Regression 
Estimate 
Regression Standard 
Error 
α (van der Waals) 0.04 0.05 
β (electrostatic) 0.07 0.01 
γ (SAS) (kJ/Å2) 0.08 0.03 
δ Intercept (kJ/mol) -43 6 
*The residual standard error from the multiple regression fit was 2.0 kJ/mol. The 
Multiple R-squared value was 0.85. 
 
117 
 
 
 
 
Figure 24. Plot of experimental versus computationally-derived binding energies. 
Data is fit to a linear regression here (solid, black) and the ± 4.2 kJ/mol (1 
kcal/mol; red) and ± 2.0 kJ/mol (mult. regression error; blue) boundaries are 
shown. The calculated slope is 0.85 ± 0.13, Y-intercept is -3.3 ± 2.9 kJ/mol, and 
the R-squared value is 0.85. 
 
3.5. Water contributions to total binding energy are strongly ligand-
dependent. 
 Another trend in the ELR data is that the relatively closed state of GR-
N75A yields, not surprisingly, more favorable         (relative to wild-type and 
GR-N75L), for both inhibitors 1 and 2. This corresponds to the smaller active site 
volumes seen for the N75A mutant, its greater degree of cleft closure around the 
ligands as well as the solvent exposure, as presented in Figure 23. These 
enhanced van der Waals contacts do not necessarily track with greater binding 
affinities, as the quality of electrostatic interactions with the protein as well as the 
water network would need to be maintained in this reduced volume cavity. In 
order to parse the electrostatic contributions in terms of protein- and water-
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mediated contacts, for all of the GR-ligand complexes in this study, we 
determined the       in the absence of water (vide infra).  
 The striking conclusion from analyzing the ligand-protein and ligand-water-
mediated contributions to       is that for most ligands there is a very large 
percentage of the interaction energy achieved through water contacts (Table 13). 
These values range from 7% for D-glutamate (3) to 54% for 4. However, the 
range for all ligands except for D-glutamate is 24-54%, indicating that all of the 
inhibitors here depend significantly more on water-mediated contacts for 
enzyme-binding than the natural substrate. In order to make the most stark 
comparison of these varying modes of water utilization, we juxtapose the ligand 
maps from the end of the MD simulation for D-glutamate- and 4-bound 
complexes (Figure 25). The ligand map of D-glutamate in Figure 25 illustrates the 
high efficiency of the natural substrate in making productive electrostatic protein 
contacts, which is highlighted by the presence of a singular water-mediated 
contact. Interestingly, this single water contact occurs at the γ-carboxylate, 
remote from the high-quality α-carboxylate-protein contacts in the rear of the 
cavity. This is not true of the inhibitors examined in this study. Compound 4 
typifies this flooding of the active site of GR, in which there is extensive use of 
water-mediated contacts that contribute to the binding energy.  
 Another GR-ligand complex that exhibits this flooding phenomenon is GR-
N75L-1, whose ligand map was presented earlier in Figure 23, and in which 
numerous water-mediated contacts could be seen. Table 13 shows that 1 bound 
to GR-WT has a 32%       due to water-mediated contacts, while 1 bound to 
GR-N75L exhibits a value of 47%, which is clearly reflected in the ligand 
interaction maps (Figure 23). Not surprisingly, 1 bound to GR-N75A has 
approximately the same dependence on water-mediated contacts as in the GR-
WT complex. This reveals that the very poor quality of ligand-protein interaction 
energy, particularly in the hydrogen-bonding between the sulfonate of compound 
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1 and the back of the active site pocket (proximal to the mutated Asn75 position) 
is present in GR-N75L. In other words, the damage due to the pharmacophore by 
swapping the amide of Asn75 for the isopropyl of leucine could be rescued by 
simply flooding this polar active site, and increasing the number of water-
mediated contacts. An astute observation made by Barandun and coworkers is 
that despite favorable interactions between imported water and the protein, these 
interactions are rarely sufficient to compensate for losses of direct ligand-protein 
interactions.20 The difference in compound 1 binding energy between GR-WT 
and GR-N75A is most likely the result of an altered binding pose that produces 
suboptimal bond distances and angles for direct contacts between ligand and 
protein. This reduction in pose quality is quantified in Table 13 where 
electrostatic interaction energy is calculated in the absence of water (-419 kJ/mol 
vs -391 kJ/mol for WT vs N75A). Additionally, distances and angles were 
calculated and averaged for all protein-ligand hydrogen bonding interactions in 
the final three snapshots of either complex's MD simulation (Figure D.6). The 
results show an increase in overall bond distance and a reduction in bond angle 
in the case of N75A, consistent with its smaller electrostatic protein-ligand 
interaction energy (Table 13). In addition, there is one less bridging water 
molecule in the N75A-complex compared to the wildtype complex.  
 
Table 13. Parsing the contributions of interstitial waters to ligand binding set.* 
 Electrostatic  interaction 
energies in the absence of 
water (     protein [kJ/mol]) 
% of       due to 
interstitial water-ligand 
interaction 
1-WT -419 32 
1-N75A -391 33 
1-N75L -314 47 
2-WT -777 53 
3-WT -993 7 
4-WT -798 54 
5-WT -377 29 
6-WT -1314 25 
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Figure 25. Ligand interaction maps for D-glutamate (A) and 4 (B) bound to wild-
type GR. Residues are indicated with labeled circles. Direct hydrogen bonding 
interactions are indicated with blue (backbone) or green (side-chain) dashed 
lines. Interstitial water-hydrogen bonding interactions are indicated with gold 
dashed lines. Solvent exposure is indicated with light blue shading and the active 
site surface proximal to the ligand is indicated with a grey line.  
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4. CONCLUSIONS 
 The optimized ELR model resulted in an α = 0.04 and β = 0.07, both 
values within error of a number of published values on various enzymatic 
systems. This solution required an offset (δ value) or -43 ± 6 kJ/mol and yielded 
an R-squared value of 0.85 and an RMS error of 2.0 kJ/mol. The MD simulations 
indicated that GR-N75A had a reduced active site volume, less open active site 
cleft, and decreased solvent exposure with 1H-benzimidazole-2-sulfonic acid (1), 
a recently identified high-efficiency competitive inhibitor. Results of the ELR study 
indicated that         for GR-N75A with 1 and another attractive competitive 
inhibitor, croconate (2), are more favorable relative to their wild-type and GR-
N75L counterparts. 
 Analysis of the contributions of water-mediated contacts to the GR-ligand 
electrostatic interaction energies reveals a surprisingly large role in all ligands 
(24-54%), except the natural substrate (7%). In the case of inhibitor 1, the N75A 
mutation results in non-optimal sulfonate-protein hydrogen bonds in the rear of 
the active site, and reduction in active site volume (relative to wild-type). While in 
the case of the N75L mutant, the sulfonate-protein hydrogen-bonding is even 
poorer, yet the larger active site volume and degree of cleft openness, led to 
water-mediated rescue of GR-ligand binding energy. These findings yield deep 
insight into potential antibacterial mutagenesis mechanisms. Despite the 
attractiveness of 1 as a scaffold, optimization should be pursued cautiously since 
it is possible to make a mutant that damages the pharmacophore,  and still 
produces a perfectly functional glutamate racemase.  
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CHAPTER 5: THE NATURE OF ALLOSTERIC INHIBITION IN GLUTAMATE 
RACEMASE: DISCOVERY AND CHARACTERIZATION OF A CRYPTIC 
INHIBITORY POCKET USING ATOMISTIC MD SIMULATIONS AND PKA 
CALCULATIONS* 
Abstract 
 Enzyme inhibition via allostery, in which the ligand binds remotely from the 
active site, is a poorly understood phenomenon, and represents a significant 
challenge to structure-based drug design. Dipicolinic acid (DPA), a major 
component of Bacillus spores, is shown to inhibit glutamate racemase from 
Bacillus anthracis, a monosubstrate/monoproduct enzyme, in a novel allosteric 
fashion. Glutamate racemase has long been considered an important drug target 
for its integral role in bacterial cell wall synthesis. The DPA binding mode was 
predicted via multiple docking studies and validated via site-directed 
mutagenesis at the binding locus, while the mechanism of inhibition was 
elucidated with a combination of Blue Native PAGE, molecular dynamics 
simulations, free energy and pKa calculations. Inhibition by DPA not only reveals 
a novel cryptic binding site, but also represents a form of allosteric regulation that 
exploits the interplay between enzyme conformational changes, fluctuations in 
the pKa values of buried residues and catalysis.  The potential for future drug 
development is discussed. 
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1. Introduction 
D-glutamate (D-glu) has been shown to be an essential feature of the 
peptidoglycan layer of bacterial cell walls in a number of pathogenic organisms, 
strongly suggesting that blocking its biosynthesis would be an attractive mode of 
action for antimicrobial drug discovery1. The enzyme glutamate racemase (GR) is 
responsible for the biosynthesis of D-glu in bacteria, employing a cofactor 
independent 1,1 proton transfer to invert the stereochemistry of the L-glutamate 
substrate. GR is a highly pursued antimicrobial drug target, and has been the 
subject of numerous ligand discovery studies2-9.  
Extensive inhibitor development against GR has been directed toward the 
CDC’s Category A agents 5,10-12. B. anthracis, the causative agent of inhalational 
anthrax and a Category A agent, is unique in possessing two functional GR 
isozymes (RacE1 and RacE2)5. These particular enzymes have been the subject 
of extensive structural and kinetic characterization5,11.  Active site differences 
between the two isozymes, specifically a key valine residue that bridges the 
active site and an adjacent hydrophobic pocket at the entrance of RacE2 (but not 
RacE1), have hampered efforts to develop a common and potent inhibitor for 
both B. anthracis GR isozymes5.  
Accurately modeling enzyme (or receptor) flexibility has long been 
recognized as one of the grand challenges in structure-based drug discovery. A 
diverse set of crystallographic, computational and screening studies have pointed 
to the extensive flexibility of the GR enzyme6-8,11,13, thus creating challenges in 
elucidating both its catalytic mechanism, as well as the functional 
pharmacophore for effective structure-based drug discovery campaigns. An 
important corollary to receptor flexibility is the possibility for allosteric regulation 
by an effector molecule, with previous successes seen across several classes of 
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enzymes14. According to the Monod-Wyman-Changeus (MWC) model15, a 
flexible (unliganded) enzyme samples a range of conformational states, which 
may be captured or recognized by a ligand or set of ligands. If significant 
distortion of a target enzyme is populated in these pre-binding equilibria, then 
capture of an inactive conformation represents a reasonable strategy for 
structure-based drug design. Accordingly, an alternative approach to finding 
inhibitors for GRs would be to identify noncompetitive (or uncompetitive) 
inhibitors, which act remotely from the active site. This strategy was utilized by 
Lundqvist and coworkers in the discovery of a pyrazolopyrimidinedione analogue 
(“Compound A”) inhibitor against H. pylori GR4. Compound A was identified in 
HTS against AstraZeneca’s compound library as an inhibitor of racemization in 
the D→L direction. Lundqvist et al. elegantly demonstrated that Compound A 
was an extremely rare uncompetitive inhibitor of a monosubstrate-monoproduct 
enzyme in the D→L direction4. Interestingly, this inhibitory approach exploits the 
fact that reduction of the kcat/KM of a racemase in one direction must equal its 
reduction in the reverse direction (vide infra), which results in a net decrease in 
the production of D-glu in vivo as indicated by the accumulation of peptidoglycan 
precursors in the cytoplasmic extract of H. pylori cells treated with Compound A4. 
This inability to produce peptidoglycan is lethal for H. pylori cells, as 
demonstrated by a minimal inhibitor concentration (MIC) of 8 μg/mL for 
Compound A4. However, the natural effector molecule acting at the Compound A 
binding pocket remains unknown.  
In the current study we have discovered a novel inhibitory property for a 
natural product, dipicolinic acid (DPA), which is acting as an allosteric inhibitor of 
both B. anthracis GR isozymes, and has a distinct binding pocket from 
Compound A of Lundqvist et al.4. Furthermore, we employ experimental and 
computational studies to elucidate this remote binding locus as well as propose 
an atomistic rationale for DPA inhibition supported by MD simulations, free 
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energy and pKa calculations of the dynamic GR ensemble. Interestingly, DPA is 
a natural product occurring at high concentrations within the B. anthracis spore 
and has been implicated to play a key role in that organism's life cycle. The 
implications for B. anthracis sporulation and drug discovery are discussed.  
2. Computational and Experimental Details 
2.1. Site-Directed Mutagenesis 
 Mutants racE2_K106A and racE2_S207A were prepared using a 
QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene, Santa Clara, CA) 
and primers obtained from Eurofins MWG Operon (Huntsville, AL). Previously 
prepared and recently isolated pET15b (Novagen, San Diego, CA) containing the 
gene of interest was used as the template DNA. A BioRad MJ Mini Personal 
Thermal Cycler (BioRad, Hercules, CA) was used for all PCR reactions. 
Mutagenesis was confirmed via in-house DNA sequencing using an ABI 3730XL 
capillary sequencer. Primer sequences are detailed in Supplementary Table 4. 
2.2. Protein Expression and Purification 
 Proteins were expressed using the BL21 strain (Novagen, San Diego, CA) 
of E. coli and pET15b expression vector (Novagen, San Diego, CA). Purification 
was composed of three key components: Cobalt-affinity chromatography, ATP 
incubation to remove chaperone contaminants, and anion-exchange 
chromatography. Expression and purification are described in full detail in 
Supplementary Information. 
2.3. Enzyme Kinetics – Circular Dichroism 
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Stereoisomerization of D-glutamate by GR was assayed by measuring 
angle of rotation (mdeg) at 220-225nm using a J-720 CD spectropolarimeter 
(JASCO, Oklahoma City, OK). Data was fit to Michaelis-Menten equations as 
well as nonlinear regression curves for noncompetitive inhibition using GraphPad 
Prism v5.0 (GraphPad Software Inc., La Jolla, CA).  Complete details of kinetic 
assay conditions can be found in Supplementary Information. 
2.4. Colloidal Aggregation Control 
 Inhibitors were analyzed for the possibility of colloidal aggregation using a 
detergent-based assay previously established by Feng and Shoichet and 
successfully applied to this particular system in Whalen et al.7,16. Further details 
can be found in Supplementary Information. 
2.5. Blue Native – Polyacrylamide Gel Electrophoresis 
 Protein samples were incubated in loading buffer (100 mM Tris-Cl, 40% 
glycerol, 0.01% Coomassie Brilliant Blue G, pH 8.0) and the compound of 
interest (1 mM or 45 mM) at room temperature for 15 minutes. Blue-native (BN) 
polyacrylamide gels were prepared at a resolving concentration of 10% (30:0.8 
total acrylamide:bis ratio) with a 5% stacking gel. The compound of interest was 
incorporated into both the gel and running buffer (100 mM Tris-Histidine, pH 8.0) 
at the desired concentration. Gels were run at constant voltage (100 V) and 
constant amperage (15 mA) for approximately 3.5 h at 4 °C. Gels were stained 
using Imperial Protein Stain and destained in water. Respective intensities of 
protein bands were analyzed by pixel quantification of a gel scan using Adobe 
Photoshop CS4 Extended v11.0 (Adobe Systems Inc., San Jose, CA). 
2.6. Docking of DPA to GR 
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 Protein Receptor Preparation: The PDB file 2GZM was downloaded from 
RCSB for use as the protein receptor. One dimer was deleted from the crystal 
cell as only one dimer would be utilized in docking. The remaining dimer was 
submitted to steepest descent minimization and 50 picoseconds of molecular 
dynamics simulation with YASARA v9.11.9 (further details below)17. All water 
molecules and ligands were removed from the finals structure as the last step of 
preparation. DPA in its deprotonated state was used as the ligand for docking. 
 AutoDock (through YASARA): A simulation cell was created 5 Å from all 
atoms with dimensions: 102 Å x 72.8 Å x 71.3 Å. The following general docking 
parameters were used: 25 independent docking runs, each with a total of 2.5 x 
106 energy evaluations, a torsional degrees of freedom value of 8, grid point 
spacing was left at the default of 0.375 Å, and the force field selected was 
AMBER03. Specific to the genetic algorithm, the following parameters were 
used: a population size of 150, 2.7 x 104 generations, an elitism value of 1, a 
mutation rate of 0.02, and a crossover rate of 0.8. Final poses were considered 
distinct if they varied by > 5 Å RMSD. 
 GOLD: The genetic algorithm parameters were defined as such: number 
of islands set to 5, population size of 100, selection pressure value of 1.1, 
maximum number of operations set to 125,000, and a niche size of 2. 
Additionally, both crossover and mutation frequency were set to 95, while the 
migration frequency was set to 10. GoldScore was used as the sole scoring 
function (without the optional fifth component, internal hydrogen bond energy). 
DPA was docked a total of 30 times and all solutions were retained.  
 FRED: A box ~200,000 Å² was drawn around the entire structure, and a 
high quality shape potential was created. In enumerating all possible ligand 
poses, a translational step size of 1 Å and a rotational step size of 1.5 Å were 
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used. Inner and outer contour filtering was enabled and no additional user-
defined constraint filters were used. Ensemble poses resulting from exhaustive 
docking are scored using Chemgauss3 and the top 100 poses are retained. DPA 
was docked a total of 32 times.  
2.7. Molecular Dynamics Simulations 
 The procedures and parameters for molecular dynamics simulations of 
GR as well as free energy calculations are described in full in the Supplementary 
Information.  
2.8. Selection of Non-Redundant Structures from MD Simulation 
 Structure snapshots taken every 150 picoseconds of the molecular 
dynamics simulations were converted to PDB format with all water molecules 
removed. The collection of structures (133 structures per complex) were then 
imported to the Multiseq extension of Visual Molecular Dynamics v1.8.6 for 
Windows (VMD, Univ. of Illinois – Urbana-Champaign)  and submitted to STAMP 
alignment (npass =1, scanscore =1, and scanslide =2). Multiseq was further used 
to create a phylogenetic tree based on RMSD of the Cα atoms. Finally, non-
redundant structures were extracted from the phylogenetic tree using a QH cutoff 
value of 0.90.  
2.9. H++ pKa Calculations 
 Structures were submitted in pdb format to the H++ server. All water, 
ligand and inhibitor molecules were deleted prior to pKa calculation. Structure 
“clean-up” is described in full by Gordon et al. 18 and the method of electrostatic 
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calculation of pKa values for all titratable groups is described in Bashford and 
Gerwert19. pKa values presented in the text were taken from the pK1/2 output of 
H++.  
 
3.  Results 
3.1. Inhibition of RacE1 and RacE2 by DPA 
 DPA was originally found in a virtual screening campaign for B. subtilis 
RacE but exhibited only low mM inhibition6. When tested on the two glutamate 
racemase isozymes from B. anthracis, RacE1 and RacE2, DPA exhibited low μM 
inhibition (Ki = 75 ± 16 μM and 92 ± 12 μM, respectively) with clear 
noncompetitive behavior, as confirmed via the F test when data is fit to varying 
models of inhibition (Fig. 26a and E.1, Table E.1 and E.2). To our knowledge, 
this is the first noncompetitive inhibitor against a glutamate racemase. In general, 
it is quite rare to find noncompetitive or uncompetitive inhibitors for any 
monosubstrate-monoproduct (i.e. Uni-Uni) enzymes20,21. The immediate 
tendency is to be wary of noncompetitive inhibitors discovered from screening 
campaigns, as they are often revealed to be colloidal aggregators that inhibit 
enzymes in a non-drug-like manner22. Colloidal aggregators can be exposed 
using a simple detergent-based kinetic assay16. Inhibition by DPA does not 
exhibit the characteristic alleviation in the presence of detergent, thus eliminating 
the possibility of colloidal-aggregation-based inhibition (Fig. E.2). Previously, our 
group successfully employed this detergent-based assay to identify a colloidal 
aggregator in a screening campaign against GR from B. subtilis that exhibited 
apparent noncompetitive inhibition in the low-μM range7. RacE2 was the main 
isozyme studied in the following work since B. anthracis genetic knockout studies 
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identified the absence of RacE2 as resulting in the more severe growth defect, 
relative to the RacE1 isozyme10. Furthermore, the inhibitor studies described 
here focus on the D→L direction, as in the studies of Lundqvist et al., on GR 
inhibition by Compound A4. However, it should be noted that the Haldane 
relationship dictates that any reduction of kcat/KM for a racemase in one direction 
will result in an equivalent reduction in kcat/KM in the opposite direction
20,23,24. This 
is because the equilibrium constant for a racemase is unity, and leads to the 
following constraint:   
     Eq. 1 
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Figure 26. Experimental results for noncompetitive inhibition of RacE2_WT (a), 
RacE2_S207A (b) and RacE2_K106A (c) by DPA. Kinetic data was attained via circular 
dichroism and three independent Michaelis-Menten curves were globally fit to a 
noncompetitive inhibition model to produce the presented Ki values (further details in 
Supporting Information). 
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3.2. Identification of a Novel Allosteric Pocket by Docking; Location of the 
DPA Binding Site 
 A blind docking campaign targeting the RacE2 dimer was carried out in 
order to identify the binding site of DPA. GOLD v4.1, FRED v2.2.5 and AutoDock 
4 (via Yasara v9.11.9) were each utilized in this campaign and represent three 
different types of docking and scoring methods17,25,26. Despite using very different 
methods of docking and scoring (these differences are expounded upon in the 
Computational Procedures section of the Supplementary Information), all three 
programs came to the same conclusion with regards to the location of the DPA 
binding site (Fig. 27a). Given a RacE2 dimer from the original crystal structure 
(2GZM) and no user-defined specifications for the binding location, DPA was 
consistently positioned with highest rank in all three docking programs in a small 
pocket at the dimer interface, making direct contacts with Lys106 and Ser207 of 
one monomer and the Lys106 of the second monomer. Specifically, the Ser207 
backbone amide acts as a H-bond donor to one carboxyl substituent of DPA 
while the Lys106 side chain of the same monomer is a donor for the second 
carboxyl substituent of DPA (Fig. 27b). The Lys106 side chain of the second 
monomer coordinates both carboxylates as well as the pyridine nitrogen of DPA. 
Interestingly, energy minimization results in the formation of an H-bond between 
the carboxylate of DPA and the beta-hydroxyl of Ser207 while the Lys contacts 
remain unchanged relative to the original docking pose (Fig. 27c). An MD 
simulation using S207A RacE2 with DPA bound was conducted to further 
elucidate the role of Ser207 in DPA binding. MD simulation shows that the 
mutagenesis of Ser207 to alanine results in a complete loss of contact with the 
backbone in that region, resulting in a highly solvent-exposed, and presumably 
unfavorable, binding position for DPA (Fig. 27d). These results point to the 
presence of Ser207 as being essential for organization in this region of the 
enzyme and accordingly, formation of the DPA binding pocket. With all three 
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docking programs in agreement, the predicted site was probed via site-directed 
mutagenesis (vide infra). Importantly, these models predicting that DPA binds at 
a site distal to the active site are consistent with the steady state kinetic data 
suggesting non-competitive inhibition. 
 
a b c d S207A RacE2WT RacE2WT RacE2
 
Figure 27. Superpose of top-docked positions of DPA (space-filling) to the RacE2 dimer 
(ribbon, 2GZM) as determined by GOLD v4.1 (magenta), Autodock v4 (blue) and FRED 
v2.2.5 (green) (a). The binding pocket is located at the dimer interface and is composed 
of residues from both monomers, as detailed by the interaction map (b). After 
minimization, the backbone contact of Ser207 is swapped for a contact with the beta-
hydroxyl group (c). After MD simulation of the top docked complex with Ser207 replaced 
by Ala, the binding site lacks any contact with the region previously containing Ser207 
(d). Letters immediately preceding the residue numbers indicate the monomer, A or B. 
Ligand interaction maps were constructed using the LigX function of MOE v2009.10. 
3.3. Validation of DPA Binding Site via Mutagenesis 
 In order to experimentally confirm the predicted DPA binding mode, the 
two residues predicted to interact directly with the inhibitor, Lys106 and Ser207, 
were mutated to alanine independently and the purified mutant enzyme was 
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assayed for inhibition via DPA. Enzyme activity was unaltered for both mutants 
relative to wild-type protein, as indicated by their kcat/KM values (Table E.3). First, 
RacE2_S207A was constructed and predicted to abolish a single H-bond 
between enzyme and ligand. The observed Ki (Ki = 1236 ± 950 μM) increased 
13x compared to wildtype RacE2, which is consistent with the loss of a single H-
bond (loss of 0.68-1.88 kcal/mol, strength of a normal hydrogen bond within a 
protein ranges from 1 to 3 kcal/mol27, Fig. 26b). Second, RacE2_K106A was 
constructed, abolishing four hydrogen bonds (according to the docking model). 
The observed Ki (Ki = 2342 ± 1300 μM) increased 24x compared to wildtype (loss 
of 1.43-2.17 kcal/mol, slightly less than predicted; Fig. 26c). The attenuation of 
DPA inhibition in both the mutant constructs agrees well with the predicted site 
being the true DPA binding site.  This is a testament to the precision of GOLD, 
FRED and AutoDock at correctly positioning a small molecule in a blind docking 
situation.  
 Cryptic binding sites are not entirely unprecedented for glutamate 
racemases. In 1994, Doublet and coworkers characterized the activation of GR 
from E. coli by UDP-MurNAc-L-Ala binding to a cryptic back pocket on the 
monomer (later co-crystallized by Lundqvist et al.)4,28. As previously mentioned, a 
team at AstraZeneca discovered Compound A, a novel uncompetitive inhibitor in 
a high-throughput screening against GR from H. pylori and determined this 
compound to bind to a pocket located on the opposite face from the active site4 . 
Thus far, these two examples have been the only homologues of GR with 
established allosteric regulation. Crystal structures of the activator bound to E. 
coli GR (2JFN) and Compound A bound to H. pylori GR (2JFZ) were superposed 
with the top-docked conformation of DPA into RacE2 in order to see whether 
DPA was exploiting either of these pre-established binding sites (Fig. 28). When 
the dimer interface is revealed by hiding one monomer, one can clearly see that 
the DPA binding site is distinct from those of the activator and Compound A. With 
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this perspective, one can envision D-glutamate bound in the active site and DPA 
bound to the back side as being on a shared horizontal plane. The uncompetitive 
inhibitor from Lundqvist et al. is bound above this plane and UDP-MurNAc-L-Ala 
is bound below4. Thus, the DPA binding site is unlike any established cryptic 
sites of GR. With the addition of DPA, three distinct cryptic sites exist within the 
GR receptor class, each exhibiting a different mode of regulation. 
 
 
Figure 28. Superpose of a variety of GR structures in order to highlight the diversity of 
known allosteric positions.  Superpose of DPA bound to B. a. RacE2, UDP-MurNAc-L-
Ala bound to E. c. GR (2JFN), and pyrazolopyrimidinedione analogue (aka Compound 
A) bound to H. p. GR (2JFZ). Only the trace of one monomer is shown for clarity and the 
perspective is looking at the enzyme face directly opposite of the entrance to the active 
site. D-glutamate (yellow) is seen in the background bound to the active site, while DPA 
(green), UDP-MurNAc-L-Ala (magenta), and Compound A (red) are seen in the 
foreground. All three cryptic binding sites are distinct. Indicated are center of mass 
distances between molecules. There is no evidence that any one GR structure 
possesses all of these allosteric pockets. Rather, the figure is meant to illustrate the 
distinctive positions and identities of these three different effectors relative to the 
glutamate binding pocket. 
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3.4. Quaternary Organization and Inhibition by DPA 
One possible mechanism of GR inhibition is a DPA-induced shift in the 
oligomeric equilibrium. For instance, Johnson and coworkers have hypothesized 
that the RacE2 monomer experiences increased conformational flexibility and 
thus higher rates of catalysis29. In order to investigate any DPA-induced changes 
of the oligomeric equilibrium of GR, RacE2 dimerization was analyzed using Blue 
Native PAGE (BN-PAGE) gels supplemented with DPA. Gels supplemented with 
the DPA-analogue, 3,4-pyridinedicarboxylic acid, were used as a control. This 
analogue shows no inhibition against RacE2 nor RacE1, and thus is predicted 
not to bind the enzyme; but its presence provides a control for nonspecific 
interactions that may affect the BN-PAGE results. Both compounds were present 
in the gel, running buffer and loading buffer (respectively) at a concentration well 
above the Ki calculated for DPA. DPA does not induce any significant change in 
the monomer-dimer equilibrium of RacE2 relative to the control (Fig. E.4). 
Although BN-PAGE rules out the occurrence of a DPA-induced shift in the 
oligomeric equilibrium, the possibility remains that allostery is the source of 
inhibition by DPA. 
 As recently reported by Johnson and coworkers, certain mutations in 
residues located at the dimer interface result in an altered RacE2 monomer-
dimer equilibrium29. Thus, both mutant constructs were analyzed via Blue Native 
PAGE to assess the monomer-dimer equilibrium and rule out this phenomenon 
as having any affect on DPA binding or overall RacE2 catalysis. Both 
RacE2_S207A (Fig. 29a) and RacE2_K106A (Fig. 29b) showed no significant 
difference in monomer-dimer equilibrium compared to wild type protein. For 
RacE2_K106A, these results are contrary to what was reported by Johnson and 
coworkers, as they observed only the monomer state for this mutant. Differences 
could be attributed to the method (Blue Native PAGE versus size-exclusion 
145 
 
chromatography) or protein concentration (45 μg/mL versus 5 mg/mL); 
particularly since we observed that the monomer-dimer equilibrium exhibited a 
dependence on protein concentration in all gels. Specifically, as protein 
concentration increased, the ratio of monomer to dimer decreased (Fig. 29 and 
E.4). We chose to examine a protein concentration in the range of those used for 
kinetic assays. Furthermore, these GR concentrations may be more 
physiologically relevant than the much higher concentrations used in the study by 
Johnson and coworkers29. 
 
Figure 29. BN-PAGE to determine the oligomerization of wild-type and mutant RacE2.  
Wildtype RacE2 and RacE2_S207A (a) or RacE2_K106A (b) were run side-by-side at 
concentrations varying from 45 to 180 μg/mL. Albumin and carbonic anhydrase were 
included as running controls. Arrowheads indicate bands representing the dimer and 
monomer. Band intensity was quantified via pixel counting and the ratio of monomer to 
dimer was plotted against protein concentration for RacE2_S207A (solid line = WT, 
dotted line = mutant; c) and RacE2_K106A (d). Data represents an average of three or 
more independent trials with standard error shown. Data was additionally fitted to the 
expression for M/C ratio as a function of total protein concentration and the 
monomer:dimer equilibrium constant (see Supplementary Methods for derivation of this 
expression and model fitting parameters).The results indicate that the two mutants do 
not have any significant effect on the oligomeric equilibrium. Additionally, see Figure E.3 
for BN-PAGE of RacE2 and running controls with NativeMark ladder. 
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3.5. Effect of DPA on Free Energy of Binding of D-Glu to RacE2 
 Molecular dynamics simulations were performed for both RacE2 dimer 
with D-glu bound to both active sites (abbreviated as E2·D-glu2), as well as the 
top-docked complex of RacE2 and DPA with glutamate bound to both active sites 
(abbreviated as E2·D-glu2·DPA). Both simulations were carried out for 20 
nanoseconds (see Materials and Methods for a complete description of the 
simulation parameters). Separately, a collection of snapshots taken every 150 
picoseconds (totally 133 structures) from each simulation were submitted to 
STAMP structural alignment30 and used to compose a structural phylogenetic 
tree based on RMSD differences between α-carbon atoms. A structural 
phylogenetic tree provides a graphical representation of the structure-based 
relationship between different simulation snapshots. Non-redundant structures 
were then selected from the collection to represent the most unique 
conformations using the widely-accepted technique of QR factorization, thus 
more efficiently examining phase space31,32 . A structural homology (QH) value of 
0.90 was used as the cutoff for structural redundancy (where QH represents the 
fraction of Cα atoms that superimpose, total overlap = 1 and no overlap = 0)33, 
resulting in 14 unique structures from E2·D-glu2 and 2 unique structures from 
E2·D-glu2·DPA.  The QR factorization results immediately indicate that the 
presence of bound-DPA results in limited conformational diversity for RacE2 
within the respective equilibrated time series. An estimate of the binding free 
energy was calculated for glutamate bound to either monomer using an 
“endpoint” approach (recently reviewed by Steinbrecher and Labahn)34. The 
method employed here, MM-BEMSA, is a variation on the popular MM-PBSA 
method, with electrostatic potentials calculated with the Boundary Element 
Method (BEM), instead of numerically solving the Poison-Boltzmann (PB) 
equation.  The details of this approach are described in the Computational 
Methods section of the Supplementary Information. Briefly, the BEM technique 
147 
 
for calculating electrostatic potentials has some advantages in dealing with highly 
curved surfaces of macromolecules, such as clefts and buried pockets, which 
made it ideal for the GR receptor35,36.  
Instead of doing an endpoint free energy calculation of D-glu binding at 
every time point of an MD simulation, we sought a more efficient use of 
computational resources. The predicted binding energy was averaged for all non-
redundant structures from each respective trajectory. In the past, McCammon 
and coworkers applied this technique to an MD simulation of Kinetoplastid RNA 
editing ligase 1 (KREL1), where non-redundant representatives were shown to 
possess as much binding energy information as the entire set of structures 
resulting from the simulation31. Thus, the non-redundant set of MD structures, 
obtained from QR factorization was used in the end point free energy 
calculations of D-glu to the RacE2 dimer, with and without DPA bound (i.e. E2·D-
glu2 and E2·D-glu2·DPA). For glutamate bound to monomer B, no significant 
difference in free energy of binding exists between E2·D-glu2·DPA and E2·D-glu2 
(-17 ± 5.0 kcal/mol versus -22 ± 2.0 kcal/mol, respectively). On the contrary, for 
glutamate bound to the A monomer, a less negative free energy of binding (i.e. 
weaker complexation) is seen in E2·D-glu2·DPA compared to E2·D-glu2 (-15 ± 1.0 
kcal/mol versus -21 ± 2.0 kcal/mol, respectively, Fig. 30d). End point free energy 
calculations (such as MM-PBSA) do not yield accurate absolute free energies37, 
but have been shown to be highly accurate in terms of relative free energy 
values38, and may be used as powerful predictor of trends in relative binding 
affinities.  
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Figure 30. Ligand interaction maps for glutamate bound to monomer A of the DPA-
lacking RacE2 complex (a) and DPA-bound RacE2 complex (b), as well as DPA bound 
to the cryptic binding site located at the RacE2 dimer interface (c). Maps were generated 
from the final structures of 20-nanosecond MD simulations using the LigX function of 
MOE v2009.10. Predicted binding energy of glutamate was averaged over the set of 
representative structures extracted from MD simulations of the binary (red, n=15) and 
ternary complex (blue, n=4, d), error bars = SEM. The details of the binding energy 
calculations are outlined in the Computational Procedures section of Material and 
Methods.   
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Ligand interaction mapping of equilibrated E2·D-glu2·DPA after the 20 
nanosecond simulation show two water bridges formed between DPA and 
Asp210 and Glu211 of the A monomer of RacE2 (Fig. 30c). Asp 210 goes on to 
form a hydrogen bond with the side-chain hydroxyl of Ser207 (previously 
implicated in DPA binding by initial ligand interaction mapping of the top-docked 
complex prior to MD). Ser207 also forms a water bridge with Glu211. This 
complex network of direct hydrogen bonds and water bridges between DPA and 
the A monomer occurs twenty residues downstream of the catalytic residues, 
separated by a short α-helix and β-sheet. The interaction maps of glutamate 
bound to the active site of the A monomer of equilibrated complexes were 
compared. Binding of DPA corresponds with altered hydrogen-bonding within the 
active site as compared to E2·D-glu2. Briefly, in E2·D-glu2·DPA, glutamate forms 
seven hydrogen bonds with active site residues as opposed to five hydrogen 
bonds in E2·D-glu2 (Fig. 30a-b). Also, glutamate of E2·D-glu2·DPA is involved in 
five water bridge contacts while glutamate of E2·D-glu2 involves only three. These 
variations in enzyme-ligand interactions point to a global conformational change 
translated from the dimer interface to the active site. Specific details regarding 
hydrogen bonding and enzyme-ligand distances for the two complexes are 
described in the Supplementary Information.  
 
3.6. Effect of DPA Binding on pKa of Catalytic Cysteine 74  
 While differences in free energy of binding of D-glu may contribute 
partially to inhibition by DPA, they cannot explain if and why the enzyme-
substrate-inhibitor (ESI) complex is enzymatically unproductive, particularly since 
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the binding pose of D-glu does not vary widely between E2·D-glu2 and E2·D-
glu2·DPA. Considering the importance of the basicity of the general acid/base for 
glutamate proton abstraction9,39 and the clear active site rearrangements that 
accompany DPA binding8, we chose to examine changes in pKa of the key 
catalytic residue, Cys74, for D→L racemization. Each structure selected from QR 
factorization of the MD simulations of both ensembles was used to calculate pKa 
values with the widely employed MEAD algorithm (implemented in the H++ 
utility18,40). The distribution of pKa values shows a significant downward shift for 
Cys74 of E2·D-glu2·DPA compared to Cys74 of E2·D-glu2 (Fig. 31). Overall, the 
E2·D-glu2·DPA structures possessed pKa values in a much more limited range 
and with reduced values (less basic) compared to E2·D-glu2 structures, which 
possess pKa values ranging from as low as 8 to as high as 20 (Fig. 31). The 
possibility that the loss of extreme basicity of Cys74 is responsible for a 
dysfunctional ESI complex is discussed below.  
 
Figure 31. Distribution of pKa values calculated for Cys74 (the catalytic base of D  L 
racemization) for E2·D-glu2 and E2·D-glu2·DPA. Each structure, selected via QR 
factorization of a collection of simulation snapshots, was each used in pKa calculation 
using the MEAD algorithm from the H++ program18.  Details of parameters employed in 
these pKa calculations are located in the Computational Procedures section of the 
Materials and Methods. 
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4. Discussion 
Here we have identified a natural compound, DPA (linked to the B. 
anthracis life cycle), which exhibits noncompetitive inhibition of GR from B. 
anthracis via binding to a remote and heretofore undiscovered allosteric pocket. 
A blind docking study, using three leading algorithms has determined the 
consensus pharmacophore for DPA, which lies at the dimer interface. This 
consensus pocket was experimentally validated via a multiple site-directed 
mutagenesis study. The loss of racemization activity due to DPA has no affect on 
the oligomeric equilibrium of GR, suggesting that inhibitor action is allosteric in 
nature.   
 A parallel computational study to understand the source of the DPA-
induced allostery was undertaken. DPA-induced changes in the phase space of 
B. anthracis RacE2 showed a significant dampening of the conformational 
flexibility of GR. Interestingly, the large conformational fluctuations of E2·D-glu2 
manifest large changes in the magnitude of the calculated pKa of the catalytic 
base, Cys74. The large pKa perturbations in the E2·D-glu2 are due to a variety of 
interactions between active site residues, particularly the interaction between the 
catalytic base and Asp11. Unsurprisingly, Asp11 was previously identified as 
being located in an area of high homology and subsequently probed via 
mutagenesis, resulting in a 1000-fold reduction in the observed kcat of GR
39. 
Remarkably, the very high basicity of some enzyme catalytic bases has been 
shown to be critical to catalytic efficiency even when the protonation state of this 
species (the so called "reverse protonation" state41) is not the dominant form at a 
given pH. The concept of the role of the reverse protonation state has been fully 
developed in the case of enolase and alanine racemase42,43. Thus, what is seen 
here in the case of GR is a manifestation of the phenomenon exhibited in 
enolase and alanine racemase, in which the reverse protonation state may be 
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the primary driver of catalytic power (i.e. a very high pKa thiolate). However, in 
GR there is the additional complexity of a quite flexible ensemble of protein 
conformations, with large fluctuations in the values of the pKa of the catalytic 
base. It is fascinating that the ensemble with the allosteric inhibitor (DPA) results 
in a conformational "freezing out" of the high pKa (i.e. catalytically reactive) forms 
of GR. We hypothesize that this is the source of allosteric inhibition by DPA, and 
refer to this mode of inhibition as Inhibition by pKa Trapping (IPKAT). We 
propose that this is a general phenomenon in GR that can be exploited in the 
DPA pocket by other small molecules, and that in principle it is possible to 
construct an IPKAT pharmacophore, in which GR inhibition can be predicted by 
the distribution of calculated pKa values of the catalytic Cys residues. 
The presence of DPA in Bacillus spores has been well-established as 
DPA constitutes approximately 10% of the dry weight of dormant spores, but its 
exact role in sporulation and germination is only loosely understood44. DPA within 
spores is found primarily in its calcium-chelated form, Ca2+-DPA. In the 
developing endospore, DPA concentrations remain low until after cortex 
formation, which requires peptidoglycan synthesis. In the dormant spore phase of 
B. anthracis, Ca2+-DPA concentrations are very high and there is no detectable 
metabolic activity.  Upon activation of spores by external factors, channel 
formation occurs allowing a large efflux of cations and Ca2+-DPA out of the spore 
core45. This event occurs concomitantly with an adjustment of the pH from 6.5 to 
7.7 and increased hydration45. All of these events are required to restart 
metabolism. Accordingly, both the reduced DPA concentration and elevated pH 
are conducive with increased GR activity (pH optimum of RacE1 and RacE2 is 
~8.011). As the spore core grows nearly 4-5x its original size, the demand for 
peptidoglycan synthesis increases and thusly the demand for D-glutamate. 
Additionally, D-glutamate is required for the poly-D-glutamic acid capsule 
surrounding the mature vegetative cell. Taking all of this into consideration, one 
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may postulate that the fluctuation of DPA concentration over the lifetime of a 
differentiating B. anthracis cell coincides with the varying necessity of D-
glutamate (Fig. 32). Thus, it is appealing to imagine the inhibition of GR by DPA 
as more than serendipitous. Of course, future in vivo studies are required to 
further investigate the interactions of GR and DPA in spores and vegetative cells. 
One point to investigate is whether the efflux of DPA actually results in a cellular 
DPA concentration less than the Kd, approximately 90 μM, capable of entirely 
alleviating GR inhibition. Compartmental distributions of DPA may allow such a 
concentration to be reached even if the net cellular concentration of DPA is still 
high.  
 
 
Figure 32. Schematic of life cycle of differentiating B. anthracis cell, with Ca2+-DPA levels 
and consequent GR activity indicated. 
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Importantly, the ligand efficiency (free energy of binding divided by the 
number of non-hydrogen atoms in the ligand) of DPA is quite high (-0.458 kcal 
mol-1 per non-H atom) compared to other known allosteric ligands such as 
Compound A (-0.242 kcal mol-1 per non-H atom) and the activator of GR from E. 
coli, UPD-MurNAc-L-Ala (-0.150  kcal mol-1 per non-H atom). Despite binding 
with higher affinity, the large MW of Compound A from Lundqvist et al. 
significantly lowers its ligand efficiency4. Ligand efficiency is one of the principal 
factors of lead optimization46. The high ligand efficiency of DPA means that 
during ligand optimization, a binding affinity in the low nM can be achieved with 
far fewer heavy atom additions and thus a lower MW compared to compounds of 
lesser efficiency. Additionally, the possible chemical modifications of DPA are 
manifold, providing a large potential library of small molecules to screen.   
Allosteric modulators represent an emerging drug class with which some 
pharmaceutical companies are having notable successes such as the HIV 
inhibitor maraviroc (Pfizer) and the hyperparathyroidism drug cinacalcet 
(Amgen)47,48. There are several advantages to using allosteric binding sites as 
drug targets over the native substrate binding site. Primarily, the allosteric sites of 
GR can accommodate a chemically diverse set of compounds compared to the 
active site, i.e. the final drug need not be a substrate analogue. A non-amino-
acid-like inhibitor will increase the selectivity for GR, while lowering the chance of 
undesirable interactions with enzymes containing analogous binding site motifs, 
such as enzymes involved in amino acid synthesis or the glutamate receptors 
that play an important role in neural chemistry.  Also, any mutations that could 
circumvent inhibition at this particular allosteric site would occur within the 
sensitive dimer interface and are thus more likely to affect dimerization and 
monomer cross-talk, potentially very key components of GR catalysis. The major 
obstacle to virtual screening campaigns targeting allostery is pharmacophore 
elucidation. Once this hurdle has been overcome (i.e. a defined structure activity 
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relationship and/or an atomistic understanding of the binding modes that lead to 
enzymatic inhibition), then reasonable metrics may be applied to assess binding 
modes and predict novel allosteric inhibitors. Such is the case now for B. 
anthracis RacE2, particularly in light of the IPKAT hypothesis outlined above, 
which permits a physical metric for inhibitory allostery. It is now possible to begin 
rational allostery-based virtual screening campaigns against the GR target class, 
potentially leading to new inhibitory small molecule anti-anthrax therapeutics.  
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RMSD plots from MD simulations) as well as extensive experimental methods 
and computational methods may be found in the Supporting Information. This 
material is available free of charge via the Internet at http://pubs.acs.org. 
Acknowledgements 
This work was supported by NIH AI076830 (M. A. S.) and NIH AI057156 
(S. R. B.). Special thanks to Dr. Keith Westcott for his contribution to the Keith R. 
Westcott Graduate Student Education Fund (K. L. W.). Additionally, thank you to 
Dr. Dylan Dodd for helpful discussions. 
 
 
156 
 
References 
 (1) Rogers, H. J.; Perkins, H. R.; Ward, J. B. Microbial cell walls and 
membranes; Chapman and Hall: London, United Kingdom, 1980. 
 (2) de Dios, A.; Prieto, L.; Martin, J. A.; Rubio, A.; Ezquerra, J.; Tebbe, 
M.; Lopez de Uralde, B.; Martin, J.; Sanchez, A.; LeTourneau, D. L.; McGee, J. 
E.; Boylan, C.; Parr, T. R., Jr.; Smith, M. C. J Med Chem 2002, 45, 4559. 
 (3) Glavas, S.; Tanner, M. E. Bioorganic and Medicinal Chemistry 
Letters 1997, 7, 2265. 
 (4) Lundqvist, T.; Fisher, S. L.; Kern, G.; Folmer, R. H.; Xue, Y.; 
Newton, D. T.; Keating, T. A.; Alm, R. A.; de Jonge, B. L. Nature 2007, 447, 817. 
 (5) May, M.; Mehboob, S.; Mulhearn, D. C.; Wang, Z.; Yu, H.; 
Thatcher, G. R. J.; Santarsiero, B. D.; Johnson, M. E.; Mesecar, A. D. Journal of 
Molecular Biology 2007, 371, 1219. 
 (6) Spies, M. A.; Reese, J. G.; Dodd, D.; Pankow, K. L.; Blanke, S. R.; 
Baudry, J. J Am Chem Soc 2009, 131, 5274. 
 (7) Whalen, K. L.; Pankow, K. L.; Blanke, S. R.; Spies, M. A. ACS 
Medicinal Chemistry Letters 2010, 8, 9. 
 (8) Ruzheinikov, S. N.; Taal, M. A.; Sedelnikova, S. E.; Baker, P. J.; 
Rice, D. W. Structure 2005, 13, 1707. 
157 
 
 (9) Puig, E.; Garcia-Viloca, M.; Gonzalez-Lafont, A.; Lluch, J. M.; Field, 
M. J. Journal of Physical Chemistry B 2007, 111, 2385. 
 (10) Shatalin, K. Y.; Neyfakh, A. A. FEMS Microbiology Letters 2005, 
245, 315. 
 (11) Dodd, D.; Reese, J. G.; Louer, C. R.; Ballard, J. D.; Spies, M. A.; 
Blanke, S. R. J Bacteriol 2007, 189, 5265. 
 (12) LoVullo, E. D.; Molins-Schneekloth, C. R.; Schweizer, H. P.; 
Pavelka, M. S., Jr. Microbiology 2009, 155, 1152. 
 (13) Gallo, K. A.; Tanner, M. E.; Knowles, J. R. Biochemistry 1993, 32, 
3991. 
 (14) Hardy, J. A.; Lam, J.; Nguyen, J. T.; O'Brien, T.; Wells, J. A. Proc 
Natl Acad Sci U S A 2004, 101, 12461. 
 (15) Monod, J.; Wyman, J.; Changeux, J. P. J Mol Biol 1965, 12, 88. 
 (16) Feng, B. Y.; Shoichet, B. K. National Protocols 2006, 1, 550. 
 (17) YASARA 9.11.9 ed.; YASARA Biosciences GmbH: Vienna, Austria, 
2010. 
 (18) Gordon, J. C.; Myers, J. B.; Folta, T.; Shoja, V.; Heath, L. S.; 
Onufriev, A. Nucleic Acids Res. 2005, 33, W368. 
158 
 
 (19) Bashford, D.; Gerwert, K. Journal of Molecular Biology 1991, 224, 
473. 
 (20) Cook, P. F.; Cleland, W. W. Enzyme kinetics and mechanism; 
Garland Science: New York City, New York, 2007. 
 (21) Cornish-Bowden, A. Fundamentals of Enzyme Kinetics; Portland 
Press, 2004; Vol. 3. 
 (22) Coan, K. E. D.; Maltby, D. A.; Burlingame, A. L.; Shoichet, B. K. 
Journal of Medicinal Chemistry 2009, 52, 2067. 
 (23) Spies, M. A.; Toney, M. D.; Hynes, J. R.; Klinman, J. P.; Limbach, 
H. H.; Schown, R. L. In Hydrogen-Transfer Reactions; Wiley-VCH: Weinheim, 
2007; Vol. 3; pp 1139. 
 (24) Cleland, W. W. An analysis of haldane relationships. In Methods in 
Enzymology; Elsevier Inc., 1982; Vol. 87; pp 366. 
 (25) FRED; 2.2.5 ed.; OpenEye Scientific Software, Inc. : Sante Fe, NM, 
USA, 2010. 
 (26) GOLD; 4.1 ed.; The Cambridge Crystallographic Data Centre: 
Cambridge, CB2 1EZ, UK, 2010. 
 (27) Frey, P. A.; Hegeman, A. D. Enzymatic reaction mechanisms; 
Oxford University Press: New York, New York 10016, 2007. 
159 
 
 (28) Doublet, P.; van Heijenoort, J.; Mengin-Lecreulx, D. Biochemistry 
1994, 33, 5285. 
 (29) Mehboob, S.; Guo, L.; Fu, W.; Mittal, A.; Yau, T.; Truong, K.; Johlfs, 
M.; Long, F.; Fung, L. W.-M.; Johnson, M. E. Biochemistry 2009, 48, 7045. 
 (30) Russell, R. B.; Barton, G. J. Proteins: Structure, Function, and 
Genetics 1992, 14, 309. 
 (31) Amaro, R. E.; Baron, R.; McCammon, J. A. J Comput Aided Mol 
Des 2008, 22, 693. 
 (32) O'Donoghue, P.; Luthey-Schulten, Z. J Mol Biol 2005, 346, 875. 
 (33) Eastwood, M. P.; Hardin, C.; Luthey-Schulten, Z.; Wolynes, P. G. 
IBM Journal of Research and Development 2001, 45, 475. 
 (34) Steinbrecher, T.; Andreas, L. current Medicinal Chemistry 2010, 17, 
767. 
 (35) Shaw, P. B. Phys. Rev. A 1985, 32, 2476. 
 (36) Warwicker, J.; Watson, H. C. Journal of Molecular Biology 1982, 
157, 671. 
 (37) Merz, K. R. Drug Design: Structure and Ligand-Based Approaches; 
Cambridge University Press: Cambridge, UK, 2010. 
160 
 
 (38) Brown, S. P.; Muchmore, S. W. J Chem Inf Model 2006, 46, 999. 
 (39) Glavas, S.; Tanner, M. E. Biochemistry 2001, 40, 6199. 
 (40) Anandakrishnan, R.; Onufriev, A. Journal of Computational Biology 
2008, 15, 165. 
 (41) Mock, W. L. Bioorganic Chemistry 1992, 20, 377. 
 (42) Spies, M. A.; Toney, M. D. Journal of the American Chemical 
Society 2007, 129, 10678. 
 (43) Sims, P. A.; Larsen, T. M.; Poyner, R. R.; Cleland, W. W.; Reed, G. 
H. Biochemistry 2003, 42, 8298. 
 (44) Slieman, T. A.; Nicholson, W. L. Applied and Environmental 
Microbiology 2001, 67, 1274. 
 (45) Setlow, P. Current Opinion in Microbiology 2003, 6, 550. 
 (46) Hopkins, A. L.; Groom, C. R.; Alex, A. Drug Discovery Today 2004, 
9, 430. 
 (47) Dorr, P.; Westby, M.; Dobbs, S.; Griffin, P.; Irvine, B.; Macartney, 
M.; Mori, J.; Rickett, G.; Smith-Burchnell, C.; Napier, C.; Webster, R.; Armour, D.; 
Price, D.; Stammen, B.; Wood, A.; Perros, M. Antimicrob Agents Chemother 
2005, 49, 4721. 
161 
 
 (48) Iqbal, J.; Zaidi, M.; Schneider, A. E. IDrugs 2003, 6, 587. 
 
 
 
 
162 
 
GENERAL CONCLUSIONS 
 
 
I. Research Objective and Main Arguments 
 
 This thesis describes the deep investigation into the nature of a flexible 
protein, with the ultimate goal of improving structure-based drug discovery. The 
previously described studies focus on protein conformational dynamics, ligand 
binding, and catalysis, with an emphasis on the role of water. The 
interdependence of these three processes has been recognized and studied 
individually, or in combination, in other systems. Here we focus on glutamate 
racemase, a validated drug target that remains a potential untapped source of 
novel antibiotic compounds. Below is a list of the main arguments put forth in this 
thesis. 
 
1. Protein flexibility can be modeled accurately and cheaply, from a structure-
based drug discovery viewpoint, by using unconventional MD simulation and 
ensemble docking, coupled with proper treatment of protein solvation. This can 
be used in hit discovery as well as lead optimization. 
 
2. Transition-state-like inhibitors can be found faster and more efficiently by 
creating and targeting a "reactive" form of the protein receptor in virtual screening. 
 
3. Interstitial water molecules play a dynamic and idiosyncratic role in the active 
site of a flexible enzyme, and their enthalpic contributions represent large 
portions of a particular ligand's binding energy. Furthermore, their contributions 
can be properly accounted for with the Extended Linear Response method of 
binding free energy calculations. 
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4. Small-molecules can regulate enzymes by exploiting protein conformational 
dynamics, specifically binding to conformations that dampen catalytic power.  
 
II. General Research Methodology 
 
 The common modus operandi in the previous chapters is the discovery of 
physical phenomenon via experimental analysis and the subsequent 
rationalization via computational modeling. The physical phenomenon range from 
highly plastic inhibitor binding (Chapter 1-3); to surprising, mutation-dependent 
alteration of enzyme kinetics and ligand binding (Chapter 4); to allosteric 
regulation (Chapter 5). Computational techniques are employed to model the 
protein system and propose a molecular rationale for experimental observations. 
There is also a feedback mechanism that allows us to incorporate what we learn 
experimentally into how we model these systems in the future, in order to 
improve the accuracy and speed of such techniques. Often, experimental studies 
are driven by original computational insights. 
  
 Questions were explored using a combination of computational and 
experimental techniques. Foremost was the use of traditional biochemistry in the 
form of recombinant protein expression , chromatography-based purification, and 
enzyme kinetics. Second most prominent is the use of computational modeling of 
physical and chemical phenomena, such as small molecule docking, molecular 
dynamics simulations of proteins, and binding free energy calculations. Finally, I 
employ a mix of biophysical assays, such as bulk fluorescence studies and 
circular dichroism; and since the end goal of this work is the development of 
antibiotic compounds, in vivo assays for determination of bacterial cell growth 
inhibition and measurement of cell wall integrity via cytotoxic leakage assays.  
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III. Discoveries and Challenges to Pre-existing Views 
 
In a systematic manner, the indications of each chapter are presented 
below.  
 
 In chapter 1, the findings indicate that an enzymatically reactive structure 
(derived from simulation) could produce a receptor that would more reliably 
discover high-efficiency hits in virtual screening than a high resolution structure of 
the receptor bound to the native substrate, the previous standard for virtual 
screening.  
 
 In chapter 2, the findings indicate that steered MD simulation offers unique 
benefits over classical MD simulation at producing diverse and physiologically-
relevant conformations of glutamate racemase. Additionally, the utilization of 
these distinct conformations in an ensemble-docking campaign is capable of 
accurately modeling large-scale motions in a more efficient way than simulation-
intensive techniques such as docking followed by individual MD simulations, 
Thermal Integration, or Free Energy Perturbation.  
 
 In chapter 3, the findings indicate that a lead optimization campaign can 
rely heavily on computational predictions in order to lower production costs and 
optimization time, if said computational techniques accurately rank the lead 
derivatives based on a binding-energy-related score.  
 
 In chapter 4, the findings indicate the role of a conserved residue in 
maintaining pocket structure and subsequent water organization, causing 
dramatic alterations to both enzyme kinetics (2200% increase in kcat) and 
inhibitor binding (600% increase  in IC50 for a competitive lead compound). These 
changes seem to be dictated by bridging water molecules, a key component of 
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the pharmacophore otherwise ignored by previous in silico drug discovery 
campaigns. 
 
 In chapter 5, the findings indicate the presence of subtle chemical 
changes being the source of allosteric inhibition in glutamate racemase, 
specifically the trapping of enzyme conformations whose lack of flexibility prevent 
the spike in catalytic base pKa required for proton abstraction on the Cα carbon 
of glutamate.  
 
IV. Significance of these Findings to the Field 
 
 Proteins vary in what is referred to as their "druggability", a combination of 
physical and chemical characteristics often related to small molecule or peptide 
binding. With the saturation of  drugs for "easy" targets, the pharmaceutical 
industry and academia must turn toward targeting less attractive proteins in order 
to find completely new treatments in the case of diseases that have yet to be 
tackled, or improved therapies for diseases where treatments exist, but are 
suboptimal.  Targets are often considered difficult if they are proteins that have 
proven harder to characterize structurally or functionally due to a large degree of 
inherent flexibility, or if the potential pockets have poor physical characteristics. A 
quantitative understanding of the link between protein flexibility and ligand 
binding would reduce the discovery barrier to developing drugs for a large swath 
of enzymes.  
  
 More specifically, the world currently finds itself in the middle of an era of 
ever increasing antibiotic resistance, including the unnerving rise of bacterial 
populations exhibiting multi- and total-drug resistance1. The need for novel 
antibiotic therapies has become a mission of paramount importance. Our 
research attacks this mission with a two-prong approach: 1) drug discovery 
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campaigns themselves and 2) the development of techniques that will expedite 
and reduce the costs of such campaigns in the future. Either approach will 
benefit the field by 1) introducing novel lead compounds into the universal drug 
pipeline and, assuming the adoption of our techniques by other pharmaceutical 
and academic teams, 2) reduce the large fiscal and time barrier of other 
discovery campaigns.  
 
 Finally, the discoveries made in the highlighted studies, specifically 
Chapter 5, have important implications for general protein biochemistry. In 
addition to being and important drug target, as a cofactor-independent amino 
acid racemase, glutamate racemase performs powerful and elegantly simple 
chemistry. The proton on the alpha-carbon of glutamate has a pKa of 
approximately 18, while cysteine (the residue responsible for abstraction) has a 
thiol pKa of approximately 8.3 (measured for the single amino acid in solution). 
The key to GR catalysis is the perturbation of the thiol pKa to a value that is high 
enough to abstract the substrate proton. Also important is the stabilization of the 
carbanionic intermediate, which is most likely achieved by a large and highly 
optimized network of hydrogen-bonding interactions in the active site. Without the 
aid of a cofactor, such as a metal or pyridoxal-5-phosphate, GR manages to 
perturb active site pKa's via modifications to the local chemical environment. This 
thesis implicates the conformational plasticity of GR as being the driving force 
behind these modifications. Such a hypothesis also opens the door to explaining 
allosteric modification of enzyme chemistry in other cases where no obvious 
changes in the active site structure are observed with the allosteric regulator  
bound.  
 
V. Limitations Encountered in This Research  
 
 The nature of both this enzyme system and the employed methodologies 
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leads to certain limitations that must be overcome for further advancement. First, 
the highest-potency inhibitor produced from lead optimization has an affinity of 
2.5 micromolar. Further optimization or combination treatments with either the 
allosteric inhibitors of GR or known antibiotics that also target peptidoglycan 
biosynthesis will be required to produce reasonable antibiotic therapies. 
Additionally, in vivo assays for antibiotic potency are limited by the 
potency/solubility of the existing in-house GR inhibitors. Thus, higher potency 
inhibitors are additionally required to more confidently establish bacterial growth 
inhibition as well as breakdown of peptidoglycan. I believe we have maximized 
the potency of an inhibitor which binds specifically to the buried active site (as 
quantified by extremely high ligand efficiency, in other words, reaching the upper 
limit of binding-energy per heavy atom). Development of inhibitors with 
nanomolar affinity will require extension of molecules out of the active site, but 
this will require modifications to our current prediction mechanisms. As is, the 
FERM-SMD method breaks down when ligands are large enough to extend out 
of the buried active site and make contacts with residues in adjacent pockets. 
This is possibly due to the dramatically different degrees of solvent exposure 
between the buried active site interior and the more exposed region surrounding 
the active site cleft. The FERM-SMD method will most likely need to be 
supplemented with additional simulation in order to overcome this obstacle. For 
instance, if FERM-SMD and the Extended Linear Response (ELR) method could 
be combined, together they may be able to properly account for protein-ligand 
interactions occurring at both the "mostly" solvent-excluded interior as well as the 
solvent-exposed exterior of the binding pocket. Currently, ELR is computationally 
expensive (requiring two individual 4-nanosecond simulations per inhibitor of 
interest) and thus scripts will need to be written that can utilize the parallel 
computing resources available at the University of Iowa High-Performance 
Computing center. 
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 Second, high-resolution co-crystal structures with the studied inhibitors are 
in dire need. GR consistently proves difficult to crystallize (possibly a result of its 
flexibility). The lack of experimental data regarding the binding mode of our 
small-molecule inhibitors leaves us relying on models created by molecular 
docking. Although using a model has proven to be accurate enough for lead 
optimization on the 1H-benzimidazole-2-sulfonic acid scaffold (Chapter 3), this 
was a pretty clear cut case, considering the compound's asymmetry and the 
presence of only one negative charge (negative charges are consistently 
positioned between the catalytic cysteines in previously reported GR co-crystals). 
There are many GR inhibitors for which molecular docking predicts several 
variable binding modes. For example, croconic acid was an interesting scaffold 
discovered in virtual screening (Chapter 1), but possesses symmetry and two 
negative charges. In this case, it would be ill-advised to conduct a lead 
optimization campaign relying on the modeled complex. In our efforts to address 
this dearth of structural information, and in addition to on-going crystallization 
efforts, the author has contructed a mutagenized form of GR, which once 
expressed with 15N-labelled histidine, is purified and sent to collaborators with 
expertise in the extremely high-resolution solid-state NMR technique, REDOR 
(Rotational Echo Double Resonance). This will be the largest protein construct to 
be subjected to REDOR measurements to date. With fluorine- or 13C-labeled 
inhibitors, this system could prove much more robust at reporting structural 
information. Additionally, this technique has the capacity to reach resolutions 
high enough to assign individual protonation states, a thrilling prospect for 
determining exact pKa values within the GR active site. 
 
  
 
VI. Areas for Further Development and Research 
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 The discoveries described here lay the groundwork for intriguing further 
studies with glutamate racemase. There are several opportunities now to 
advance drug discovery for allosteric inhibitors of glutamate racemase. The 
creation of a glutamate racemase model that accurately represents the transition-
state conformation and its subsequent employment as the receptor for virtual 
screening has proven successful in discovering new competitive inhibitors 
(Chapter 1). If one was also able to model the conformation of glutamate 
racemase under the effects of an allosteric inhibitor, it may be possible to 
effectively target an allosteric pocket in a similar manner. There has been a 
general upswing of the development of allosteric regulators as viable 
therapeutics by the pharmaceutical industry, eg. FDA-approved, antiretroviral 
drug, Maraviroc (Pfizer)2 and an antiparathyroidism drug, Cinacalcet (Amgen)3. 
Allosteric regulators provide unique opportunities for combination therapy against 
a single protein target. Along the same lines, the FERM-SMD method was 
proven effective at ranking  congeneric derivatives of a lead scaffold using a 
steered molecular dynamics simulation to generate distinct and functionally 
relevant protein conformations for ensemble docking. Similar simulations can be 
performed with known allosteric inhibitors (eg. dipicolinic acid bound to GR from 
B. anthracis, or AstraZeneca's pyrazolo-pyrimidinedione analogue bound to GR 
from H. pylori) from their respective pockets in order to apply the same method to 
lead optimization of current allosteric scaffolds. A high-resolution x-ray crystal 
structure exists in the case of the AstraZeneca compound, but one would need to 
be acquired in the case of dipicolinic acid to provide a confident starting structure 
for such simulations. 
 
 Taking a more fundamental path, the key hypothesis proposed in Chapter 
5, Inhibition by pKa Trapping (IPKAT) can be tested directly via the exact 
determination of the catalytic cysteines' pKa's. Previous work by the lab of Dr. 
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Leslie Poole (Wake Forest University) established a method that accomplishes 
just that by using a cysteine-specific label, iodoacetanilide, to covalently modify 
the target protein at varying pH4. The extent of labeling can be measured with 
MALDI-TOF mass spectroscopy and the rate of labeling at varying pH can be 
plotted to determine the pKa of specific cysteines. One could perform such 
experiments with GR in the presence and absence of an allosteric inhibitor to 
determine any shifts in the pKa of the catalytic base incurred by inhibitor binding. 
Preliminary work on this project has already been completed by the author, but 
was not included in this thesis. Mass spectroscopy has confirmed the ability of 
the pH-sensitive label to reach and covalently modify both catalytic cysteines 
within the buried active site. Depending on the results obtained with allosteric 
inhibitors, it may also be interesting to similarly investigate the GR from E. coli, 
which is the only known GR to be regulated by an endogenous activator, UDP-
MurNAc-L-Ala. If enzyme inhibition is achieved via a environmental perturbation 
that lowers the pKa of the catalytic base, one would expect a change in the 
opposite direction in order to achieve activation. 
 
 An important aspect of this work was the development of methods that 
improve the drug discovery and development processes. In order for these 
methods to be universally applicable, they must be tested with other enzyme 
systems. The "reactive conformation" approach to virtual screening and the 
FERM-SMD method of lead optimization should be applied to the other in-house 
systems: glucokinase, a drug target related to type II diabetes; and caspase-7, a 
drug target implicated in both cancer and inflammation. The distinct nature of 
each of these proteins will present new issues to troubleshoot and result in more 
robust and universal methodologies. 
 
 
  Finally, an additional line of work that was completed by this author, but 
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was not near enough to publication to be included as a thesis chapter, has 
entailed the incorporation of a local, highly fluorescent probe into GR as a means 
of monitoring the conformational changes induced by small-molecule binding. 
The results revealed surprising structural alterations incurred by ligand binding 
that were confirmed via Small-Angle X-Ray Scattering. These results corroborate 
the assumptions made during the development of the FERM-SMD method 
(Chapter 2 and 3), specifically that different small-molecules binding to the same 
buried active site have the ability to induce distinct conformational changes.  
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APPENDIX A 
 
SUPPORTING INFORMATION FOR CHAPTER 1 
 
 
Exploiting Enzyme Plasticity and Reactivity in Virtual Screening and Ligand 
Discovery: the discovery of glutamate racemase inhibitors with high ligand 
efficiency values. 
 
Katie L. Whalen§, Katherine L. Pankow§, Steven R. Blanke† and M. Ashley 
Spies‡§* 
 
§Department of Biochemistry, ‡Institute for Genomic Biology, and †Department of 
Microbiology, University of Illinois, Urbana, Illinois 61801 
 
Computational Methods 
 High-throughput database virtual screening. The docking of the Chemical 
Computing Group’s Conformational Data Base, version 2007, (lead-like 
compounds, based on the parameters set forth by Oprea1, and consisting of ~ 1 
million compounds from public catalogs of 45 chemical suppliers) into the active 
site of the reactive conformation of B. subtilis glutamate racemase was 
performed as described in Spies et al.,2 However, the method is briefly outlined 
as follows: Docking was performed using the program LigandFit3 within the 
Cerius2 suite (Accelrys, Inc.) The receptor was an energy minimized snap shot 
for MD simulations with the glutamate carbanion, which was later validated to 
173 
 
lead to ab initio upon geometry 
optimization, as described in Spies et al.2 All compounds in the database were 
protonated, energy minimized, and docked in the binding site, performing in-situ 
ligand conformational search and rigid-body minimization of the docked poses in 
the receptor’s binding site. All docked compounds were scored using the 
LigScore scoring function available in LigandFit. The resulting docked poses 
were analyzed for biological and computational consistency by i) verifying that 
the known carbanion ligand was ranked among the best compounds, and ii)  
verifying that the carbanion was docked in a geometry that reproduces the initial 
pose.   
  
 Scoring and Ranking of Docked Poses. In the initial virtual screen, 
detailed above, LigScore was used in ranking docked poses, and the top 500 
compounds were selected for further analysis. A more rigorous and 
computationally expensive ranking was employed hereafter to re-rank these 
compounds in order to determine compounds for actual experimental 
examination for GR inhibition activity. The LigX utility within the Molecular 
Operating Environment (MOE)4, Version 2008.10, was used to predict the 
binding free energy for the docked complex (i.e. the pKi value). The scoring 
procedure involved first a local energy minimization, in which only the ligand and 
all atoms (including protein receptor and water) in a sphere of 8 Ǻ from the ligand 
are allowed to move in the geometry optimization. The force field used in the 
energy minimization was MMFF94x, using a nonbonded cutoff of 10 Ǻ. After 
energy minimization, the complex is scored using the MOE’s London dG scoring 
function4 (vide infra), which is similar to the often cited scoring function used in 
AutoDock5. Briefly, the functional form of the London dG scoring function is as 
follows:  
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∆𝐺 =  𝑐 +  𝐸𝑓𝑙𝑒𝑥  +   𝑐𝐻𝐵 ∗ 𝑓𝐻𝐵
ℎ−𝑏𝑜𝑛𝑑𝑠
 +   ∆𝐷𝑖
𝑎𝑡𝑜𝑚𝑠  𝑖
 
 
 
where c is the average gain/loss of translational and rotational entropy; Eflex 
equals the energy from loss of flexibility of the ligand; fHB is a measure of the 
degree of imperfections of hydrogen bonds (ranging from zero to 1); Di is the 
desolvation energy of atom i.  
∆𝐷𝑖 = 𝑐𝑖𝑅
3{   𝑢 −6𝑑𝑢
𝑢∈𝐴∪𝐵
−  𝑢 −6𝑑𝑢
𝑢∈𝐵
} 
 
  
 
where A and B are the protein and ligand volumes, respectively, with atom i 
belonging to B; R is the solvation radius of atom i; ci is the desolvation coefficient 
of atom i. The values of c, cHB and ci were fitted from ~ 400 x-ray crystal 
structures of protein-ligand complexes and their corresponding experimentally 
determined pKi values. The triple integrals were approximated using the 
Generalized Born integral. For additional information the reader is referred to the 
MOE (2008.10) manual (Chemical Computing Group, Inc.)4.   
The London dG scoring function was a far superior ranking system than 
sampling using MMFF94 protein-ligand interaction energies from globally energy 
minimized complexes, as had been employed on GR studies in the past, which 
led to only weak competitive inhibitors with low mM binding dissociation 
constants, as described in Spies et al.,2 The MMFF94 interaction energy 
approach, as employed previously, was computationally more expensive, and did 
not locate any M lead compounds.   In the current approach, using the ranking 
based on the London dG scoring led to the discovery of two M competitive 
inhibitors, one weak inhibitor and one compound which was shown to be a 
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colloidal aggregator (by employing the well-established detergent tests of 
Shoichet and coworkers6, 7). 
 
Detailed Docking of 3 into the Reactive Conformation of GR versus 
Docking into GR Crystal Structure Using Docking-Energy Minimization. The goal 
was to look at all reasonable poses of 3 docked into the reactive form of GR and 
the crystal structure of GR (PDB 1ZUW), retaining all docked poses and allowing 
each pose to undergo minimization and rescoring with London dG, as above. 
The Dock utility of MOE (Version 2008.10) was employed. Briefly, the Alpha 
Triangle method4 was employed for the placement stage, followed by scoring 
using the London dG scoring function. The next step was a refinement stage, 
consisting of a full force field (MMFF94) energy minimization of each pose into 
the rigid receptor, followed by a rescoring using the London dG scoring function. 
This procedure was followed for both the reactive form of GR as receptor and the 
crystal structure of GR as receptor, respectively. All explicit solvent was included 
in the receptor, and the energy minimization convergence is defined as an RMSD 
gradient of 0.01 kcal/mol/Ǻ2, with an upper limit of 500 iterations. The MMFF94 
force field is used in the energy minimization; receptor residues over 6 Ǻ away 
from ligand poses are not included in the energy calculation. The final energy 
was calculated using the Generalized Born solvation model4.  
 
 Calculation of Tanimoto Volumes for 3 Docked into Reactive 
Conformation of GR and the Crystal Structure of GR. Tanimoto volumes (Tvol) is 
a measure of the goodness of overlap between docked poses (or between a 
docked pose and an experimentally determined receptor-ligand complex), which 
has the following form8-10: 
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𝑇𝑣𝑜𝑙 =
𝑂𝑥𝑦
𝐼𝑥 + 𝐼𝑦 − 𝑂𝑥𝑦
 
 
 
where, Oxy is the overlap in molecular volume between  two docked 
poses; Ix and Iy are the molecular volumes of docked poses x and y, respectively. 
For the case of perfect overlap between pose x and y, Oxy is equal to the 
molecular volume overlap between compounds x and y, which reduces Tvol to a 
value of unity. When there is no overlap at all between poses, then Oxy 
approaches zero, and Tvol approaches zero.  Tvol is considered a superior method 
for the similarity of placement between complexes, because it accounts for cases 
where a ligand may be rotated ~ 180˚ (i.e. flipped), but which accurately 
describes the available and occupied active site space8-10.  
 
 Calculations of Molecular Volumes Using Yasara. The solvent excluded 
(ie Connolly) surface of 3, from docked poses, was calculated using the program 
YASARA11 (Version 9.5.10), using the ‘Numeric’ algorithm option, with the default 
grid resolution.  
 
 
Experimental Methods  
Materials. Materials for Luria-Bertani (LB) medium were purchased from BD 
Diagnostics (Franklin Lakes, NJ). Isopropyl-β-D-thiogalactoside (IPTG) was 
purchased from Fisher Scientific (Fair Lawn, NJ). Ampicillin, dithiothreitol (DTT), 
and β-mercaptoethanol were obtained from Sigma Aldrich (St. Louis, MO). 
Amicon centrifugal filter devices with a molecular weigh cutoff of 10,000 were 
purchased from Millipore (Billerica, MA).  Ni-NTA His-Bind Resin was obtained 
from Invitrogen. Materials for preparing the Ni-NTA bind, wash, and elute buffers 
were obtained from Sigma Aldrich. Iodonitrotetrazolium chloride, Nicotinamide 
adenine dinucleotide hydrate (NAD+), Diaphorase from Clostridium kluyveri and 
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L-Glutamate Dehydrogenase from bovine liver (obtained as an ammonium 
sulfate suspension) was purchased from Sigma Aldrich. Adenosine-5’-
Diphosphate, Disodium Salt, Dihydrate was obtained from USB Corporation 
(Cleveland, OH). Compound 4 (ID# S364169) was obtained from Sigma-Aldrich. 
Compound 5 (ID# BAS 00124393) was obtained from Asinex (Salem, NC). 
Compound 1 (ID# MMSA-1076) was obtained from Scientific Exchange (Center 
Ossipee, NH). Compound 3 (ID# LT00453399) was obtained from Labotest OHG 
(Niederschöna, Germany). Compound 7 was obtained from InterBioschreen (ID# 
BB_NC_0417). Compound 8 was obtained from Sigma (ID# 297763). Compound 
2 was obtained from Sigma’s Rare Chemical Library (ID# S819670).     
 
GR Expression and Purification. The expression and purification of RacE (B. 
subtilis GR)2, RacE1 and RacE2 (isozymes of B. anthracis GR)12 were as 
described previously. A 10 mL starter culture of LB medium with 100 μg/mL 
ampicillin was prepared from the stock E. coli BL21 (DE3) cells containing a pET-
15b-racE plasmid and grown overnight at 37 degrees Celsius with rotation. The 
10 mL starter culture was back-diluted into 1 L fresh LB medium with 100 μg/mL 
ampicillin. Cells were grown at 37 degrees Celsius with shaking until the optical 
density at 600 nm reached ~ 0.5. RacE expression was induced upon addition of 
a final concentration of 0.1 mM IPTG. Following induction, cells were grown for 
an additional 16 h at 37 degrees Celsius with shaking. Cells were harvested by 
centrifugation at 5,000 x g for 15 min.  Supernatant was discarded and cell 
pellets were resuspended in Ni-NTA bind buffer (50 mM phosphate, 300 mM 
NaCl, 20 mM imidazole, 0.5 mM Tris carboxyethyl phosphine, pH 8.0). Cell lysis 
was achieved through sonication (3x 20 sec cycles, 23 kHz and 20 W), using a 
100 Sonic Dimembrator from Fisher Scientific. Insoluble materials were pelleted 
by centrifugation at 30,000 x g for 30 min and clarified lysate was applied to 4 mL 
bed volume of Ni-NTA His-Bind resin. Bound protein was washed with 2X 16 mL 
of wash buffer (50 mM phosphate, 300 mM NaCl, 40mM imidazole, 0.5 mM Tris 
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carboxyethyl phosphine, pH 8.0). Bound protein was eluted twice with 4 mL 
elution buffer (50 mM phosphate, 300 mM NaCl, 250 mM imidazole, 0.5 mM Tris 
carboxyethyl phosphine, pH 8.0) and the collected eluant was exchanged into 
protein storage buffer (50 mM Tris, 100 mM NaCl, 0.2 mM DTT, pH 8.0) utilizing 
a 10,000 MWCO Amicon centrifugal filter device from Millipore. Concentration by 
centrifugation and resuspension in protein storage buffer was repeated twice 
more for a total of 3 buffer exchanges. 
 Protein concentration was quantified by absorbance spectroscopy based 
on previously employed methods13. Based on the primary amino acid sequence, 
the extinction coefficient for RacE was calculated to be 24,401 M-1 cm-1 at 
280nm. Absorbance readings were acquired using a Cary 300 Bio UV-Visible 
Spectrophotometer from Varian Incorporated (Palo Alto, CA). Finally, protein 
stocks (final concentration = 0.420 mM) were stored in protein storage buffer with 
20% glycerol at -20 degrees Celsius.  
  
 
Enzyme Kinetics – Circular Dichroism. Stereoisomerization of D-glutamate by 
glutamate racemase was assayed using a J-720 CD spectropolarimeter from 
JASCO (Easton, MD). A jacketed cylindrical cuvette with a volume of 750 μL and 
a path length of 10 mm was used for each assay. Readings were measured at 
220nm or 225nm depending on contributions to the signal by the inhibitor. All 
measurements were conducted at 25 ˚C. Concentrations of D-glutamate were 
varied from 0.25–5 mM in an optically clear borate buffer (50 mM boric acid, 100 
mM KCl, 0.7 mM DTT; pH 8.0). Reactions were initiated upon addition of RacE 
(0.84 μM), RacE2 (0.47 μM) or RacE1 (0.49 μM) . Data acquisition was 
performed using a JASCO Spectra Manager v1.54A software and Excel, and 
fitting was performed using GraphPad Prism v5.0 software from GraphPad 
Software (San Diego, CA). For weaker inhibitors with high absorbance, where 
higher concentrations were employed, a 1 mm path length cuvette was used in 
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order to avoid saturating the instrument. Data was also presented as 
Lineweaver-Burke plots, using KaleidaGraph v4.03 by Synergy Software 
(Reading, PA). 
 
No Observed Time-Based Inhibition of GR by 5. Inhibitors were analyzed for 
time-dependent inhibition by mixing RacE (0.56 μM) and inhibitor (50 μM) in 
optically clear borate buffer (50 mM boric acid, 100 mM KCl, 0.7 mM DTT; pH 
8.0) and incubating on ice for various amounts of time (0 min, 2.5 min, 5 min, and 
10 min). Reactions were initiated upon addition of D-glutamate (1 mM) and initial 
velocity was measured using circular dichroism as described above. Differences 
in initial velocity are negligible (less than 10%) for both compounds (Figure S1). 
  
Testing for Colloidal Aggregation. It has been well established that the 
identification of non-competitive inhibition, which has often arisen in high 
throughput screenings (both virtual and non-virtual), may be the result of colloidal 
aggregation of the ligand of interest. This phenomenon occurs exclusively with 
(apparent) non-competitive, not competitive inhibitors, and has been extensively 
characterized and reviewed by Shoichet and co-workers6, 7. In the current study, 
a single non-competitive inhibitor was identified (1; Table 1). Thus, 1 was 
analyzed for the possibility of colloidal aggregation using a previously established 
detergent-based assay6. First, we describe the coupled enzyme assay used in 
this study14, followed by the details of the detergent assay for colloidal 
aggregation.  
 
   
Enzyme Kinetics – Coupled-Enzyme Assay. The D- to L-glutamate 
racemization activities of RacE, RacE1 and RacE2 were assayed through a 
previously established coupled method14, utilizing L-glutamate dehydrogenase 
and diaphorase. Absorption data was collected on a Cary 300 UV-VIS 
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Spectrophotometer from Varian Incorporated (Palo Alto, CA). In this coupled-
enzyme assay, the stereoinversion of D-glutamate by glutamate racemase 
provided the L-glutamate required by L-glutamate dehydrogenase. The NADH 
by-product of dehydrogenation is then oxidized by diaphorase to produce the 
reduced form of iodonitrotetrazolium (INT). Reduced iodonitrotetrazolium can be 
quantified by measuring the absorption at 500 nm.  
Coupled-Enzyme Assay Calibration. The stoichiometric relationship 
between absorption at 500 nm and the concentration of L-glutamate produced 
was calculated to be approximately 0.00103 AU/nmol, with some variance 
depending on the absorptivity of each new batch of iodonitrotetrazolium (INT). 
Absorptivity of INT was determined by titrating 10 nmol-aliquots of L-glutamate 
into a cuvette containing diaphorase, INT, L-glutamate dehydrogenase, ADP and 
NAD+. Absorption at 500 nm is plotted as a function of L-glutamate added. The 
slope of this plot is the conversion factor used in the coupled-enzyme assay to 
convert AU/min to nmol/min.  
Coupled-Enzyme Assay: test for inhibition of glutamate dehydrogenase 
coupling enzyme. The coupled-enzyme assay was utilized in order to determine 
any possible incidence of L-glutamate dehydrogenase inhibition by the added 
inhibitor. Michaelis-Menten curves were composed under three sets of 
conditions: without inhibitor, with a concentration of inhibitor that causes 
significant inhibition (of the full coupled system), and with the same concentration 
of inhibitor and twice the concentration of glutamate racemase. All other reagent 
concentrations remain the same. If L-glutamate dehydrogenase is not being 
inhibited, one would expect to see an exactly two-fold increase in activity in the 
presence of two-fold more glutamate racemase15. In other words, the ratio of 
initial velocity in the presence of 1X enzyme to the initial velocity in the presence 
of 2X enzyme should be 1:2. For 1, the ratio is 1: 1.91 ± 0.07, which is within 
error due to factors of the coupled-enzyme system. Thus, 1 would not appear to 
be inhibiting the coupled enzyme and any inhibition witnessed is that of 
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glutamate racemase alone. For 4, the ratio is 1: 1.75 ± 0.01 indicating that some, 
but not the majority, of the total inhibition is contributed by inhibition of L-
glutamate dehydrogenase. It should be noted that neither compounds 1 nor 4 
could be studied using circular dichroism due to their high absorbance in the UV 
range. 
 
Detergent Assay for Colloidal Aggregation (false positive for non-
competitive inhibition)-Activity of RacE was measured in the presence and 
absence of inhibitor in buffer containing 0.01% Triton X-100 (vol/vol). The percent 
inhibition was compared to that acquired when conducting the same 
measurements in buffer without Triton-X 100. If the inhibitor is indeed 
aggregating, one would expect to see a decrease in the percent inhibition in the 
presence of detergent. A greater than two-fold decrease in inhibition confirms 
colloidal aggregation6. These tests were all performed using the coupled enzyme 
assay14 (vide supra), together with controls and calibration. Figure 3 shows that 1 
is, indeed, a colloidal aggregator (1 was the only non-competitive inhibitor found 
in the current study). As a further control for this study, we also performed said 
detergent test on the competitive inhibitors 3 and 5, which did not have any effect 
on rate as a function of increasing concentrations of detergent, as expected.  
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Figures 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1. Initial velocity of stereoinversion of D-glutamate catalyzed by RacE 
in the presence of inhibitor (3 or 5) as a function of increasing incubation time. 
Differences in initial velocity are negligible (less than 10%) for both compounds.  
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Figure A.2 A.  
 
 
 
 
 
 
 
Figure A.2 B.  
 
 
 
 
 
Figure A.2. IC50 curves for compound 3 against Bacillus anthracis glutamate 
racemase isozymes, RacE1 (a) and RacE2 (b). The Log[Inhibitor] vs. Response 
equation (constraints: TOP = 0.22, BOTTOM = 0.04, and SLOPE = -1.0) was fit 
using GraphPad Prism v5.0 software.  
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Figure A.3. Superpose of GR complex with 3 onto GR complex with Cyclic 
Glutamate Carbanion. The top scoring complex from docked compound 3 into 
the reactive form of GR (as outlined in Figure 1) is shown with its molecular 
volume, while the cyclic glutamate carbanion is rendered in stick form. The 
overlap image derives from a full superpose of the two complexes, and only the 
ligands are shown for clarity. The Tvol value (see Computational Methods section, 
above, for a full description of this metric) for this overlap was calculated to be 
0.55. This indicates a reasonable volume overlap between the two complexes; 
however, there is clearly a far from ideal electrostatic mapping between the two 
complexes, especially around the C  and C  carbons of the carbanion. The 
docking procedure is described above in the Computational Methods section.  
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Table B.1. Complete set of bona fide GR inhibitors discovered in-house (in 
addition to the native substrate) with predicted binding constants (Kd), acquired 
from docking to the crystal structure alone or FERM-SMD structures and the 
actual binding constant as approximated by experimentally-derived Ki, Km, and 
IC50 values. Purity and method of analysis noted for each ligand. 
Compound Predicted Kd (mM) Actual Kd (mM) Purity, Method 
 Crystal Only FERM-SMD   
1  
0.29 0.002 0.009 99.9%, HPLC 
2  
0.61 9.1 0.042 > 95%, HPLC 
3  
0.002 0.001 0.059 > 99%, NMR 
4  
0.96 0.24 0.1 > 99%, TLC 
5  
276 0.05 0.43 99.8%, HPLC 
6  
0.76 0.44 0.6 > 99%, TLC 
7  
0.15 1.7 1.3 
See Komarov et 
al. 2008 
8  
1.9*10-5 1.9 1.5 100%, PAT 
9  
4.4 0.41 1.9 99.8%, GC 
10  
0.23 0.91 1.9 96.1%, OxForm 
11  
0.005 6.0 1.9 > 99%, TLC 
12    
3.0 34 2.7 99.6%, GLC 
13  
1.6 59 14 96.8%, GLC 
14  
16 28 16 100%, SHT 
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15  
62 8.9 63 99.1%, IET 
16  
1.4*10
4
 112 70 99.9%, GC 
17  
1.9*103 89 110 99.7%, PAT 
 
Abbreviations: HPLC, high performance liquid chromatography; NMR, nuclear magnetic 
resonance; TLC, thin layer chromatography; PAT, perchloric acid titration; GC, gas 
chromatography; OxForm, oxime formation; GLC, gas liquid chromatography; SHT, 
sodium hydroxide titration; IET, ion exchange titration 
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Figure B.1. Front (A) and side (B) view of active site entrance of superposed GR 
structures (ribbon) with Prolines shown (stick) and direction of expansion 
indicated (white arrows). Structures were superposed so that the RMSD of all 
atoms is minimal. The three structures of GR selected for ensemble docking 
correspond to the following distances between glutamate and GR (centers of 
mass): 41.9 Å (red), 43.7 Å (green), and 46.7 Å (blue). Prolines shown are the 
following: Pro150 (top, foreground), Pro146 (bottom, foreground), Pro44 (bottom, 
background) and Pro41 (top, background). Length and direction of white arrows 
are arbitrarily assigned and meant only as a visual aid.  
 
 
 
 
 
 
 
 
 
A B
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Figure B.2. Correlations of binding energies as predicted by docking to a single 
structure from the FERM-SMD ensemble and experimentally-determined binding 
affinities. Structure numbers are arbitrarily assigned and the corresponding 
simulation time is listed in parentheses. Data is fit to a logarithmic equation and 
the Spearman correlation coefficient, denoted R, is indicated.  
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Figure B.3. Correlation of predicted FERMScore values and experimental binding 
affinities where the described FERM-SMD method is performed on structures 
acquired from a 16-nanosecond classical MD simulation of apo-RacE, in place of 
structures acquired from SMD. Three structures were selected from the classical 
MD by composing a structure-based phylogenetic tree of snapshots taken every 
150 picoseconds and performing QR analysis to select for non-redundant 
structures, using a QH cutoff of 0.89. All other steps of the FERM-SMD method 
remaining the same. 
193 
 
 
Figure B.4. Global fitting to a competitive inhibition model and non-linear fitting to 
a dose-response curve for derivation of Ki and IC50 values, respectively. Enzyme 
kinetics were measured via circular dichroism and colorimetric coupled-enzyme 
assays (See Methods for details) in the presence of saturating D-glutamate. 
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Figure B.5. Equilibration achieved over 500 picoseconds of molecular dynamics 
simulations. Differences between the backbone carbons of each subsequent 
simulation snapshot structure (interval = 25 psec) and the original structure, 
expressed as RMSD (Å), plotted against simulation time for each GR-ligand 
complex (a-q).  
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Figure B.6. Detergent assay for elimination of false positives due to non-specific 
inhibition by aggregation. Percent inhibition was analyzed for each inhibitor at a 
concentration near the IC50 with saturating D-glutamate (1 mM) and in the 
presence or absence of 0.01% Triton X-100. Detergent assays were not 
performed for substrate analogs nor known active site binders. 
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Figure B.7. Electrospray ionization mass spectrometry for confirmation of ligand 
structure of compounds presented here for the first time as being active against 
GR. 
a. 12 (4-pyridazine carboxylic acid) 
 
b. 5 (alpha-ketoglutarate) 
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c. 1 (1H-benzimidzole-2-sulfonic acid 
 
d. 6 (2-chloroaniline-4-sulfonic acid) 
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d. 8 (D-glucuronic acid) 
 
e. 13 (D-pyroglutamate) 
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f. 10 (2-formylbenzene-sulfonic acid) 
 
g. 4 (D-glutamate) 
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h. 14 (L-pyroglutamate) 
 
i. 15 (2-methyl-2-propene-1-sulfonic acid) 
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j. 11 (2-hydroxy-5-nitrobenzenesulfonic acid) 
 
k. 16 (citrate) 
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l. 9 (dipicolinic acid, DPA) 
 
m. 17 (L-tartrate) 
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Figure B.8. Area of active site entrance and corresponding protein solvation 
energy at varying time points along the trajectory of a Steered Molecular 
Dynamics simulation. The x-axis corresponds to the distance between the center 
of the mass of D-glutamate and the center of mass of GR as D-glutamate is 
being pulled out of the active site. Protein solvation energy was calculated for 
each time-point using the Poisson-Boltzmann method with an internal dielectric 
of 2, a solvent dielectric of 78, and a salt concentration of 0.1 M.   
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Supplemental Data 
 
1H-NMR Peaks  
The following compounds were selected from a previous virtual screening 
study or were analogues based on hits from the same virtual screening study[1]. 
Nuclear magnetic resonance (NMR) was used to confirm the structure of each hit 
and all experimentally-attained spectra agree strongly with chemical shifts 
predicted by ChemDraw Ultra v12.0 (CambridgeSoft Corp., Cambridge, MA). All 
1H-NMR spectra were acquired in-house on a Varian Unity 400 MHz with a 5mm 
Nalorac QUAD probe, unless indicated otherwise. All samples analyzed in-house 
were suspended in D2O.  
1 (1-benzimidazole-2-sulfonic acid). δ (ppm) 7.05 (d, 2H), 7.45 (d, 2H). 
2 (Croconic acid). δ (ppm) 16.78 (s, 1H). 
3 (4-Hydroxy-1,3-benzenedisulfonic acid). (1H-NMR performed by Asinex, 
Moscow, Russia) δ (ppm) 7.03 (d, 1H,), 7.81 (d, 1H), 8.14 (s, 1H). 
6 (2-Chloroaniline-4-sulfonic acid). δ (ppm) 4.54 (s, 2H), 6.78 (d, 1H), 7.35 (d, 
1H), 7.55 (s, 1H). 
9 (2,6-Pyridinedicarboxylic acid [dipicolinic acid]). (1H-NMR performed by 
Sigma-Aldrich, St. Louis, MO) δ (ppm) 8.1-8.3 (m, 3H). 
10 (2-Formylbenzenesulfonic acid). δ (ppm) 7.55-7.60 (dt, 2H), 7.80 (t, 2H), 
10.55 (s, 1H). 
11 (2-Hydroxy-5-nitrobenzensulfonic acid). δ (ppm) 3.22 (s, 1H), 6.35 (d, 1H), 
7.90 (d, 1H), 8.38 (s, 1H). 
12 (4-pyridazinecarboxylic acid). δ (ppm) 7.82 (d, 1H), 9.15 (d, 1H), 9.20 (s, 
1H). 
13* (D-pyroglutamic acid). δ (ppm) 1.68 (m, 2H), 2.40 (t, 1H), 2.60 (m, 1H), 
3.95 (t, 1H). 
14* (L-pyroglutamic acid). δ (ppm) 1.68 (m, 2H), 2.40 (t, 1H), 2.60 (m, 1H), 3.95 
(t, 1H). 
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15 (2-Methyl-2-propene-1-sulfonic acid). δ (ppm) 1.69 (s, 3H), 3.42 (s, 2H), 
4.85 (d, J = 2.1, 2H). 
*Compounds  13  and  14  were not derived from virtual screening, but rather 
were substrate analogs.  
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Description of Sources of Active Compounds 
The following compounds were direct hits from a virtual screening of  ~ 1 
million compounds (Chemical Computing Group Conformational Database 
Version 2007, Chemical Computing Group, Montreal, Canada) conducted 
previously by Spies et al.[1]: compounds 2 (croconic acid, ranking = #75), 3 (4-
hydroxy-1,3-benzenedisulfonic acid, ranking = #57), 9 (dipicolinic acid, ranking = 
#62) and 11 (2-hydroxy-5-nitrobenzenesulfonic acid, ranking = #59). The 
following compounds were analogs derived from virtual screening hits: 1 (1-
benzimidazole-2-sulfonic acid), 6 (2-chloroaniline-4-sulfonic acid), 10 (2-
formylbenzenesulfonic acid), 12 (4-pyridazinecarboxylic acid) and 15 (2-methyl-
2-propene-1-sulfonic acid). Glutamate analogs include the following compounds: 
4 (α-ketoglutarate), 7 (a restricted glutamate derivative), 8 (D-glucuronic acid), 13 
(D-pyroglutamate), 14 (L-pyroglutamate), 16 (citrate), and 17 (tartrate).  D-
glutamate itself was also included in this study (compound 5). 
 
 
 
 
 
 
 
 
[1] M. A. Spies, J. G. Reese, D. Dodd, K. L. Pankow, S. R. Blanke and J. Baudry, 
J Am Chem Soc 2009, 131, 5274-5284. 
Reprinted (adapted) with permission from Whalen, K. L.; Chau, A. C.; Spies, M. A. 
ChemMedChem, published online August 8th, 2013; DOI: 10.1002/cmdc.201300271. Copyright 
2013 John Wiley and Sons.  A. C. Chau contributed in silico docking. M. A. Spies contributed 
intellectual direction. 
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APPENDIX C 
 
SUPPORTING INFORMATION FOR CHAPTER 3 
 
IN SILICO OPTIMIZATION OF A FRAGMENT-BASED HIT YIELDS 
BIOLOGICALLY ACTIVE, HIGH EFFICIENCY INHIBITORS FOR GLUTAMATE 
RACEMASE. 
Katie L. Whalen[a,b], Anthony C. Chau[b], and M. Ashley Spies *[a] 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C.1. SDS-PAGE analysis of purified glutamate racemases from B. subtilis 
(*), B. anthracis (*), and F. tularensis (**).  Two isozymes exist in the case of B. 
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anthracis. Molecular weight of glutamate racemases from B. subtilis and B. 
anthracis is ~31,500 and F. tularensis is ~29,300.  
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Figure C.2. Circular dichroism of purified proteins to assess protein foldedness.  
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Figure C.3. 1H NMR spectra for compound 4. Experiment conducted at ambient 
temperature. Peak at 2.50 corresponds to the employed solvent, DMSO. 
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Figure C.4. 1H NMR spectra for compounds 18. Experiment conducted at 
ambient temperature. Peak at 2.50 corresponds to the employed solvent, DMSO. 
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Figure C.5. 1H NMR spectra for compounds 29. Experiment conducted at 
ambient temperature. Peak at 2.50 corresponds to the employed solvent, DMSO. 
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Figure C.6. HPLC analysis of compound 4, showing 98.1% purity.  
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Figure C.7. HPLC analysis of compound 18, showing 99.0% purity.  
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Figure C.8. HPLC analysis of compound 29, showing 100.0% purity. 
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Figure C.9. Example of MIC50 reagent volumes for a single replicate of one 
inhibitor. Inhibitor concentration varies along the X-axis of the plate. Two 
compounds could be assayed in triplicate per 96-well plate of bacteria. Blank 
wells contain 100 μL of phosphate-buffered saline (PBS) and 100 μL of 2X 
media.  
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Figure C.10. Colloidal aggregate testing for newly synthesized derivatives of 1H-
benzimidazole-2-sulfonic acid. Racemase activity tested in the presence of a 
fixed concentration of inhibitor (200 μM), 1 mM D-glutamate, and with or without 
0.01% Triton X-100 included in the working buffer. %-Inhibition determined in 
triplicate with standard deviation shown (error bars). 
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Figure C.11. MIC50 analysis of select derivatives of  1H-benzimidazole-2-sulfonic 
acid against Lactococcus lactis. Compounds 18 and 26 show no growth inhibition 
within the tested range of inhibitor concentrations. Compound 29 starts to show 
growth inhibition at the highest tested concentration. Surprisingly, compound 4 (a 
potent growth inhibitor against B. subtilis) causes noticeable growth activation 
compared to untreated cells. This is an unexpected phenomenon, which may be 
the result of productive metabolism of the inhibitor compound. 
 
Reprinted (adapted) with permission from Whalen, K. L.; Spies, M. A. J. Chem. Inf. Mod., 
published online August 21, 2013; DOI: 10.1021/ci400244x. Copyright 2013 American Chemical 
Society. M. A. Spies contributed MD simulations and calculations related to ELR binding energy 
evaluations. 
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APPENDIX D 
 
SUPPORTING INFORMATION FOR CHAPTER 4 
 
Flooding Enzymes: quantifying the contributions of interstitial water and cavity 
shape to ligand binding using Extended Linear Response free energy 
calculations 
 
Katie L. Whalen1,2,3 and M. Ashley Spies1,2 
 
1College of Pharmacy, Division of Medicinal and Natural Products Chemistry, and  
2 Carver College of Medicine, Department of Biochemistry, the University of Iowa, 
Iowa City, Iowa; 3Department of Biochemistry, University of Illinois at Urbana-
Champaign, Urbana, Illinois 
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Table D.1. Primers used in site-directed mutagenesis to create desired GR 
mutations.  
Desired 
Mutation 
Template 
DNA 
Primer Primer Sequence (5' to 3') 
N75A 
pET15b-
racE_WT 
RacEN75Afor gctcgtgatcgcctgtgctacagcaacagcgatcg 
RacEN75Arev cgatcgctgttgctgtcgaacaggcgatcacgagc 
N75L* 
pET15b-
racE_C74A 
RacEN75AC74Afor caaaatgctcgtgatcgccgctaatacagcaacagcgatc 
RacEN75AC74Arev gatcgctgttgctgtattagcggcgatcacgagcattttg 
*The production of GR-N75L was a serendipitous result of mis-priming in PCR 
during parallel attempts to construct racE-C74A-N75A with the listed primers and 
pET15b-racE-C75A as template. Sequencing confirms racE-N75L is the only 
resulting mutation. This result was highly repeatable.  
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Table D.2. Active site analysis of inhibitor-bound GR complexes via MOE Site 
Finder. * 
Enzyme Inhibitor Size PLB Hyd Side Residues 
GR-WT 
BISA 189 2.49 18 140 
D10 S11 G12 V13 G14 G15 T37 C40 P41 Y42 
G43 A73 C74 N75 T76 A77 V96 T118 N120 
T121 V149 E153 G184 C185 T186 H187 F246 
I249 
CA 192 2.43 21 147 
D10 S11 G12 V13 G14 G 15 T37 C40 P41 
Y42 G43 A73 C74 N75 T76 A77 T118 N120 
T121 V149 E153 C815 T186 H187 Q245 I249 
GR-
N75L 
BISA 187 2.94 16 141 
D10 S11 G12 V13 G14 G15 T37 C40 P41 Y42 
G43 A73 C74 L75 T76 A77 V96 G117 T118 
N120 T121 V149 E153 G184 C185 T186 H187 
Q245 I249 
CA 156 3.02 11 117 
D10 S11 G12 V13 G14 G15 C40 P41 Y42 G43 
P44 C74 A75 T76 A77 V96 G117 T118 N120 
T121 V149 E153 G184 C185 T185 H187 Y188 
GR-
N75A 
BISA 131 2.98 10 93 
D10 S11 G12 G14 G15 P41 Y42 G43 A73 C74 
A75 T76 A77 G117 T118 N120 T121 V149 
G184 C185 T186 H187 
CA 127 2.86 8 93 
D10 S11 G12 V13 G14 G15 C40 P41 Y42 G43 
P44 C74 A75 T76 G117 T118 N120 T121 
V149 P150 E153 G184 C185 T186 H187 
* Final snapshots from MD simulation were imported to MOE v2011.10. "Size" 
indicates the number of contact atoms in the receptor.  "PLB" corresponds to the 
Propensity for Ligand Binding [Soga 2007] score. "Hyd" indicates the number of 
hydrophobic contact atoms in the receptor. "Side" indicates the number of 
sidechain contact atoms in the receptor. Finally, "Residues" indicates the 
residues that make up the calculated site. 
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Figure D.1. Cα-atom RMSD plots for GR inhibitors (A) and substrate (B) over the 
course of each complex's 4-ns MD simulation. 
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Figure D.2. SDS-PAGE analysis of purified recombinant RacE (B. subtilis). 
Molecular weight is approximately 31,000 Da with the 6X-His-tag. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
223 
 
 
 
 
 
 
 
 
 
Figure D.3. Quantification of the active site cleft for BISA (1) and CA (2) in 
complex with GR-WT, GR-N75L, or GR-N75A. Cleft measurements made by 
calculating the area between four points which form a circumference about the 
active site entrance (A). Measurements made for the final three snapshots of 
each complex simulation with standard deviations shown (B). 
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Figure D.4. Molecular surface representations of GR-BISA complexes. Structures 
were obtained from the final snapshot of each 4-ns MD simulation. Solvent 
accessible surface area is rendered in white using the YASARA Structure 
package. Surfaces are cut away to show the ligand binding pocket shape. Key 
residues interacting with the ligand (directly or via interstitial bonds) are shown 
(stick, magenta). BISA is shown bound to the active site (stick, elemental 
coloring). Hydrogen bonds are shown (yellow, dotted line), and all interstitial 
waters are shown (stick, elemental coloring). Each structure is oriented with the 
entrance to the active site positioned at the left of the image. 
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Figure D.5. Titration of D-glutamate to RacE-C74A for determination of 
dissociation constant. RacE-C74A is a functionally-inactive form of glutamate 
racemase that can bind D-glutamate, but cannot abstract the Cα proton. Intrinsic 
tryptophan/tyrosine fluorescence (excitation at 280 nm, emission at 343 nm) was 
measured continuously at 25°C using a Cary Eclipse Fluorescence 
Spectrophotometer (Agilent).  A 90 μM solution of purified RacE-C74A in 50 mM 
Tris-HCl, 100 mM NaCl, pH 8.0, 2 mM DTT was incubated in a quartz cuvette 
(pathlength = 10 mm) for 10 min at 25°C prior to the first injection.  A 50 mM 
solution of D-glutamate in the same buffer was used for substrate injections. The 
titration was repeated three times. Data was fit to a "Total binding - one site" 
model with GraphPad Prism v5.0. The dissociation constant is within error of the 
reported KM value.  
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Figure D.6. Average angle and distance measurements for ligand-protein 
hydrogen bonds observed in the final 3 snapshots of MD simulation. 
Measurements made for 3 individual snapshots per simulation. Each complex 
contained between 3-4 hydrogen bonding interactions between ligand and 
protein. The 1-WT complex possessed the most optimal overall bonding 
distances and angles, where both 1-N75A and 1-N75L complexes suffer from 
increased bond distances and decreased bond angles.  
Reprinted (adapted) with permission from Whalen, K. L.; Tussey, K. B.; Blanke, S. R.; Spies, M. 
A. J. Phys. Chem. B, 2011, 115, 3416-3424. Copyright 2011 American Chemical Society. K. B. 
Tussey contributed molecular docking with FRED and GOLD. S. R. Blanke contributed helpful 
insights into biological implications. M. A. Spies contributed intellectual direction and assistance in 
manuscript composition. 
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Supplemental Methods 
 
Protein Expression and Purification 
A 10 mL starter culture of LB medium with 100 μg/mL ampicillin was 
prepared from the stock E. coli BL21 (DE3) cells containing pET-15b plasmid 
with the gene of choice and grown overnight at 37 °C with rotation. The 10 mL 
starter culture was back-diluted into 1 L fresh LB medium with 100 μg/mL 
ampicillin. Cells were grown at 37 °C with shaking until the optical density at 600 
nm reached 0.5-0.8. Protein expression was induced upon addition of a final 
concentration of 0.1 mM IPTG. Following induction, cells were grown for an 
additional 16-20 h at 37 °C with shaking (16 °C for mutant proteins). Cells were 
harvested by centrifugation at 5,000 x g for 15 min.  Supernatant was discarded 
and cell pellets were resuspended in bind buffer (50 mM phosphate, 300 mM 
NaCl, 20 mM imidazole, 0.5 mM Tris carboxyethyl phosphine, pH 8.0). Cell lysis 
was achieved through sonication (3x 20 sec cycles, 23 kHz and 20 W), using a 
100 Sonic Dimembrator from Fisher Scientific. Insoluble materials were pelleted 
by centrifugation at 30,000 x g for 30 min and clarified lysate was applied to 4 mL 
bed volume of His-Select Cobalt Affinity Gel. Bound protein was washed with 2X 
16 mL of wash buffer (50 mM phosphate, 300 mM NaCl, 40mM imidazole, 0.5 
mM Tris carboxyethyl phosphine, pH 8.0). Bound protein was eluted twice with 4 
mL elution buffer (50 mM phosphate, 300 mM NaCl, 250 mM imidazole, 0.5 mM 
Tris carboxyethyl phosphine, pH 8.0) and the collected eluant was concentrated 
via centrifugal filtration. Eluant was incubated at 37 °C for 15 min in the presence 
of 1 mM ATP and 1 mM MgCl2 to remove molecular weight contaminants 
suspected to be chaperones. Eluant was then diluted 10X with H2O and 
submitted to ion exchange chromatography using a BioRad Uno Q1 column on a 
BioRad BioLogic DuoFlow HPLC. Pooled fractions were then exchanged into 
protein storage buffer (50 mM Tris, 100 mM NaCl, 0.2 mM DTT, pH 8.0) and 
concentrated utilizing a 10,000 MWCO Amicon centrifugal filter device.  Finally, 
protein stocks were stored at a final concentration of 7-10 mg/mL with 20% 
glycerol at -20 °C. 
Colloidal Aggregation Control 
 Inhibitors were analyzed for the possibility of colloidal aggregation using a 
previously established detergent-based assay1 (successfully applied this system 
to expose colloidal aggregators in Whalen et al.2). Activity of RacE was 
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measured in the presence and absence of inhibitor in buffer containing 0.01% 
Triton-X 100 (vol/vol). The percent inhibition was compared to that acquired 
when conducting the same measurements in buffer without Triton-X 100. If the 
inhibitor is indeed aggregating, one would expect to see a decrease in the 
percent inhibition in the presence of detergent (as seen in Whalen et al.2). Feng 
and Shoichet stated that a greater than two-fold decrease in inhibition confirms 
colloidal aggregation1.  
Enzyme Kinetics – Circular Dichroism 
Stereoisomerization of D-glutamate by GR was assayed by using a J-720 
CD spectropolarimeter from JASCO, Inc. (Easton, MD). A jacketed cylindrical 
cuvette with a volume of 750 μL and a path length of 10 mm was used for each 
assay. Readings were measured at 220nm or 225nm depending on contributions 
to the signal by the inhibitor. All measurements were conducted at 25 ˚C. 
Concentrations of D-glutamate were varied from 0.25–5 mM in an optically clear 
borate buffer (50 mM boric acid, 100 mM KCl, 0.7 mM DTT; pH 8.0). Reactions 
were initiated upon addition of enzyme (approx. 0.5 μM). Data acquisition was 
performed using a JASCO Spectra Manager v1.54A software and Excel, and 
fitting and statistical analysis was performed using GraphPad Prism v5.0 
(GraphPad Software, Inc., La Jolla, CA).  
Monomer:Dimer Equilibrium Model and BN-PAGE Data Fitting 
A monomer:dimer equilibrium model was formulated using the following 
relationships: 
    
  
 
     Eq. 1                     
           Eq. 2 
, where M is the monomer concentration, C is the complex, or dimer, 
concentration and PT is the total protein concentration.  
      
        
    Eq. 3 
Substitution via Eq. 1 and solving for C gives: 
   
          
 
 
     Eq. 4 
where            .  A similar procedure for monomer concentration leads to: 
   
      
        
 
                                          Eq. 5 
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The M/C ratio was measured via pixel quantification of BN-PAGE gels and the 
total protein concentration is known. The initial value of Kd was set arbitrarily to 
0.01 μg/mL and solved by fitting the data. All data fitting was executed using 
GraphPad Prism v5.0.  Additionally, combining equations 3 and 4 leads to the 
simpler expression in Eq. 6.  
 
 
  
    
 
  
  
  
      Eq. 6 
  
Supplemental Computational Methods 
 
Molecular Dynamic Simulations 
The molecular dynamics simulations were performed with the YASARA 
Structure package version 9.11.9 (YASARA Biosciences)3. A periodic simulation 
cell with boundaries of 99.64 Å, 70.54 Å, and 68.98 Å was employed with explicit 
solvent , using the dimer (A and B chains) of PDB 2GZM (B. anthracis RacE2 GR 
with ligand D-glu). The AMBER03 force field was used with long-range 
electrostatic potentials calculated with the Particle Mesh Ewald (PME) method, 
with a cutoff of 7.864 Å4-6. The substrate force field parameters were generated 
with the AutoSMILES utility7, which employs semi-empirical AM1 geometry 
optimization and assignment of charges, followed by assignment of AM1BCC 
atom and bond types with refinement using RESP charges, and finally the 
assignments of general AMBER force field atom types. The hydrogen bond 
network of GR is optimized using the method of Hooft and coworkers8, in order to 
address ambiguities from multiple side chain conformations and protonation 
states that are not resolved by the electron density. YASARA’s pKa utility was 
used to assign pKa values at pH 7.0
9. The box was filled with water, with a 
maximum sum of all bumps per water of 1.0 Å, and a density of 0.997 g/ml.  The 
simulation cell was neutralized with NaCl (0.9% final concentration; % by mass). 
Waters were deleted to readjust the solvent density to 0.997 g/ml.  A short MD 
was run on the solvent only. The entire system was then energy minimized using 
first a steepest descent minimization to remove conformational stress, followed 
by a simulated annealing minimization until convergence (<0.05 kJ/mol/200 
steps). The MD simulation was then initiated, using the NVT ensemble at 298 K, 
and integration time steps for intramolecular and intermolecular forces every 1.25 
fs and 2.5 fs, respectively.  
Docking Program Specifications 
GOLD employs a traditional genetic algorithm for exploring ligand 
conformations and binding modes within a partially flexible active site 10. The 
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GOLD scoring function for ranking binding modes is composed of terms that 
account for three conditions: hydrogen bonding between ligand and enzyme, the 
hydrophobic contribution of the energy of binding, and the internal energy of the 
ligand10. Quite contrary, FRED employs a non-stochastic sampling of ligand 
conformations by systematically rotating and translating conformers within the 
binding site in a stepwise fashion. Docked complexes are filtered by several 
default and user-defined constraints, such as the requirement that ligand 
conformers fit within the active site volume, and then ranked by the scoring 
function Chemgauss 3. The Chemgauss 3 scoring function is comprised of terms 
for: steric interactions, ligand hydrogen-bond donors and acceptors, interactions 
with active site metal atoms, and desolvation11. Lastly, AutoDock uses a 
Lamarckian genetic algorithm to sample ligand conformations and binding 
modes, which varies slightly from the traditional genetic algorithm employed by 
GOLD in that conformers are also allowed to search local conformational space 
to find local minima12. AutoDock uses a semiempirical free energy force field to 
predict free energies of binding which accounts for intermolecular and 
intramolecular energies, as well as charge-based desolvation.  
D-Glu Free Energy Binding Calculations with the Fast Boundary Element 
Method (BEM)  
The method employed here falls under the class of free energy 
calculations known as Endpoint Methods, which includes the popular MM-PBSA 
approach. These methods were recently reviewed by Steinbrecher and Labahn13, 
and involve calculating ΔGbind from constituent parts of a thermodynamic box that 
involves solvation of the individual components. The binding energy expression 
is: 
 
           
              
                
                
                
   
     
                                
 
In the MM-PBSA method the procedure is based on numerical solution of 
the differential Poisson equation (also called the finite difference method) and the 
solvent is represented as a continuum having a relatively high dielectric constant, 
while the protein and ligand may be viewed as point charges projected onto a 
grid in a low dielectric continuum. The molecular surface of the protein and ligand 
is the important interface between these two dielectrics. However, we employ an 
alternative approach to the finite-difference method called the Boundary Element 
Method (BEM) 14,15. In this method much of the focus is placed on accurately 
representing the boundary between the two dielectrics, in which a very accurate 
boundary charge distribution is used to represent a uniform dielectric at the 
interface between the low and the high dielectric continuum. From this boundary 
region of uniform dielectric strength, Coulomb's Law is used to calculate the 
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electrostatic potentials. Each method has distinct strengths and weaknesses, yet 
the latter has not been as widely employed in the literature even though there 
have been significant advances in the speed and accuracy of this appraoch16-18. 
The BEM method was designed to perform optimally for such curved protein 
surfaces, by accurately representing the geometry of the protein boundaries. The 
work of Zauhar and Morgan19 have shown that the geometry of the boundary 
region is of central importance to representing the electrostatic potential of 
proteins15, and may avoid some of the difficulties inherent in assignment of the 
protein dielectric in the finite difference approach of MM-PBSA (recently reviewed 
by Warshel and co-workers20). A major difficulty in Endpoint methods is assigning 
an internal dielectric. Here we used a wide range of values for εp, which did not 
affect the relative binding energies or the trends seen in Fig. 5d, but only the 
absolute free energies of binding. It is important to note that ΔGbinding values 
obtained from Endpoint methods, such as MM-PBSA or BEM, should be viewed 
as accurate scoring functions, which have enhanced rank-ordering value, rather 
than as metrics of accurate absolute binding free energy21. For the current study, 
BEM, the boundary between solvent (dielectric constant 78) and solute (dielectric 
constant ranged from 2 to 28) was formed by the latter's molecular surface, 
constructed with a solvent probe radius of 1.4 Å and the following radii for the 
solute elements: polar hydrogens 0.32 Å, other hydrogens 1.017 Å, carbon 1.8 Å, 
oxygen 1.344 Å, nitrogen 1.14 Å, sulfur 2.0 Å. The solute charges were assigned 
based on the AMBER03 force field22, using GAFF/AM1BCC23 for the ligands. The 
term for the hydrophobic component of ligand binding, ΔGnp was calculated by 
using the empirical treatment of Tan et al.24 (SAV probe = 1.80 Å, surface tension 
(ɣ) = 0.0480 kcal/mol-Å3, and constant offset (c) = -3.2655 kcal/mol.).  
 
Supplemental Results 
 
Monomer versus Dimer Docking 
DPA was docked to the same site with only a single monomer present 
using AutoDock and showed severely attenuated binding affinity (Interaction 
Energy = -27.45 kcal/mol (dimer) versus -14.81 kcal/mol (monomer), calculated 
by LigX25). 
Hydrogen-Bond Network of Active Site 
In E2·D-glu2, the distance between the side chain of Thr186 and His187 
and the amine of glutamate was 4.34 Å and 5.32 Å, respectively. For E2·D-
glu2·DPA, the distance between Thr186 and His187 and the amine was 2.99 Å 
and 3.77 Å, respectively. Thus, only in E2·D-glu2·DPA is Thr186 within hydrogen-
bonding distance of the substrate. In addition to increased contact with 
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glutamate, the movement of Thr186 brings the side chain hydroxyl within 
hydrogen-bonding distance of Ala73 of an adjacent loop. This hydrogen bond 
may be responsible for bringing both the side chain and backbone amines of 
Asn75 close enough to glutamate to form hydrogen bonds with either oxygen of 
its α carboxylate (3.59 Å and 2.92 Å, respectively), interactions that are 
completely absent in the E2·D-glu2 (6.50 Å and 4.99 Å, respectively). 
Structures were critically analyzed to find the source of the weaker free 
energy of binding of monomer A of E2·D-glu2·DPA. It was previously reported 
that a main conformational change related to glutamate binding occurs in a loop 
containing His187 and Thr186 which have both been indicated in binding and 
catalysis26. Thus, we began by examining the effect of DPA binding on this loop. 
Ligand interaction mapping of equilibrated E2·D-glu2·DPA after the 20 
nanosecond simulation show two water bridges formed between DPA and 
Asp210 and Glu211 of the A monomer of RacE2 (Fig. 5c). Asp 210 goes on to 
form a hydrogen bond with the side-chain hydroxyl of Ser207 (previously 
implicated in DPA binding by initial ligand interaction mapping of the top-docked 
complex prior to MD). Ser207 also forms a water bridge with Glu211. This 
complex network of direct hydrogen bonds and water bridges between DPA and 
the A monomer occurs twenty residues downstream of the catalytic residues, 
separated by a short α-helix and β-sheet. It is possible then that interactions 
between DPA and Ser207, Asp210 and Glu211 result in a rearrangement in the 
enzyme conformation that is translated down the backbone to the catalytic 
residues, His187 and Thr186. 
Solvation and DPA Inhibition 
An additional water molecule interacting with glutamate of the E2·D-
glu2·DPA further indicates an active site rearrangement coincident with binding of 
DPA. The active site solvent accessible volume for the E2·D-glu2 monomer A is 
1214.35 Å3 which decreases to 1171.15 Å3 for the E2·D-glu2·DPA monomer A, a 
difference of 43.2 Å3. Thus, the additional water bridge seen in E2·D-glu2·DPA is 
not due to more water molecules in the active site but instead more optimal 
positioning of present water molecules. Thus, greater protein solvation energy of 
E2·D-glu2·DPA appears to contribute at least partially to the source of the weaker 
D-glu binding free energy. 
Monomer-Monomer Interactions 
According to the equilibrated structure resulting from MD simulation, 
binding of DPA to the RacE2 dimer interface disrupts two inter-monomer 
hydrogen bonds occurring between Lys106a and Asp210b (and vice versa, 
Lys106b to Asp210a), forcing either Lys106 to instead hydrogen bond to Glu211. 
There is no net loss of direct contact between the monomers with DPA bound, 
which agrees well with the results of Blue Native PAGE. 
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Supplementary Tables and Figures 
 
Supplementary Table E.1. Fitting parameters of RacE2_WT activity versus DPA 
data to varying inhibition models via GraphPad Prism v5.0. 
Inhibition Model 
Degrees of 
Freedom 
Abs. Sum of 
Squares 
Competitive 13 0.001858 
Noncompetitive 13 0.0009267 
Uncompetitive 13 0.001597 
Mixed Model 12 0.0009108 
 
 
Supplementary Table E.2. Comparison of global fitting via F test of RacE2_WT 
activity versus DPA data to varying inhibition models. 
Parameter Comparison 1 Comparison 2 Comparison 3 
Null Hypothesis Competitive Inhibition Uncompetitive Inhibition Noncompetitive Inhibtion 
Alternative Hypothesis Mixed Model Inhibition Mixed Model Inhibition Mixed Model Inhibition 
P Value 0.0041 0.0109 0.6548 
Conclusion (alpha = 0.05) Reject Null Reject Null Do Not Reject Null 
Preferred Model Mixed Model Inhibition Mixed Model Inhibition Noncompetitive Inhibition 
F (DFn, DFd) 12.48 (1,12) 9.037 (1,12) 0.2102 (1,12) 
 
Supplementary Table E.3. Steady-state kinetic parameters of WT and mutant 
RacE2 enzymes as determined by circular dichroism. Fit to the Michaelis-Menten 
equation via GraphPad Prism v5.0.  
 
 
Protein 
D  L Racemization 
kcat (s
-1) Km (mM) kcat/ Km (10
3 M-1 s-1) 
RacE2 WT 2.13 ± 0.1 1.27 ± 0.3 1.68 ± 0.2 
RacE2 K106A 5.68 ± 0.8 2.27 ± 0.7 2.50 ± 0.3 
RacE2 S207A 0.73 ± 0.1 0.29 ± 0.1 2.52 ± 0.4 
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Supplementary Table E.4. Description of primers used for site-directed 
mutagenesis of racE2.  
Gene Desired Mutation Primer Primer Sequence (5’3’) 
racE2 Lys106Ala 
K106Afor 5’-agttattcacccaggatcacgtacagctttagcagtgacaaacacatac-3’ 
K106Arev 5’-gtatgtgtttgtcactgctaaagctgtacgtgatcctgggtgaataact-3’ 
racE2 Ser207Ala 
S207Afor 5’-ggagataaagtacaactcattgcttcaggtgatgaaacagcgc-3’ 
S207Arev 5’-gcgctgtttcatcacctgaagcaatgagttgtactttatctcc-3’ 
 
 
 
Supplementary Table E.5. Comparison of global fitting via F test of RacE1_WT 
activity versus DPA data to varying inhibition models. 
Parameter Comparison 1 Comparison 2 Comparison 3 
Null Hypothesis Competitive Inhibition Uncompetitive Inhibition Noncompetitive Inhibtion 
Alternative Hypothesis Mixed Model Inhibition Mixed Model Inhibition Mixed Model Inhibition 
P Value 0.0221 0.0484 0.6915 
Conclusion (alpha = 0.05) Reject Null Reject Null Do Not Reject Null 
Preferred Model Mixed Model Inhibition Mixed Model Inhibition Noncompetitive Inhibition 
F (DFn, DFd) 6.156 (1,20) 4.418 (1,20) 0.1621 (1,20) 
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Supplementary Figure E.1. Inhibition of RacE1 by DPA assayed via circular 
dichroism and globally fit to a noncompetitive inhibition model, resulting in a Ki 
value of 78 ± 12 μM.  
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Supplementary Figure E.2. Colloidal aggregate test for false positives. Inhibition 
of RacE2 by 50 μM DPA was assayed in the presence and absence of 0.01% 
Triton-X 100 detergent. The percent inhibitions of either set of conditions were 
within error (< 10%) proving DPA not to act through aggregate formation. Data 
represents the average of three separate trials with standard deviation shown. 
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Supplementary Figure E.3. Blue Native PAGE of WT RacE2 and running controls 
with NativeMark ladder (10% resolving gel, 4% stacking gel). Monomer band 
appears to migrate slightly slower than the 20 kDa marker, as expected (RacE2 
monomer MW = 30 kDa). Dimer band appears to migrate slightly slower than the 
66 kDa marker (RacE2 dimer MW = 60 kDa) which is most likely due to the fact 
that the RacE2 homodimer has a more elongated oval shape (see diagram 
adjacent to arrow head) than the globular marker protein, and thus migrates 
slower. Higher order oligomers are also present on the gel in negligible 
quantities. 
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Supplementary Figure E.4. BN-PAGE to determine the effect of DPA on RacE2 
dimerization.  Loading buffer, running buffer and PAGE gel contained 1 mM DPA 
(a) , 1mM 3,4-pyridinedicarboxylic acid (b), or buffer (c). Albumin and carbonic 
anhydrase were included as running controls. Arrowheads indicate bands 
representing the dimer and monomer. Band intensity was quantified via pixel 
counting and the ratio of monomer to dimer was fitted to an expression for 
monomer:dimer equilibrium (derivation of expression detailed above in 
Supplementary Methods). Data represents an average of two or more 
independent trials with standard error shown.  Fitting of data resulted in the 
following Kd values for RacE2 in the presence of DPA, analogue, or buffer: 48 ± 
13, 39 ± 5, and 30 ± 7 μg/mL, respectively. Thus, BN-PAGE would confirm that 
there is no significant change in the Kd of dimerization due to the presence of 
DPA. 
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Supplementary Figure E.5. Ligand interaction maps for glutamate bound to the 
active site of monomer B when DPA is absent (a) and bound (b). Maps were 
constructed from the equilibrated structures of the 20 nanosecond MD 
simulations.  
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Supplementary Figure E.6. Equilibration achieved over 20 nanoseconds of 
molecular dynamics simulations. Differences between the backbone carbons of 
each subsequent simulation snapshot structure and the original structure, 
expressed as RMSD (Å), plotted against time for the E2·D-glu2 (a) and E2·D-
glu2·DPA complex (b). 
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Supplementary Figure E.7. Purification of recombinant 6x-His-tagged 
RacE2_S207A, RacE2_K106A, and WT RacE2 via Co2+-affinity chromatography 
followed by UNO-Q anion-exchange chromatography.  
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